Structural and immunological studies of pertussis toxin: effect of toxoiding by Fowler, Sarah
Open Research Online
The Open University’s repository of research publications
and other research outputs
Structural and immunological studies of pertussis
toxin: effect of toxoiding
Thesis
How to cite:
Fowler, Sarah (2002). Structural and immunological studies of pertussis toxin: effect of toxoiding. PhD thesis
The Open University.
For guidance on citations see FAQs.
c© 2001 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
Structural and Immunological Studies of Pertussis Toxin: Effect of Toxoiding 
A thesis submitted to the Open University for the degree of 
Doctor of Philosophy 
by Sarah Fowler BSc. Hons 
November 2001 
Division of Bacteriology 
National Institute for Biological Standards and Control 
Division of Infection and Immunity, Institute of Biomedical and Life Sciences, 
University of Glasgow (collaborating establishment) 
Au*iop-S ND: R732°1669 
OAT6 OF 5J3i`-S17-ClN 
: 1c NOY 'IEM4 7-001 
t1AT6 oC 
f ARb: 1 Cý SANJARY 2002. 
Dedication 
For my Nana 
Acknowledgements 
First of all I must thank my two supervisors, Dr Barbara Bolgiano and Dr Dorothy Xing, 
for their guidance and support throughout this project. Barbara's unbounded dedication 
and enthusiasm for the physico-chemical work always made it exciting, and kept me 
going all the way through. Without Dorothy's strong discipline and positive 
encouragement during my time working with her in the latter immunological part of the 
project, I would not be writing this at this time. I am grateful to Dr Olwyn Byron, my 
external supervisor not only for introducing me to analytical ultracentrifugation, but also 
for reviewing all of my work throughout the years. I thank Dr Kornelia Jumel for 
schooling me in the techniques of laser light scattering and also for assessing my work. In 
addition I thank Dr John Coote for his comments and ideas. I must also thank Dr Mike 
Corbel for his valuable input and constant positive support. I am indebted to Dr Mark 
Forster for all of his guidance in the molecular modelling studies, and for sharing his 
fascination for the subject with me. Of course, I am entirely grateful to all of my 
colleagues who helped me along the way, particularly Dennis Crane, C-T Yuen, Penny 
Newlands, Cathy Canthaboo and Alex Douglas. 
It would not have been possible to do this work without the backing of my family, so I 
thank Mum, Dad and Grandad and my late Grandma for their love and support 
throughout school, university and this PhD. Lastly, and most of all, I thank Clive for his 
endless encouragement and love, and for always believing in me. 
3 
Abstract 
A detoxified form of pertussis toxin (PT) is used as a component of acellular pertussis 
vaccines, to prevent whooping cough in children. In this study five commercial PT 
toxoids, and a series of formaldehyde-treated (0 - 1.00 %, w/v) native and non-toxic 
mutant PT (PT-9K/129G) preparations were analysed, to investigate the effects of 
detoxification on the structure and immunogenicity of PT. 
Native PT and a non-toxic mutant PT, compared using physico-chemical methods and 
molecular modelling, were found to be structurally comparable. Analysis of the PT 
toxoids demonstrated the variation in folding, conformation and subunit association 
induced by the different chemical methods of detoxification. A good murine IgG 
response to the toxoids was dependent on the maintenance of local structure such as the 
integrity of the protective SI epitope, but molecular aggregation did not appear to be 
detrimental. Sizing analysis of formaldehyde-treated mutant and native PT preparations, 
illustrated that both mutant and native PT molecules increased in size and heterogeneity, 
as a function of formaldehyde concentration. Immunoblotting of the formaldehyde- 
treated preparations confirmed the presence of covalent inter-subunit cross-linking. 
Immunological analysis of formaldehyde-treated mutant PT preparations demonstrated 
that a small degree of aggregation may be beneficial for the immune response in mice, 
but that increasing amino acid modification, cross-linking and aggregation alters the type 
of immune response and causes a decrease in the neutralising antibodies. Toxicity assays 
demonstrated that formaldehyde detoxification of PT is due to modification of both the 
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A- and the B-domain, and is subject to reversion. Evidence for antibody suppression and 
enhancement by different amounts of residual active PT was also obtained. The 
observations made here will help us to understand the complex relationships between 
antigen structure and immune response in vaccines containing PT. 
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Chapter 1 Introduction 
1.1 Overview 
Only with the right balance between the immunological efficacy and toxicity of pertussis 
toxin (PT) will the ultimate whooping cough vaccine be found. PT is an ADP- 
ribosylating protein toxin secreted by the whooping cough bacteria Bordetella pertussis, 
and is one of the most virulent and immunogenic factors of the bacteria. 
Descriptions of the infant disease of whooping cough date back to the 1500s. The 
causative agent, B. perlussis, was first described by Bordet and Gengou in 1906 (Bordet 
and Gengou, 1906). There are many virulence factors produced by the bacteria but it 
appears that the major systemic effects of whooping cough are primarily due to PT 
(Pittman, 1984; Pittman, 1979; Weiss and Hewlett, 1986; Monack et al., 1989). Despite 
the success of the whole cell vaccine in reducing mortality of the disease, uncertainty 
about the safety and effectiveness of the whole cell vaccine (Romanus, Jonsell, and 
Bergquist, 1987; Fine and Clarkson, 1987; Fine and Clarkson, 1982) has urged the 
development of more defined vaccines composed of protective B. pertussis antigens, 
which could be safer and more reliable for mass vaccination. Some methods of testing the 
efficacy of these vaccines are in use but reliable laboratory tests of protective efficacy are 
still being developed. 
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PT is the primary component of all current acellular pertussis vaccines. High-resolution 
structures of PT (Stein et al., 1994a; Stein et al., 1994b; Hazes et al., 1996) show that it is 
of the AB class of protein toxins and the functions of its domains in the host have been 
described (Locht and Antoine, 1999). Many important biological and immunological 
properties have been observed (Munoz, 1985), although their complex mechanisms 
continue to be investigated. Studies on the effects of toxoiding PT by genetic mutation 
and chemical treatment have assessed modifications to some toxic properties of PT, cell 
binding activities and a small number of T- and B-cell epitopes (Nencioni et al., 1991; 
Nencioni et al., 1990; Petre et al., 1996; Pizza et al., 1989; Di Tommaso et al., 1994). 
There is some physico-chemical evidence to suggest that formaldehyde (FA), one of the 
chemicals used to toxoid PT, causes an increase in the molecular size of PT (Bolgiano et 
al., 1999). This thesis presents a detailed structural analysis of PT, and investigates the 
effects of different toxoiding on its physico-chemical, antigenic and immunological 
properties, with emphasis on the effects of FA treatment. 
1.2 Whooping cough 
1.2.1 Clinical characteristics 
Whooping cough, also known as pertussis, is caused by B. pertussis bacteria, and is an 
acute infectious respiratory disease primarily affecting young children. B. pertussis 
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colonises the tracheal epithelium (Figure 1.1) and produces the disease effects (Gordon 
and Hood, 1951). The disease has an incubation period, which lasts between seven and 13 
days. The initial catarrhal stage lasts for about two weeks and is characterised by nasal 
congestion, mild fever and cough (Hodder and Mortimer, Jr., 1992). Damage to the 
respiratory epithelial cells, including the destruction of cilia, can be seen at this stage. As 
the second, paroxysmal, stage of the disease ensues, the coughing becomes increasingly 
forceful and the patient may experience ten to 20 or more paroxysms in 24 hours with up 
to about 30 coughs per spasm (Gordon and Hood, 1951). In infants older than six months, 
the characteristic whooping noise occurs as the child inhales through the constricted 
glottis between coughing spasms, the child has difficulty breathing and apnoea is 
common. At this stage, bronchopulmonary damage includes ciliary destruction, oedema 
and emphysema, and the extent of this damage is related to the mortality of the disease. 
In severe cases the patient may suffer from seizures and may develop encephalopathy 
caused by anoxia of the brain. The paroxysmal stage lasts between one and four weeks 
before the effects begin to gradually subside as the convalescent period commences. 
Although the patient is free of B. pertussis after the paroxysmal stage, the convalescent 
period can last one to six months or more before the effects of the disease cease 
altogether. Complications of the disease may include pneumonia, due to severe damage 
to the respiratory epithelium, secondary bacterial infections and acute neurological 
manifestations such as persistent seizures, hemiplegia, paraplegia, decerebrate rigidity, 
ataxia, aphasia, blindness and deafness (Gordon and Hood, 1951). 
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Figure 1.1 Bordetella pertussis infection of the tracheal epithelia 
Enhanced scanning electron micrograph of live B. pertussis cells infecting 
murine tracheal epithelia. Taken from the NIBSC photographic library. 
B. pertussis cells - yellow; cilia - orange; epithelia - red 
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In clinical trials the definition of a positive diagnosis for whooping cough set by the 
World Health Organisation is paroxysmal cough for 21 or more days and positive culture 
for B. pertussis, as well as serologic confirmation, or contact with a culture-proven case 
within 28 days of the disease (WHO, 1991). 
1.2.2 Epidemiology 
An epidemic in Paris in 1578, recorded by Guillaume De Baillou, was the first evidence 
of a disease characteristic of whooping cough (Holmes, 1940). Settlers carried the disease 
to the New World and there are records of a whooping cough epidemic in Plymouth, 
Massachusetts in 1649 (Gordon and Hood, 1951). 
In the pre-vaccine era, in the USA and in parts of the UK, whooping cough was endemic 
with epidemics every three to five years. There is evidence that 70 % of children had 
contracted whooping cough by the age of 17 years (Cherry, Brunell, and Golden, 1988; 
Fine and Clarkson, 1987; Cherry, 1984). In the USA around 150 cases per 
100 000 population were reported per year in the period 1920 - 1945. Since mass 
vaccination, it has been estimated that this has fallen to about 1 per 100 000 population 
(Mortimer, Jr. and Jones, 1979; Cherry, 1984). Incidence of whooping cough in the UK is 
shown in Figure 1.2, and illustrates about a 40-fold decrease in reported whooping cough 
cases since mass vaccination. However, the epidemic cycle of infection has not changed 
(Fine and Clarkson, 1982). 
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Whooping cough- Quarterly notifications England and Wales 1940-1986 
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Figure 1.2 Incidence of whooping cough in the UK 
Notifications of whooping cough and annual vaccination rates in England and 
Wales from 1940- 1986. Taken from Collee and Watt, 1990. 
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In the USA and in England and Wales the whooping cough epidemic runs in a cycle 
characteristically peaking every 3 to 4 years (Fine and Clarkson, 1982). Regular cycles of 
whooping cough infection are determined by the interaction of several factors: the 
probabilities of infection transmission, rates of recovery from infection and rates of influx 
of new susceptibles into the population (e. g., by births). An epidemic is initiated when the 
number of susceptibles reaches a certain threshold level, which can support the increase 
in disease incidence. Eventually the disease incidence exceeds the rate of influx of new 
susceptibles and inevitably the numbers of susceptibles decrease until they are below the 
threshold level. Then the cycle enters an interepidemic phase during which the rate of 
introduction of susceptibles exceeds the incidence of infection, until the number of 
susceptibles reach the threshold level once again; and so the cycle continues. Data studied 
from week 1 of 1950 until week 3 of 1982 showed that the interepidemic periods do not 
shorten with B. pertussis vaccination (Fine and Clarkson, 1982). Therefore, although the 
incidence of disease is lower due to vaccination, B. pertussis is still circulating in the 
population at the same rate. 
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1.3 Bordetella pertussis 
1.3.1 Classification and description 
Introduction 
The genus Bordetella encompasses four species that cause respiratory tract infections. 
They all bind to the host's pulmonary ciliated epithelium and produce common 
pathological effects including, loss of ciliated cells, reduced weight gain of the host, 
excessive mucus production, a form of cough or sneezing and frequent secondary 
infection. B. parapertussis is responsible for a mild whooping cough-like infection in 
humans. B. bronchiseptica is primarily a pathogen of animals causing kennel cough in 
dogs and rhinitis in pigs, but is also capable of infecting humans. B. avium causes 
rhinotracheitis of birds and B. pertussis, is responsible for whooping cough in humans 
(Parton, 1989). 
B. pertussis is a Gram-negative, non-motile, pleomorphic, coccobacillus (Figure 1.1) 
measuring 0.2 to 0.8 µm in size. It was first isolated and implicated as the etiological 
agent of whooping cough in 1906 by Bordet and Gengou (Bordet and Gengou, 1906). B. 
pertussis shares a variety of virulence factors with its related species but is unique in 
producing PT (Parton, 1989), esteemed the most potent and immunogenic determinant of 
whooping cough (Weiss et al., 1984; Pittman, 1979; Trollfors et al., 1995). 
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1.3.2 B. pertussis virulence factors and their role in pathogenesis 
B. pertussis produces a multitude of virulence factors, ranging from general attachment 
factors, assisting pulmonary bacterial colonisation, to toxins with highly specific catalytic 
activity involved in the systemic disease. These virulence factors are co-expressed, and 
can also be differentially expressed, under the regulation of a virulence locus, which 
encodes for a regulatory two-component system, Bvg, responsive to environmental 
stimuli (Kinnear, Marques, and Carbonetti, 2001). The virulence factors of B. pertussis 
are not produced when the bacteria are grown at much under 37 °C, or in certain types of 
media, and resume their virulent state again under permissive conditions. Phenotypic 
variation may occur in vivo as a method of thriving in the host in an unrecognised carrier- 
state (Weiss and Hewlett, 1986; Weiss and Falkow, 1984). 
The long-accepted mechanism of B. pertussis pathogenesis is by means of epithelial 
attachment, extracellular colonisation and systemic invasion by toxins (Weiss, 1997). An 
additional mechanism of evading the hosts defences has been discovered in the 
intracellular growth of B. pertussis in macrophages (Ewanowich et al., 1989; Friedman et 
al., 1992). The major virulence factors of B. pertussis are described in the text below and 
in the accompanying schematic diagram (Figure 1.3). 
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1.3.2.1 Adhesins 
Fimbriae 
Fimbriae are proteinaceous filaments that protrude from the surface of bacteria (Figure 
1.3). Two types of fimbriae on B. pertussis, Fim2 and Fim3, have been described as 
helical structures (Steven et al., 1986), composed of multiple copies of their 
homogeneous subunits (- 20 kDa), distinct for Fim2 and Fim3 (Irons, Ashworth, and 
Robinson, 1985). The fimbriae are serotype-specific agglutinogens, that is, they have the 
ability to give rise to specific antibodies capable of agglutinating B. pertussis cells 
(Ashworth, Irons, and Dowsett, 1982; Irons, Ashworth, and Robinson, 1985). They are 
capable of binding to ciliated cells in the respiratory tract and are believed to play a role 
in the pathogenesis of whooping cough by aiding B. pertussis colonisation (Robinson et 
al., 1991). 
Filamentous haemagglutinin (FHA) 
FHA is a cell surface rod-shaped monomeric protein (Figure 1.3) with a molecular weight 
of 220 kDa and has multiple adhesin properties. It possesses haemagglutinating 
properties (Sato et al., 1983) and can bind to a variety of cultured cells (Cowell et al., 
1986). FHA is involved in colonisation of B. pertussis in the respiratory tract by binding 
to both ciliated epithelial cells (Tuomanen and Weiss, 1985; Tuomanen et al., 1985) and 
to alveolar macrophages via the integrin CR3 (Relman et al., 1990). 
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toxin 
Virulence factors of B. pertussis. Toxins include secreted pertussis 
toxin and TCT or tracheal cytotoxin (peptidoglycan), surface- 
associated adenylate cyclase toxin, and cytoplasmic dermonecrotic 
toxin. Attachment factors include FHA (filamentous hemagglutinin), 
pertactin, BrkA, TCF (tracheal colonization factor), and fimbriae. 
Figure 1.3 Virulence factors of Bordetella pertussis 
A schematic diagram representing B. pertussis and some of its virulence 
factors. Taken from Weiss, 1997. 
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Pertactin 
Introduction 
Pertactin (Figure 1.3) is a surface exposed domain (Mr 60.4 kDa) of a 93 kDa outer 
membrane protein. It is also referred to as P69 owing to its migration on sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels at a relative molecular 
mass of 69 kDa. It mediates adhesion to respiratory tract epithelial cells and may also 
bind integrin CR3 on alveolar macrophages (Emsley et al., 1996). 
1.3.2.2 Toxins 
PT 
PT is an extracellular protein toxin (Figure 1.3) of 105 kDa, encompassing a cell-binding 
domain and a catalytic domain with ADP (adenosine diphosphate)-ribosyl transferase 
activity. PT can enter host epithelial cells and modify the host G-proteins. This results in 
altered host cell-signalling and is the cause of the main systemic manifestations of the 
whooping cough disease (Pittman, 1979). PT will be described in more detail later in this 
chapter (section 1.5). 
Adenylate cyclase toxin (ACT) 
ACT is an extracytoplamic protein toxin (Figure 1.3) of 200 kDa which has adenylate 
cyclase and haemolytic activity (Rogel, Meller, and Hanski, 1991). ACT is required in 
the initial colonisation of the bacteria (Goodwin and Weiss, 1990). The haemolytic 
domain allows it to enter many types of eukaryotic cell, perhaps by charge interactions 
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with lipids (Raptis et al., 1989; Locht and Antoine, 1999). The adenylate cyclase domain 
is activated by calmodulin and catalyses the conversion of adenosine triphosphate (ATP) 
to cyclic adenosine monophosphate (cAMP). High levels of cAMP disrupt normal 
intracellular signalling. ACT can inhibit chemotaxis and superoxide production of human 
polymorphonuclear leukocytes (Friedman et al., 1987) and induces apoptosis in 
macrophages, promoting bacterial growth at the site of infection (Khelef and Guiso, 
1995). 
Tracheal cytotoxin 
Tracheal cytotoxin is a small peptide (Figure 1.3), which appears to be secreted, and may 
be derived from bacterial peptidoglycan. It is not required in the pathogenesis of 
whooping cough but is specifically toxic to ciliated cells apparently by inhibiting DNA 
synthesis (Cookson et al., 1989; Cookson, Tyler, and Goldman, 1989; Goldman, 1986). 
Dermonecrotic toxin (DNT) 
DNT is an intracellular protein toxin (Figure 1.3) of 159 kDa known for producing skin 
lesions when used to vaccinate laboratory animals (Bordei and Gengou, 1909). It is also 
known as heat labile toxin since it is completely inactivated by heating to 56 °C for 60 
minutes (Livey and Wardlaw, 1984). DNT does not appear to be required for B. pertussis 
virulence in humans although it may be important in the pathogenesis of B. 
bronchiseptica infections in pigs (Roop et al., 1987). 
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Lipopolysaccharide 
Introduction 
Lipopolysaccharide is a stable substance located in the cell envelope of Gram-negative 
bacteria. Lipopolysaccharide in B. pertussis is distinct from that of other Gram negative 
bacteria in that it is composed of two immunochemically different lipids, lipid A and X, 
with two different oligosaccharide chains. The lipid X fraction possesses typical 
endotoxin activities of pyrogenicity and toxicity, while lipid A has potent adjuvant and 
anti-viral activities (Ayme et al., 1980). 
1.4 Pertussis vaccines 
1.4.1 B. pertussis whole cell vaccine 
Soon after the isolation of B. pertussis in 1906 attempts were made to produce a vaccine 
using the attenuated organism (Lapin, 1943). By the 1930's there was evidence from 
controlled clinical trials that several whole-cell pertussis vaccines could provide 
statistically significant protection against acquisition and severity of the disease 
(Kendrick, 1936). The need for an adequate test for vaccine standardisation was met in 
the 1940's by P. Kendrick et al. (Kendrick, Eldering, and Dixon, 1947) who developed 
the mouse intracerebral (IC) challenge test also known as the Kendrick test. By the 1950s 
the Medical Research Council (MRC) was able to show that vaccine performance in the 
37 
Chapter 1 Introduction 
mouse IC challenge test correlated with protection against pertussis in children (Medical 
Research Council, 1956; Medical Research Council, 1959). 
Despite the success in most areas, estimates of whole-cell vaccine efficacy were 
extremely varied, ranging from 0 to 100 %. This depended on factors such as the study 
design of efficacy testing but also on real differences in the vaccine preparations (Fine 
and Clarkson, 1987). For example, studies designed to compare the protective efficacy of 
different whole cell vaccines illustrated the considerable variation that can arise from 
vaccines from different manufacturers (Public Heath Laboratory Service Whooping- 
Cough Committee and Working Party, 1973). As well as differences in methods of 
attenuation and formulation of the whole cell vaccine, there may also have been 
differences in the content of virulence factors, which is now known to be affected by the 
bacterial culture conditions (Lacey, 1960). The whole-cell vaccine was also shown to 
have a limited duration of protection, exemplified by the common carriage of the mildly 
symptomatic disease in adults. Due to its disputed efficacy the decision was made to 
discontinue use of the whole-cell vaccine in Sweden in 1979 (Romanus, Jonsell, and 
Bergquist, 1987). 
The major issue for the whole-cell B. pertussis vaccine is that it can have severe side 
effects, and this has led to waning vaccination in most countries (Golden, 1990; Hodder 
and Mortimer, Jr., 1992; Miller et al., 1981). There is well established clinical evidence 
for certain adverse reactions caused by whole-cell pertussis vaccines: local reactions, 
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such as erythema, tenderness and, less frequently, sterile abscess formation; and systemic 
reactions including fever, lethargy, anorexia, drowsiness, and prolonged crying (Cherry, 
1984; Hewlett and Cherry. J. D., 1997; Cody et al., 1981). All of these responses may not 
be specific to pertussis vaccine but they occur with more frequency in combined 
diphtheria, tetanus and pertussis (DTP) vaccine recipients than in recipients of combined 
diphtheria and tetanus alone (Cody et al., 1981). A significant association was also shown 
between serious neurological illness and pertussis vaccine, although the cases were few 
and most children recovered completely (Miller et al., 1981). Moreover some unresolved 
issues have dealt with the possibility of pertussis being associated on rare occasions with 
later neurological problems (Miller et al., 1993) and more frequently with acute 
encephalopathy (Stephenson, 1988). 
1.4.2 B. pertussis acellular vaccine 
The reactogenicity and questionable efficacy of the whole cell vaccine, combined with 
the realisation that a toxin is involved in the production of whooping cough, (Pittman, 
1979), impelled the design of an acellular vaccine (Hewlett and Cherry. J. D., 1997). In the 
mid 1970s the Hiroko and Yuji Sato first undertook this task in a national effort in the 
form of the Committee on Improved Pertussis Vaccine controlled by the Ministry of 
Health and Welfare for Japan (Sato, Kimura, and Fukumi, 1984). They identified two of 
the most abundant extracellular proteins, now known as FHA and PT, in the growth 
media of B. pertussis. Co-purified vaccines containing these antigens were found to be 
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protective. In addition, PT and FHA were purified and used in more defined acellular 
pertussis vaccines (Sato and Sato, 1999; Sato, Kimura, and Fukumi, 1984). PT was 
treated with FA, to destroy its leukocytosis and histamine sensitising properties, (Sato, 
Kimura, and Fukumi, 1984). The toxoiding procedure involved FA additions every three 
days up to a concentration of 0.4 % (w/v) and the mixture incubated at 37 °C for several 
days. The vaccine was clinically tested and in 1981 it was licensed for use in children of 
two years old. The endeavours of the committee resulted in the production of acellular 
pertussis vaccines by six Japanese manufacturers and a triumphant reduction in disease 
(Sato, 1997), and so a second generation of whooping cough vaccines was born. 
Meanwhile, Europe and the United States also started to develop acellular whooping 
cough vaccines (Rappuoli, 1996). Most manufacturers largely followed the Japanese 
practice using FA as the detoxifying agent, while some employed other chemicals and 
included additional B. pertussis antigens. There has not been much change in the 
formulation of acellular vaccines over the years. Today commercial vaccines are 
minimally composed of detoxified PT and may also include FHA, pertactin and fimbriae 
(Fim2 and Fim3), in various combinations. FA is still the most widely used detoxifying 
agent of PT for use in acellular vaccines, but some manufacturers employ hydrogen 
peroxide, tetranitromethane or glutaraldehyde. 
One company, Chiron-Biocine, has created genetically detoxified PT as a component for 
their acellular vaccine (Rappuoli, 1996). They started with a cloned and sequenced 3.5- 
Kb DNA fragment, which contained the sequence for subunits Si - S5 (Locht and Keith, 
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1986; Locht et al., 1986; Nicosia et al., 1986). To identify amino acids essential to 
enzymatic activity, a series of mutants was created, in the region of the Si subunit 
containing amino acids 2- 180, on the basis of sequence comparison with other bacterial 
toxins and computer modelling (Barbieri and Cortina, 1988; Burnette et al., 1988; Locht 
et al., 1990; Pizza et al., 1988). The most successful mutant, and the one they use in their 
vaccine today, has two amino acid substitutions in the Si catalytic site, Arg-9 -> Lys and 
Glu-129 --+ Gly (PT-9K/129G) (Nencioni et al., 1990). This antigen lacks ADP- 
ribosylation activity and other toxic effects of PT such as lymphocytosis and histamine 
sensitising activity. The antigen PT-9K/129G is also treated with FA, but at a much lower 
concentration (0.035 %, w/v) than required for detoxification, and for only 48 hours, in 
order to stabilise the protein (Nencioni et al., 1991; Petre et al., 1996). 
Various clinical trials were carried out in the early 1990s in the USA, Italy, Germany, 
Sweden and Senegal, sponsored by The National Institute for Allergy and Infectious 
Diseases to compare the safety and immunogenicity of experimental pertussis vaccines 
(Klein, 1995; Decker et al., 1995; Edwards et al., 1995). In addition, manufacturers also 
conducted independent trials (Annunziato et al., 1994; Marcinak et al., 1993; Pichichero 
et al., 1994; Halperin et al., 1994). Although there were differences in the study designs 
between the different trials, some general comparisons and conclusions can be made 
(Hewlett and Cherry. J. D., 1997). The results showed that the acellular vaccines always 
produced fewer adverse reactions than the whole-cell vaccine. There was variation 
between the efficacy of the acelluar vaccines (59 - 96 %), with most performing as well 
as or better than, and some performing worse than the whole cell vaccines. In general, the 
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efficacy of the acellular vaccines improved with an increasing number of antigen 
components. When the quantities of antigen in the acellular vaccines were compared, 
those vaccines containing genetically detoxified PT were more immunogenic than the 
acellular vaccines containing chemically detoxified PT (Klein, 1995). 
In the search for the most efficacious combination of vaccine components, research has 
provided increasing information on the immunogenic properties of pertussis antigens, and 
is ongoing. Most antigens, with the exception of toxoided PT, are not protective on their 
own. FHA has been shown to be a poor immunogen in mice (Zackrisson, Taranger, and 
Trollfors, 1990; Sato and Sato, 1985) and anti-FHA does not contribute to the therapeutic 
activity of pertussis vaccines in children (Granstrom et al., 1991). Pertactin only provides 
partial protection from pulmonary B. pertussis infection in mice (Shahin et al., 1990) and 
has been shown not to be responsible for protection by pertussis vaccines (Aoyama et al., 
1989; Sato, 1997). Fimbriae have been shown to give some protection in mice (Robinson 
et al., 1989; Jones et al., 1995), but are not required for the elimination of pertussis in 
children (Aoyama et al., 1989; Sato, 1997). Adenylate cyclase in contrast has been shown 
to confer protection against pertussis infection in mice (Brezin et al., 1987; Imaizumi et 
al., 1985) but due to its toxicity has not been included in the already successful acellular 
vaccines. PT is highly immunogenic conferring 100 % protection against B. pertussis 
pulmonary infection and intracerebral challenge in mice and a high degree of immunity in 
humans (Sato et al., 1980; Sato et al., 1981; Oda eta!., 1984; Sato and Sato, 1985; 
Robbins et al., 1993; Trollfors et al., 1995; Schneerson et al., 1996). Studies show that a 
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combination of PT and other less immunogenic pertussis antigens is more protective than 
PT alone (Mills et al., 1998; Sato and Sato, 1984). 
Although the whole cell vaccine is still successful in many parts of the world, the arrival 
of the acellular vaccine has increased the scope for controlling whooping cough. Earlier 
vaccination of infants, vaccination of adolescents and mothers, and the production of 
combination vaccines are all advantages of the less reactogenic acellular over the whole 
cell vaccine (Rappuoli, 1996). 
1.4.3 Vaccine testing 
The study of disease in a suitable animal model in which the disease effects correlate as 
closely as possible with those in humans is essential for effective standardising and 
controlling of vaccine products. Humans are the only known hosts of B. pertussis, 
therefore establishing a suitable animal model is an ongoing challenge. Primates are the 
only. known animals to suffer the paroxysmal cough and mucous production, which are 
characteristic of the human disease (Rich et al., 1936). Rats also produce a cough and 
accumulate serum in the lungs but do not secrete the mucous as primates do (Hornibrook 
and Ashburn, 1939) and rabbits become infected but do not develop any systemic disease 
effects. Mice do not exhibit the classical cough or mucous secretions, but the bacteria 
attach and colonise mice lungs in the same way, and produce many of the same biological 
effects as they do in humans (Sato et al., 1980). The mouse has become the model of 
43 
Chapter 1 Introduction 
choice for studying B. pertussis disease, and in the standardisation and testing of pertussis 
vaccines. 
The disease that develops in mice following intranasal inoculation or aerosol challenge 
resembles the disease in humans in a number of respects, including manifestations of PT 
action such as lymphocytosis (Sato et al., 1981), hyperinsulinemia (Pittman, Furman, and 
Wardlaw, 1980), and mitogenesis (Morse et al., 1977; Kong and Morse, 1977). Infant 
mice, like infant humans, may have significant mortality from the disease while older 
mice, like older humans, have less severe disease and are less likely to die (Pittman, 
Furman, and Wardlaw, 1980). In addition, both human and mice survivors of a sublethal 
dose of B. pertussis often develop a chronic infection that lasts several weeks to several 
months (Dolby, Thow, and Standfast, 1961; Weiss et al., 1984; Sato et al., 1981). 
Protection against mouse IC challenge is widely used to test the efficacy of whole cell 
pertussis vaccines since protection in this model has been shown to correlate with whole 
cell vaccine efficacy in humans (Medical Research Council, 1956). However, the results 
have been variable, and the mechanism of protection by this route is not fully understood 
(Cameron, 1988; Preston and Stanbridge, 1976). Moreover, this method has been shown 
not to be suitable for potency testing of acellular vaccines. This may be due to the fact 
that protective potencies determined by IC challenge appear to be dependent largely on 
the presence of active PT in the vaccines. This is believed to be due to the ability of PT, 
even in minute quantities, to increase the permeability of the blood-brain barrier, 
allowing entry of antigens, antibodies and immune cells into the brain (Robinson and 
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Irons, 1983). Therefore, a small amount of active PT in the acellular vaccine may cause it 
to appear highly protective by the Kendrick test, even if it is poorly immunogenic. It has 
been considered that this test is better for the testing of whole cell vaccines since amounts 
of active PT will generally correlate with the presence of co-ordinately expressed 
immunogenic factors (Robinson and Funnell, 1992). 
Efforts were made to design new animal protection tests for pertussis vaccines which 
more closely imitated natural challenge with B. pertussis, and which correlated with 
human protection. Intranasal infection by B. pertussis was studied (Dolby, Thow, and 
Standfast, 1961), and the protection of mice from lung colonisation was shown to 
correlate with vaccine efficacy in humans (Standfast, 1958). The aerosol challenge model 
was investigated and found to be a suitable alternative to the use of the Kendrick test 
(Xing et al., 1999; Canthaboo et al., 2000). Respiratory infection tests, by both aerosol 
and intranasal challenge, are being used increasingly in pertussis research, as alternatives 
to the Kendrick test. 
Serum antibody responses are also analysed in vaccine testing. Although clinical trials 
have shown that levels of antibody do not always correlate with protection (Ad Hoc 
Group for the Study of Pertussis Vaccines, 1988; Tran Minh et al., 1999), there is 
evidence that individuals without antitoxin are susceptible to whooping cough 
(Zackrisson, Taranger, and Trolifors, 1990; Isacson et al., 1994). Vaccine testing in mice 
includes analysis of antibody production and safety, as well as antigen evaluation, to test 
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consistency of manufacture (Arciniega et al., 1998), and studies of the immunological 
mechanisms of B. pertussis infection in mice and humans are ongoing. 
1.5 Pertussis toxin (PT) 
During their studies, Bordet and Genou noted that B. pertussis organisms were non- 
invasive and that disease continued after bacterial clearance (Bordet and Gengou, 1906). 
On this basis they proposed that whooping cough was a toxin-mediated disease but failed 
to isolate a toxin that imitated the disease effects. Seventy years later, a toxin that had 
been characterised with respect to a variety of biological activities, was implicated as the 
main immunogenic and toxic determinant of whooping cough, and it was named pertussis 
toxin (PT) (Pittman, 1979). 
1.5.1 Structure and function 
PT (Figure 1.4) is the best characterised virulence factor of the whooping cough 
bacterium. It belongs to the A-B class of bacterial protein toxins, which includes the 
cholera toxin and Shiga toxin families, Pseudomonas exotoxin-A and diphtheria toxin, all 
possessing functionally distinct catalytic (A) and cell-binding (B) domains (Sixma et al., 
1991; Stein et al., 1992; Allured et a!., 1986; Choe et al., 1992). The B-domain of PT 
binds to the host cell-surface sugar ligand, which is believed to facilitate membrane 
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Figure 1.4 Pertussis toxin 
The crystal structure of pertussis toxin, adapted from Stein, P. et al., 1994a. 
Molecular weight labels match the subunit colours; the white arrow 
indicates the predicted NAD-binding cleft. 
47 
0 CI 
-NH2 I 
+/ 
0 
11 
-0-P-0-CH2 
H 
H 
0 
O 
N' 
HC 
-O-CH2 -O-11 
O 
H 
Figure 1.5 
0 
HýH 
H 
NH2 
ýC-N 
CH 
N N 
Ii I 
Structure of NAD+ 
48 
Chapter 1 Introduction 
translocation of the A-domain into the cytoplasm (Locht and Antoine, 1999). Following 
internalisation, the A-domain, or Si subunit, catalyses the transfer of the ADP-ribosyl 
group from nicotinamide adenine dinucleotide (NAD) (Figure 1.5) to certain G-proteins, 
disrupting normal cellular signalling (Locht and Antoine, 1999). 
The sequence (Locht and Keith, 1986) and X-ray crystal structure (Stein et al., 1994a) of 
PT are known, including the structures for the ATP cofactor (Hazes et al., 1996) and 
sugar ligand complexes (Stein et al., 1994b). The X-ray structure for the NAD+ substrate 
complex is yet to be resolved. PT is a hexameric protein with a molecular weight of 105 
kDa (Figure 1.4), which comprises a catalytic A (Si) subunit (Mr, 26 kDa), and a cell- 
binding pentameric B-oligomer (Mr, 79 kDa). The B-oligomer consists of subunits S2, 
S3, two copies of S4, and S5. These are assembled as two dimers, S2-S4 and S3-S4, 
associated by extensive anti-parallel ß-sheet interactions and joined together with S5 to 
form a central asymmetric pore lined by five a-helices. The Si subunit is orientated on 
top of this ring structure with its C-terminal `tail' penetrating the pore, and contacts in the 
A/B-domain interface are made by hydrogen bonds and other electrostatic interactions 
(Stein et al., 1994a). 
The subunits of PT can be resolved on an SDS-PAGE gel into four bands with S4 and S5 
co-migrating (Sekura and Zhang, 1985). The subunits cannot be resolved using size 
exclusion chromatography even in the presence of guanidine hydrochloride. In these 
conditions a broad main peak and a small trailing shoulder is obtained from which elution 
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fractions contain mainly Si at the start of elution, then Sl/S2/S3 and lastly S4/5 (Sekura 
and Zhang, 1985). 
The protein has a high ß-sheet, low cc-helix content, calculated to be 16 % cc-helix and 
37 % ß-sheet, 11 % turns and 35 % other secondary structure, from the x-ray crystal 
structure (Appendix 1); and 10 % a-helix, 53 % ß-sheet and 37 % ß-turn/loop secondary 
structure from analysis of the protein in solution using circular dichroism (Seabrook, 
Atkinson, and Irons, 1991). It contains six tryptophan residues distributed between the 
subunits (Si W26, W215; S2 W52, W143; S3 W52; S5 W52), which makes intrinsic 
fluorescence spectroscopy a valuable tool of PT tertiary structural analysis. 
Si subunit 
In host cells, the SI subunit of PT modifies certain inner cell membrane proteins, known 
as guanyl nucleotide-binding proteins (G-proteins). G-proteins translocate cell receptor 
signals, commonly to adenlyate cyclase as well as other signal mediator proteins. The Si 
subunit catalyses the ADP-ribosyl transfer from NAD+ to a cysteine residue of the 
inhibitory a-subunit (ia) of heterotrimeric G-proteins. This uncouples the G; subunit 
from its receptor, which leads to permanent activation of adenylate cyclase to produce the 
second messenger cAMP, and thus activation rather than inhibition of the receptor 
mediated signal (Ui, 1990). 
The active site of the Si subunit is in the form of a cleft, which appears to be a structural 
motif common to other ADP-ribosylating toxins such as Escherichia coli heat-labile 
enterotoxins (LT1 and LT2), cholera toxin (CT), Pseudomonas aeruginosa exotoxin-A 
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(PAETA) and diphtheria toxin (DT) (Stein et al., 1994a; Sixma et al., 1991; Sixma et al., 
1993; Allured et al., 1986; Choe et al., 1992). Conserved amino acids have been located 
at identical positions in the three-dimensional structures of these toxins, which have been 
shown through site-directed mutagenesis to be essential for ADP-ribosylating activity 
(Domenighini et al., 1994; Pizza et al., 1988). The motif is composed of an a-helix, ß- 
strand and a large loop creating a partially open hydrophobic cavity. In DT, this pocket is 
the binding site for NAD+ (Bell and Eisenberg, 1996) and has therefore been postulated 
as a structurally conserved NAD+ binding site. The dissociation constant (Kd) for the PT- 
NAD+ interaction was determined to be 24 pM at 30 °C, by measuring quenching of PT 
fluorescence by NAD+ (Seabrook, Atkinson, and Irons, 1991). 
The enzymatic mechanism has been studied by transition-state modelling by studying 
kinetic isotope effects of the ADP-ribosylation reaction of PT with the G; a1 subunit, in the 
presence of NAD+ (Figure 1.5) (Scheuring, Berti, and Schramm, 1998). The results 
suggest a mechanism involving PT-induced cleavage of the C-N bond between the 
anomeric carbon of ribose and the nicotinamide nitrogen, and transfer of the ADP-ribosyl 
group to an ionised sulphydryl of the G;,,, subunit cysteine residue. 
The ADP-ribosyl transferase activity of the Si subunit of PT is fully activated in vitro by 
chemical reduction (Moss et al., 1986; Moss et al., 1983). Observation of its three 
dimensional structure has lead to the suggestion that effective NAD+binding in the 
catalytic site requires cleavage of the Cys-41 - Cys-201 disulphide bond to allow 
51 
Chapter 1 Introduction 
displacement of the a-helix (amino acids 184 - 203), which appears to occlude the NAD+ 
binding site (Stein et al., 1994a; Bell and Eisenberg, 1996). 
B-oligomer 
The B-oligomer is required for entry of the toxin into the host tracheal epithelial cells. 
The B-oligomer binds by at least two binding sites, located on its S2 and S3 subunits 
(Stein et al., 1994b). Studies have shown that the most likely host cell ligands are 
oligosaccharides with terminal sialyllactosamine residues on glycolipids or N-linked 
glycoproteins (Witvliet et al., 1989; Brennan et al., 1988; Sandros et al., 1994). 
Binding to the host cell surface is believed to initiate endocytosis of the holotoxin. 
Experiments have implicated that the toxin is trafficked through the Golgi and 
endoplasmic reticulum (Xu and Barbieri, 1995). However, the sequence of events leading 
to targetting of the A subunit to its substrate is not fully understood. 
It is known that the A subunit must be separated from the B-oligomer for catalytic 
activity and that dissociation of the domains is likely to be promoted by ATP binding to 
the B-oligomer (Hazes et al., 1996; Moss et al., 1986). ATP-binding is believed to 
destabilise the interaction between the B-oligomer and A subunit. However, it is not 
known where in the host cell this happens. 
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1.5.2 Biological activities 
Introduction 
PT is a unique protein possessing many important biological properties most of which 
were described before the purification and characterisation of the toxin. Accumulation of 
early evidence indicated that these properties were the actions of one protein (Munoz, 
1985). The mechanisms of the varied effects of PT are now beginning to be appreciated 
and are still the subject of intense study. It is now known that many of the diverse actions 
of PT, observed in vivo and in in vitro cell cultures such as CHO-cells, are dependent 
ultimately on the catalytic activity of the protein, and some are dependent on the binding 
properties of the B-oligomer alone. PT-modified G-proteins are unable to regulate normal 
homeostatic inhibition of signal-mediating proteins, such as adenylate cyclase. PT- 
induced effects, on adenylate cyclase-mediated pathways, include histamine sensitisation 
and insulin secretion. G-protein modification can also affect other signal-mediating 
proteins (Munoz, 1985). Another important biological effect of PT is its adjuvanticity, in 
which the B-oligomer and catalytic activity may have defined roles. In contrast, the 
haemagglutinating and mitogenic activities of PT are dependent on B-oligomer binding 
alone (Nencioni et al., 1991). 
Chinese hamster ovary (CHO)-cell toxicity 
Numerous effects of PT on cells in vitro have been described, including the enhancement 
of insulin release from rat pancreatic islet B-cells, the enhancement of agonist-induced rat 
C6 glioma cell activity and rat heart cell activity and toxicity to CHO-cells (Munoz, 
1985). These activities are all dependent on both translocation of the toxin into the cell 
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and catalytic modification of G-proteins, thus on both the A- and the B-domain. CHO- 
cells are used in many laboratories as model cell lines to study the cellular exploits of PT. 
CHO-cells bear a 165-kDa glycoprotein on their surface that is recognised by PT B- 
oligomer (Brennan et al., 1988), and contain a 41-kDa inner-membrane protein that is 
ADP-ribosylated by PT Si subunit (Bums, Kenimer, and Manclark, 1987). 
Unaffected CHO-cells can be observed under a light microscope as elongated cells in a 
uniform monolayer. Culture in the presence of as little as 30 pg of PT per 5000 cells, 
causes a characteristic clustering effect and change in the cell morphology, to a more 
square shortened cell, 16 hours following the addition of PT (Hewlett et al., 1983; 
Gillenius et al., 1985). The toxic effect of PT on CHO-cells has been employed in the 
development of assays to test the toxicity of PT-based vaccines and the PT neutralising 
capacity of anti-PT serum (Gillenius et al., 1985). It is an accepted alternative to the 
animal toxicity test (histamine-sensitising test) as described in the European 
Pharmacopoeia (European Pharmacopoeia, 2001). 
Histamine-sensitising activity 
One of the first recognised biological activities of PT was its histamine sensitising effects 
for which it was known as histamine sensitising factor. Early experiments showed that 
mice immunised with the pertussis vaccine had increased susceptibility to the effects of 
histamine (Parfentjev and Goodline, 1948; Clausen, Munoz, and Bergman, 1968; Munoz 
and Bergman, 1968). Histamine causes vasodilation, promotes capillary permeability and 
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bronchoconstriction and can cause rapid death in mice previously immunised with active 
PT. Sensitivity to histamine occurs about 90 minutes after inoculation with PT and is 
long lasting, being detected months later. Histamine sensitisation is now known to be 
dependent on the ADP-ribosylating activity of PT (Nencioni et al., 1991). However, the 
mechanism of PT-induced hypersensitivity to histamine is not clear but is thought to be 
due in part to PT mediating its effects via the histamine receptors H 1, H2 and H3, or via 
pathways controlled by histamine receptors such as the nitric oxide synthase system 
(Vleeming et al., 2000; Nilsson, Kockum, and Rosengren, 1997). Laboratories test the 
toxicity of pertussis vaccines and PT preparations by challenging mice with histamine 
after immunisation. Toxic vaccines or PT preparations cause anaphylactic shock and 
death of the mice within minutes of the challenge. 
Leukocytosis promoting activity 
Leukocytosis promoting factor was another agent subsequently revealed as PT. This 
activity was first observed in children infected with B. pertussis (Fröhlich, 1897) and 
since then in experimental animals receiving the pertussis vaccine or PT (Munoz and 
Bergman, 1977). Leukocytosis, an increase in the number of circulating leukocytes, is 
evident one day after injection of PT, reaches a maximum after about four days and then 
gradually declines to normal levels. Leukocytosis is predominantly due to an increase in 
lymphocytes including B- and T-cells, but other white blood cells such as 
polymorphonuclear leukocytes are also increased (Morse and Morse, 1976). Leukocytosis 
is followed by a decrease in the weight of the thymus and lymph nodes and an increase in 
spleen weight (Munoz, 1985). Even after extensive in vitro cultivation in the absence of 
55 
Chapter 1 Introduction 
PT, the PT-treated leukocytes retained their inability to migrate into lymph nodes in vivo 
(Spangrude, Braaten, and Daynes, 1984). It has been concluded that leukocytosis is not 
due to multiplication of leukocytes, but to the prevention of their re-circulation through 
the lymphoid tissue once they have been released (Morse, 1976; Spangrude, Braaten, and 
Daynes, 1984). Leukocyte promoting activity is dependent on the ADP-ribosylating 
activity of PT (Nencioni et aL, 1991), and it has been proposed that the mechanism of 
PT-induced leukocytosis is dependent on adenlyate cyclase-activated events (Braaten, 
Spangrude, and Daynes, 1984). Counting lymphocyte numbers in the whole blood of 
immunised mice is used as a check for pertussis vaccine toxicity. 
Other activities 
A whole host of other effects of PT have been observed, the most noteworthy of which 
include its islet activating effect, potent adjuvant activity, mitogenic and 
haemagglutination activities. 
PT possesses the ability to activate pancreatic islets to produce insulin and thus was 
previously known as islet activating factor. This was initially observed as the attenuation 
of catecholamine inhibition of insulin release in rats, which had been previously 
immunised with pertussis vaccine (Munoz, 1985). Subsequent studies revealed that PT, 
via G-protein modification, attenuates the inhibitory effects of a variety of other 
hormones (Ui, 1988). 
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Greenberg and Fleming first observed the adjuvant activity of the pertussis vaccine in 
1947 (Greenberg and Fleming, 1947), when they noted that tetanus and diphtheria 
toxoids given to children in combination with pertussis vaccine induced a higher 
production of antitoxins than when the toxoids were given alone. The adjuvant properties 
of the vaccine are now known to be due to the actions of lipid A of LPS (Ayme et al., 
1980) and to PT (Munoz and Bergman, 1977). Various groups have studied the nature of 
the immune response and mechanism of PT action in adjuvanticity. The current literature 
implies a role for both the A- and B- domains in this activity. The adjuvant action of PT 
will be discussed in more detail later in this chapter (section 1.5.3). 
Other activities of PT are the T-cell mitogenic and haemagglutination activities which, in 
contrast to the above, are conferred by the B-oligomer alone (Nencioni et al., 1990). 
Separate B-oligomer dimers (i. e. S2 - S4, S3 - S4) cannot induce mitogenicity therefore 
it has been suggested that cross-linking of cell-surface proteins causes mitogenic activity 
(Tamura et al., 1983). In contrast to mitogenic activity, haemagglutination by the S2-S4 
dimer is as effective as by the whole B-oligomer (Irons and MacLennan, 1979) 
(Nogimori et al., 1985), suggesting different B-oligomer binding sites for the 
erythrocytes than for T-cells. 
1.5.3 Immunological characteristics 
PT has proved to be the most protective of the B. pertussis antigens alone in mice, and 
some believe PT alone to be adequate to compose a protective acellular pertussis vaccine 
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(Robbins et al., 1993). Both humoral and cellular responses, specific for PT, appear to 
play a key role in clearing B. pertussis infection. One of the most intriguing aspects of PT 
is that it can induce a heightened immune response to coinjected antigens either from B. 
pertussis or other unrelated antigens, although the mechanism of the adjuvant action of 
PT has still to be elucidated. Many protective T- and B-cell epitopes have been identified 
in the PT molecule. 
Immunogenicity 
PT is a potent immunogen. Passive immunisation with antibodies specific for PT, has 
been shown to have a therapeutic effect in both mice (Sato et al., 1981) and children 
(Granstrom et al., 1991) infected with B. pertussis. PT, in active immunisation, can also 
confer high levels of protection against murine pulmonary infection or intra-cerebral 
challenge with B. pertussis (Oda et al., 1984; Sato and Sato, 1985). Moreover, a 
monocomponent PT vaccine has been shown to confer good protection in humans 
(Trollfors et al., 1995). 
The clearance of B. pertussis infection is dependent on humoral (mediated by Th2 cells) 
and cell-mediated immunity, (mediated by Thl cells) (Mills et al., 1998) directed against 
PT as well as other B. pertussis antigens (Thomas et al., 1989; Tran Minh et al., 1999). 
Antibody responses, especially against PT, have long been regarded as important in 
fighting B. pertussis infection (Sato et al., 1981; Granstrom et al., 1991; Thomas et al., 
1989). Further evidence from studies using transgenic mice, have shown that B-cells or 
their antibody products are essential for the clearance of B. pertussis from the lungs 
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(Mahon et al., 1997; Mills et al., 1998). However, a direct correlation between serum 
antibody titres and protection from disease has not been established (Duchen et al., 1997; 
Ad Hoc Group for the Study of Pertussis Vaccines, 1988; Tran Minh et al., 1999). It has 
been shown in mice and humans that acellular vaccines tend to preferentially induce the 
production of IL-4 and IL-5 cytokines and antibodies, typical of a Th2 response (Ausiello 
et al., 1997; Hall, Parton, and Wardlaw, 1998; Redhead et al., 1993; Nilsson et al., 1998) 
but depending on the preparation they can induce a mixed Thl/Th2 response (Ausiello et 
al., 1997; Ryan et al., 1997a; Ryan et al., 1998a; Di Tommaso et al., 1997). 
Cellular immunity is more recently being recognised as an important mechanism of 
protection, although it has been known for some time that macrophage activity is 
associated with B. pertussis infection (Cheers and Gray, 1969) and that B. pertussis can 
survive within human macrophages (Cheers and Gray, 1969; Masure, 1993; Bromberg, 
Tannis, and Steiner, 1991; Ewanowich et al., 1989). Experiments have shown correlation 
between protection and various cell-mediated responses. One study reported that the least 
severe clinical symptoms of school children infected with B. pertussis correlated with 
good in vitro proliferative responses of their peripheral blood mononuclear cells when 
induced by PT, FHA and/or pertactin (Tran Minh et al., 1999). Also, the induction of 
Thl-mediated cellular immune responses such as interferon (IFN)-gamma and interleukin 
(IL)-2 has been shown to be essential for protection against B. pertussis infection 
(Redhead et al., 1993; Mahon et al., 1997). Infection with B. pertussis or inoculation with 
the whole cell vaccine has been shown to preferentially induce these Thl type responses 
(Ryan et al., 1997b; Ausiello et al., 1997; Mahon et al., 1996). 
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Adjuvant activity 
Introduction 
PT is not only a protective immunogen, but also has potent adjuvant activity. This 
phenomenon was originally observed as the enhancement of local and systemic antibody 
responses, including IgE, IgA and IgG, to antigens co-administered with native PT 
(Greenberg and Fleming, 1947; Munoz and Bergman, 1977; Munoz et al., 1981; Munoz 
and Peacock, 1990; Roberts et al., 1995). Native PT has also been shown to enhance 
protection against IC and aerosol challenge with B. pertussis when co-administered in 
small amounts with other B. pertussis antigens (Robinson and Irons, 1983; Xing, 
Canthaboo, and Corbel, 2000). Furthermore, this protection has been shown to correlate 
with an increase in nitric oxide production by macrophages, an indication of macrophage 
activation (Xing, Canthaboo, and Corbel, 2000). In addition, it has been demonstrated 
that PT potentiates both Thl and Th2 murine responses to co-injected antigen by causing 
an increase in IL-2, IFN-gamma, IL-5, IL-4, IgGI and IgG2a production and in the 
proliferative response of spleen cells (Ryan et al., 1998b). 
The mechanism of the immunopotentiating action of PT is not yet fully understood, but 
the available data suggest that the A and B-domains have distinct effects. In one 
experiment, both native PT and catalytically inactive mutant PT (5 µg/dose) were shown 
to have adjuvant activity, as demonstrated by the enhanced stimulation of Thl and Th2 
cytokines in mice (Ryan eta!., 1998b). Two other studies in mice showed that a much 
smaller amount of native PT (0.12 or 0.2 µg/dose) stimulated an enhanced cytokine 
response (Shive et al., 2000), nitric oxide production by macrophages, and protection 
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(Xing, Canthaboo, and Corbel, 2000), but that the same quantity of the isolated B- 
oligomer, or mutant PT, caused considerably less enhancement. 
Immune epitopes 
Many studies of the T- and B-cell epitopes of PT have been carried out. Details of the PT 
subunit amino acid sequences that have been identified as T- or B-cell antigenic regions 
are presented (Table 1.1). 
Protective B-cell epitopes are abundant on the PT molecule, exemplified by the abundant 
protective PT subunit-specific mAbs produced by Hiroko Sato and co-workers. They 
have identified a total of 32 mAbs specific for epitopes on PT subunits Si - S5. (Sato, 
Sato, and Ohishi, 1991; Sato et al., 1984). Of these, the 1 B7 mAb specific for an epitope 
on the Si subunit, contained within residues 8- 15 (Table 1.1), has proved to be the most 
protective (Cieplak et al., 1988; Sato, Sato, and Ohishi, 1991; Sato et al., 1984; Sato and 
Sato, 1990). Some B-cell epitopes may be discontinuous or conformational, or both, and 
therefore difficult to map by mAb screening of linear peptides, as was found for epitopes 
of the S4 subunit (Ibsen et al., 1993). 
Human T-cell antigenic regions of Si and S4, and mouse T-cell antigenic regions of S3 
and S4 have also been identified, by studying T-cell proliferative responses to synthetic 
peptides or recombinant subunit fragments (Table 1.1). Within the human T-cell 
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Table 1.1 Antigenic sequences of PT 
A summary of published studies, identifying T- and B-cell antigenic sites on the pertussis 
toxin (PT) molecule. 
PT Amino acid Epitope type Experimental details Reference 
Subunit sequence 
SI 8-15 1 B7 mouse First 30 amino acids (Sato eta!., 
antibody progressively truncated; blots 1984a) 
binding region probed with 1B7 
Si 1-42 T-cell antigenic T-cell proliferation using a (de Magistris 
181-211 regions (human) series of recombinant et a1., 1989; 
212-235 truncated fragments; 
Peppoloni et 
computer analysis 
a1., 1995) 
Si Leu33 and DR1 binding Peptide containing amino (de Magistris 
Leu36 acids 30-42 and alanine- eta!., 1992) 
substituted analogues 
Asp34, T-cell receptor screened for DR1 binding and 
His35, recognition T-cell proliferation 
Thr37 and (human) 
Ar 39 
S3 18-41 T-cell antigenic Synthetic peptides induced (Chong eta!., 
78-108 regions (mouse) T-cell proliferation 1992) 
134-154 
149-176 
S4 1-15 T-cell antigenic Proliferation assays using (Petersen et 
21-45 sites (human) synthetic peptides al., 1992) 
41-65 
S4 21-45 T-cell antigenic Proliferation assays using (Petersen et 
72-88 sites (mouse) synthetic peptides a!., 1993) 
93-106 
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antigenic region encompassing residues 1- 42 of the Si subunit (de Magistris et al., 
1989), specific residues required for interaction with the major histocomptibility (MHC) 
molecule, DR1, (Leu-33 and Leu-36) and for specific T-cell receptor recognition (Asp- 
34, His-35, Thr-37 and Arg-39) have been identified using alanine-substituted analogues 
of subunit peptides (de Magistris et al., 1992). In support of these results, computer 
algorithms designed to identify T-cell binding determinants, selected Si residues 31 - 34 
(de Magistris et al., 1992) as a T-cell-binding consensus motif (Rothbard and Taylor, 
1988). Furthermore, Si residues 26 - 42 were predicted to form an amphipatic helix 
common to T-cell binding sequences (Margalit et al., 1987). On the B-oligomer, 
particularly noteworthy is the epitope on the S4 subunit (residues 21 - 45) which was 
identified as a T-cell antigenic region in both mice and humans (Petersen et al., 1993; 
Petersen et al., 1992). 
Antigenic variation of PT 
It has identified that specific amino acid differences beween known Si variants, A (Asp- 
34) and D (Glu-34) and beween A (Ile-194) and B (Met-194), lie within T-cell epitopes 
in the Si subunit (Mooi et al., 1998). It has been speculated that such antigenic 
differences between vaccine strains of B. pertussis and those circulating in the population 
may make for a less effective pertussis vaccine, and that this was partly the cause of the 
re-emergence of pertussis in The Netherlands (Mooi et al., 1998). This group has 
postulated that it may be important for the efficacy of acellular vaccines, which are based 
on a few purified antigens, to ensure the antigen type in the vaccine matches the 
circulating antigen type. However, this issue is yet unresolved. 
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1.6 Effect of toxoiding on PT 
1.6.1 Genetic detoxification 
Introduction 
Unlike wild-type PT, the genetically detoxified PT (PT-9K/129G) used in the Chiron- 
Biocine acellular pertussis vaccine, is devoid of ADP-ribosyl transferase activity. Thus, 
PT-9K/129G cannot induce CHO-cell toxicity, leukocytosis, hyperinsulinemia or 
histamine sensitivity (Nencioni et al., 1990). However, PT-9K/129G has an SDS-PAGE 
pattern indistinguishable from wild-type PT (Nencioni et al., 1990). Also comparable 
with wild-type PT, are its T-cell mitogenic activity, haemagglutinating activity and 
affinity for PT-specific polyclonal antibodies and the protective monoclonal antibody 
(mAb) 1B7 (Nencioni et al., 1990). PT-9K/129G can also protect mice in a dose- 
dependent fashion against IC challenge with B. pertussis (Nencioni et al., 1990). Chiron- 
Biocine have reported that they stabilise the mutant PT with 0.035 % (w/v) FA 
(Rappuoli, 1994). 
1.6.2 Chemical detoxification 
A variety of chemicals, notably glutaraldehyde, tetranitromethane, hydrogen peroxide, 
and FA are used by different manufacturers to toxoid the PT component of their DTP 
vaccine (Edwards et al., 1995; Siber et al., 1991). With the exception of FA, there have 
been few studies on the effects of these chemicals on PT, and to date they have focused 
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on PT-specific murine antibody responses, and mAb binding to PT epitopes. One study 
showed that DPT vaccines containing PT detoxified with glutaraldehyde, 
tetranitromethane or FA, or containing PT-9K/129G stabilised with 0.035 % FA, induced 
good PT-specific antibody responses in mice, relative to the DTP vaccine containing the 
whole cell pertussis component. The order of this antibody response to the different DTP 
vaccines (referred to by PT toxoid), from highest to lowest was: FA-stabilised PT- 
9K/129G, gluteraldehyde-treated PT, whole cell B. pertussis, FA-treated PT, 
tetranitromethane-treated PT (Edwards et al., 1995). Another study has shown that 
hydrogen peroxide and FA cause a reduction in PT epitopes, as determined by PT- 
neutralising murine mAb binding (Ibsen, 1996). It has also been demonstrated that 
glutaraldehyde treatment reduces the toxicity of crude PT preparations more effectively 
than FA, as determined by histamine sensitisation, CHO-cell toxicity assay and IC 
challenge, (Gupta et al., 1990; Gupta et al., 1991). The effect of glutaraldehyde on the 
neutralising capacity of anti-PT serum was also found to be less damaging than FA 
(Gupta et al., 1991). The effects of these chemicals on the structural properties of PT and 
a full comparison of antigenic and protective properties of the non-combined PT toxoids 
have not yet been investigated. 
1.6.3 FA-treatment 
The effects of FA on properties of PT have been more extensively analysed than the 
effects of the other toxoiding chemicals. In addition, the chemistry of FA reactions with 
amino acids has been studied (Tome and Naulet, 1981; Tome, Kozlowski, and Mabon, 
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1985; Walker, 1964; Feeney, Blankenhorn, and Dixon, 1975; Means and Feeney, 1968). 
FA was employed as the PT toxoiding agent in the first acellular pertussis vaccine 
developed in Japan, and is still used world-wide to toxoid PT and in lower concentrations 
to stabilise PT-9K/129G (Edwards et al., 1995; Sato, Kimura, and Fukumi, 1984; 
Nencioni et al., 1991). The Japanese DTP vaccine containing the PT toxoid was tested for 
residual biological activities of PT using leukocyte proliferation and histamine 
sensitisation tests (Sato, Kimura, and Fukumi, 1984). More direct studies were performed 
using a partially purified native PT preparation to assess the effect of FA on PT toxic 
properties and anti-PT neutralising antibodies (Gupta et al., 1991). Studies on the effects 
of FA on PT-9K/129G have involved more detailed analysis on biological and 
immunological properties of the antigen (Nencioni et al., 1991). Preliminary structural 
studies on the effects of FA on PT-9K/129G and native PT have also been undertaken 
(Nencioni et al., 1991; Bolgiano et al., 1999). 
1.6.3.1 Chemistry of FA reaction with amino acids 
FA reacts with groups containing a reactive hydrogen atom (nucleophile) to form a 
reactive hydroxymethyl compound, which may undergo a condensation reaction with 
another nucleophile to produce a methylene bridge (Walker, 1964; Tome and Naulet, 
1981). In proteins, lysine is one of the most reactive amino acids with FA (Tome, 
Kozlowski, and Mabon, 1985). The first stage in the reaction is the hydroxymethylation 
of the c-amino group of lysine, which is rapid and reversible (Feeney, Blankenhorn, and 
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Dixon, 1975; Means and Feeney, 1968) and then a slow condensation reaction proceeds 
with another amino acid side-chain to form a methylene bridge (Tome, Kozlowski, and 
Mabon, 1985). Methylene bridges and other FA-induced amino acid modifications have 
been detected in FA-treated bovine serum albumin using NMR spectroscopy (Tome, 
Kozlowski, and Mabon, 1985). 
Lysine is added to the reaction mixture during FA-treatment of PT and PT-9K/129G, for 
the production of vaccine toxoids, and in the production of experimental toxoids in this 
study. In the absence of added lysine, extensive denaturation, aggregation and 
precipitation occurs presumably due to extensive inter- and intra-molecular bridging 
(Petre et al., 1996). The amino acid additives serve to quench the massive denaturing 
effects of FA by creating active lysine species, which can then specifically react with 
amino acid side chains in a slower controlled reaction. The reaction of FA with free 
lysine most readily occurs with lysine at the c-amino group of the side-chain, since the a- 
amino group is usually unreactive under the conditions of the reaction (Tome and Naulet, 
1981). 
1.6.3.2 Biological and Immunological properties of FA-treated PT 
FA-treated native PT antigen was developed as a component of the first acelluar vaccine 
in Japan, in the early 1980's (Sato, Kimura, and Fukumi, 1984), and is still used in 
current acellular vaccines. In the Japanese acellular vaccine PT is treated with increasing 
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amounts of FA every 3 days to a final concentration of 0.4 % (w/v) FA at 37 °C and 
incubated further for an unspecified number of days (Sato, Kimura, and Fukumi, 1984). 
However, the effect of FA on PT has not been examined. The FA-treated PT component 
has not been examined individually, but the DTP vaccine containing the acellular 
pertussis component was compared with the DTP vaccine containing whole-cell 
pertussis. The DTP vaccine containing the acellular pertussis component was shown to be 
as protective as the conventional Japanese whole cell vaccine as determined by IC 
challenge, and had one-tenth of the toxicity of the whole cell vaccine as determined by 
mouse-body-weight-decreasing activity, leucocyte-promoting activity and histamine- 
sensitising assays. The Japanese PT toxoid has been used to immunise mice, for the 
production of hybridomas to generate mAbs. Some of these mAbs were found to 
recognise native PT epitopes. They also protected mice against B. pertussis by both IC 
and aerosol challenge (Sato et al., 1984; Sato and Sato, 1984; Sato and Sato, 1990; Sato 
et al., 1987; Sato, Sato, and Ohishi, 1991). 
Another group analysed the effect of FA on partially purified PT preparations treated 
with up to 0.2 % FA, at 37 °C for 24 hours (Gupta et al., 1991). These samples exhibited 
a decrease in CHO-cell toxicity, leukocytosis activity and histamine sensitising activity. 
However, residual activity was still present even with 0.2 % FA-treatment and the 
preparations did not pass the mouse weight gain test. These preparations also 
demonstrated a decrease in the induction of PT neutralising antibodies with FA- 
treatment. Studies on the FA-treatment of PT-9K/129G were more detailed and focused 
on specific changes in antigenic properties. The effects of FA on the genetic mutant PT- 
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9K/129G have been investigated, in view of using FA as a stabilising agent, since without 
FA treatment this antigen and other purified B. pertussis antigens were unstable and 
subject to degradation (Petre et al., 1996). 
PT-9K/129G is devoid of toxic biological properties, dependent on the SI catalytic 
activity, but retains biological activities associated with the B-oligomer as well as 
protective and antigenic properties. Studies were carried out on PT-9K/129G, which had 
been treated with various concentrations of FA, up to 0.42 % (w/v), at 37 °C for 48 hours. 
At low concentrations of FA, up to about 0.05 % (w/v), mitogenic and haemagglutinating 
activities, as well as PT-specific polyclonal antibody affinity, were comparable with 
untreated PT-9K/129G (Nencioni et al., 1991). With the highest FA-treatment, mitogenic 
and haemagglutinating activities were almost totally eliminated and antibody-binding 
affinities declined, although recognition of PT-9K/129G by human T-cell clones was not 
affected. Another study showed that much larger concentrations of FA, 3.5 % FA (w/v), 
constrained the presentation of PT-9K/129G T-cell epitopes on S4, and promoted the 
presentation of epitopes on S1, S2 and S3 (Di Tommaso et al., 1994). 
1.6.3.3 Physico-chemical properties of FA-treated PT 
There is evidence that commercial PT toxoids, including FA-treated PT9K/129G and FA- 
treated native PT, contain higher molecular weight species than untreated PT. These 
toxoids displayed the typical SDS-PAGE band pattern of untreated PT, but with 
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additional higher molecular weight bands (Bolgiano et al., 1999; Nencioni et al., 1991). 
Moreover, in Western blotting the Si subunit of PT-9K/129G appeared in a higher 
molecular weight band after FA treatment. It was also shown to produce earlier eluting 
species in size exclusion chromatography (SEC) (Ceccarini et al., 2000). In addition, the 
commercially toxoided native PT produced a modified intrinsic fluorescence 
spectroscopy spectrum (Bolgiano et al., 1999). The structural nature of these different 
forms of PT produced by FA treatment has not been explored nor their sizes confirmed, 
and the effect of FA on PT conformation has not been clarified. 
There is little understanding of the effect of the different toxoiding procedures on 
secondary, tertiary and quaternary protein structure. Furthermore, no attempt has yet been 
made to associate any of the molecular forms of PT, which may arise with toxoiding, 
with antigenicity or immunological responses. A thorough understanding of the 
molecular forms produced from toxoiding is a necessary prelude to determining the roles 
of these molecules forms in directing the immune response. In addition, guidelines by the 
World Health Organisation have emphasised the importance of physicochemical in 
addition to immunogenicity testing for the standardisation of pertussis vaccines 
(Arciniega et al., 1998). The advantages of establishing molecular correlates of 
immunogenicity or protection also extend to the development of in vitro assays as 
alternatives to the use of animals. Determining how the physico-chemical nature of PT 
toxoids relate to their antigenic and protective properties will drive the development of 
better-defined and potentially more immunogenic pertussis vaccines. 
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1.7 Thesis format 
Introduction 
Following the general introduction (Chapter 1) is the Materials and Methods section 
(Chapter 2) which describes the experiments of the entire thesis, and is divided up by 
experiment type. Five Results chapters follow this, each including a specific introduction 
and summation. The final chapter is an overall discussion including a general review of 
the data and a discussion of their implications in the context of the thesis. 
Chapter 1 Introduction 
The Introduction is a general assessment of the background work 
explaining the context and the overall aims of the thesis. 
Chapter 2 Materials and Methods 
This Chapter covers the materials and methods for all of the experiments 
described in the thesis. 
Chapter 3 Effect of `activation' and NAD+binding on the structure of the Si 
subunit of PT 
The effect of `activation' (by cleavage of disulphide bond Cys-41 - Cys- 
201) and NAD+ binding on the PT structure were studied using intrinsic 
fluorescence spectroscopy. Computer modelling of PT was carried out to 
generate an NAD+-bound model of PT and the results compared with 
those from fluorescence spectroscopy. 
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Chapter 4 Effect of chemical toxoiding on PT structure, epitopes and murine 
immune response 
Different commercial PT toxoids, which include the FA-stabilised mutant 
PT and those which are produced by treatment with different chemicals, 
were analysed for structural changes using SDS-PAGE, size exclusion 
chromatography (SEC) and fluorescence spectroscopy. Immunological 
changes were analysed by immunoblotting and ELISA, using subunit- 
specific mAbs. In addition, PT-specific murine IgG antibodies raised 
against each PT preparation were quantified and the protective efficacy of 
each preparation was also investigated using an aerosol challenge assay. 
Chapter 5 Effect of FA on the molecular structure of PT 
The structure of native PT and mutant PT samples before and after 
treatment with a range of FA concentrations, covering the concentrations 
employed in commercial pertussis vaccines, was analysed using SDS- 
PAGE, SEC, circular dichroism, analytical ultracentrifugation (AUC) and 
SEC multi-angle laser light scattering (SEC/MALLS). The effects of FA 
on protein conformation were explored using fluorescence spectroscopy. 
Chapter 6 Effect of FA on PT epitopes and murine anti-PT immune response 
The antigenic properties of FA-treated native and mutant PT were 
analysed by assessing the binding of a panel of mAbs to the samples by 
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ELISA and SDS-PAGE. FA-treated native PT and mutant PT samples 
were also used to immunise mice, and total IgG and IgG subclasses in the 
sera were quantified, as well as the serum neutralising capacity for PT 
using CHO-cells. 
Chapter 7 Effect of FA on toxic biological activities of native PT 
The toxic activity of the FA-treated native PT preparations was measured 
by four methods, namely ADP-ribosylation assay, CHO-cell neutralisation 
assay, leukocyte proliferation assay and histamine sensitisation assay. 
Chapter 8 Discussion 
A summary and discussion of the main results. 
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2.1 General Materials 
PBS: The phosphate buffered saline (PBS) used consisted of 137 mM NaCl, 2.7 mM 
KC1,1.5 mM KH2PO4 and 8 mM Na2HPO4, (Ana1R reagents; BDH, Poole, Dorset, UK), 
pH 7.5, unless otherwise stated. 
De-ionised water: All water used in experiments, for making solutions and buffers for 
samples, chromatography and dialysis, was de-ionised by ultra-violet (UV) radiation 
using an ELGA water purification system (ESF-ELGA, Buckinghamshire, UK), to a 
resistivity quality of 18.2 M)-cm. 
Dialysis: SpectraPor7 dialysis tubing (regenerated cellulose, I mUcm, molecular weight 
cut-off 3000 Da; Pierce and Warriner, Essex, UK), closed with SpectraPor dialysis 
tubing-clips, was used in all dialysis procedures. 
Volume measurements: All volumes less than 5 mL were measured using Gilson 
pipettes, or multi-channel pipettes in 96-well plate assays where appropriate. Volumes 
greater than 5 mL were measured using plastic pipettes using an electric pipette filler. 
Large buffer volumes were measured in measuring cylinders. Percentage solute 
concentrations, including formaldehyde concentrations, were measured as weight by 
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volume (w/v) unless stated otherwise. 
2.2 PT preparations 
2.2.1 Commercial PT 
Materials and methods 
Untreated PT and PT toxoids from five different manufacturers (A - E) were analysed 
using structural and immunological methods, in the study of the effect of different 
chemicals on PT (Chapter 4). 
Untreated PT received from different manufacturers (A - E) 
A. This PT sample was a genetically inactivated PT, which had a double amino acid 
substitution in the Si subunit, Arg-9 --f Lys and Glu-129 -)º Gly (PT-9K/129G) 
(Nencioni et al., 1990), and is referred to herein as `mutant PT'. The sample was received 
from the manufacturer, at a protein concentration of 100 pg/ml in 50 mL volumes. It was 
sterilely aliquoted into 2 mL volumes in 2 mL plastic cryo-tubes, and stored at -20 °C, in 
0.5 %, trehalose (crystalline (D+)trehalose dihydrate, Sigma), by adding 0.2 mL of a 50 
%, trehalose stock solution to 1.8 mL PT solution, in PBS, and used within three years of 
receipt. 
B. This PT sample was received from the manufacturer at a protein concentration of 
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191 µg/mL, in 5.8 mM NaH2PO4i 59.6 mM K2HPO4,500 mM NaCl, at 4 °C, in 4 mL 
aliquots in 5 mL polypropylene screw-cap tubes. Analysis of the sample was within five 
years. 
C. This PT sample was received from the manufacturer at a protein concentration of 
200 µg/ml,, in glycerol stabiliser (final concentration, 50 %, v/v), at -20 °C, in 2 mL 
aliquots in 2 mL plastic cryo-tubes. Analysis of this sample was within three years. 
D. This PT sample was received from the manufacturer at a protein concentration of 
200 µg/mL, in 50 mM Tris, 500 mM NaCl, 0.01 M glycine and glycerol stabiliser (final 
concentration, 50 %, v/v), at 4 °C, in 2 mL aliquots in 2 mL plastic cryo-tubes. Analysis 
of this sample was within three years. 
E. This PT sample was received from the manufacturer at a protein concentration of 
221 µg/mL, as an ammonium sulphate suspension, at -20 °C, in 2 mL aliquots in plastic 
cryo-tubes. Analysis of this sample was within three years. 
Toxoids prepared by different chemical treatments 
A. Low FA-treated mutant PT: The mutant PT was prepared for commercial use by 
treatment with a low concentration of FA (0.035 % (w/v); (Nencioni et al., 1991)). It was 
received from the manufacturer in a 50 mL-volume, at a concentration of 
200 µg/mL, and stored under the same conditions as the untreated mutant PT, but without 
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trehalose. 
Materials and methods 
B. Glutaraldehyde and formaldehyde-treated PT: This sample was received from the 
manufacturer at a concentration of 483 gg/mL, in 150 mM NaCl, at 4 °C, in 4 mL 
aliquots in 5 mL polypropylene screw cap tubes. Analysis of this sample was within five 
years. 
C. Glutaraldehyde-treated PT: "This sample was received from the manufacturer at a 
protein concentration of 71 µg/mL and under the same conditions as the untreated PT. 
D. Tetranitromethane-treated PT: This sample was received from the manufacturer at 
a protein concentration of 300 µg/mL and under the same conditions as the untreated PT. 
E. Hydrogen peroxide-treated PT: This sample was received from the manufacturer at 
a protein concentration of 225 µg/mL, in glycerol (final concentration, 10 %, v/v) 
stabiliser, at -20 °C, in 2 mL aliquots in 2 mL plastic cryo-tubes. Analysis of this sample 
was within 3 years. 
All untreated PT and toxoided PT preparations, from the different manufacturers (A - E) 
were dialysed (section 2.2.4) in PBS before any analysis and kept on ice during 
experiments. The different toxoids are referred to herein as toxoids A-E. 
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2.2.2. Native and mutant PT: For FA studies, and NAD+binding 
studies 
The effect of FA on native and mutant PT was studied using physico-chemical methods 
(described in Chapter 5), and immunological techniques (described in Chapter 6). Mutant 
PT and native PT were also used to study the NAD+ binding properties of PT using 
intrinsic fluorescence spectroscopy, (described in Chapter 3). 
Native PT 
This PT is the only sample referred to as `native PT' throughout the study. Native PT was 
received from manufacturer D at a protein concentration of 200 gg/mL, with glycerol 
stabiliser (final concentration, 50 %, v/v), in sterile 1 mL aliquots, in I mL-glass 
ampoules. This sample was stored at 4 °C and used within 5 months, or was stored at 
-20 °C and used within 1 year. 
Mutant PT 
Untreated mutant PT was from manufacturer A, (described in section 2.2.1). Newly 
received sample was stored at 4 °C and used within 1 year of receipt; or stored at -20 °C 
(as described in section 2.2.1). 
The mutant and native PT samples, stored at either 4 °C or at -20 °C, were dialysed 
(section 2.2.4) in PBS, and checked for consistency with previous analytical results by 
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SEC (section 2.3.4) and fluorescence spectroscopy (section 2.3.8) before each analysis or 
FA-treatment. All PT samples were kept on ice during experiments. 
2.2.3 FA-treatment of native and mutant PT 
Mutant and native PT were treated with a range of formaldehyde (FA) concentrations, up 
to 1.0 % (w/v), which covers the range of FA concentrations used in the treatment of 
commercial PT antigens (Sato, Kimura, and Fukumi, 1984; Nencioni et al., 1991). Within 
this range two groups of PT preparations, low and high FA-treated, were produced. The 
low FA-treatment, 0-0.5 %, involved a short incubation time of 48 hours, as used in the 
stabilising of mutant PT. The high FA-treatment, 0.25 -1.00 %, involved a longer seven- 
day incubation time, as employed by some manufacturers in native PT detoxification 
(Sato, Kimura, and Fukumi, 1984; Petre et al., 1996). 
Low FA-treated mutant PT samples were used in the majority of the physico-chemical 
studies (Chapter 5) and in the in vitro immunological studies, (Chapter 6). The high FA- 
treated native and mutant PT samples were compared using physico-chemical studies 
(Chapter 5). They were also used in the murine in vivo immunological studies, designed 
to examine the immune response to the PT preparations, (Chapter 6). Low FA-treated 
native PT could not be used in mice due to its high toxicity. 
Lysine was present as a quencher in the reaction mixture during FA-treatment. The lysine 
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prevents excessive non-specific FA damage to the protein by producing the reactive 
lysine intermediate, hydroxymethyl lysine, which reacts with amino acid side chains 
(Petre et al., 1996; Tome and Naulet, 1981; Tome, Kozlowski, and Mabon, 1985; 
Means. G. E. and Feeney. R. E., 1971a). In this study the concentrations of lysine were 
chosen in order that lysine was in molar excess of FA. This is the case for all of the 
preparations with the exception of the low FA-treated 0.5 % FA-treated sample. 
Low FA-treated PT: The reaction mixture (2 mL final volume) consisted of 0.5 µM PT 
CAO'lý/°zsonm= 0.06), 0.05 M lysine (400 µL of 0.25 M stock; L-lysine, free base, Sigma , 
Poole, Dorset, UK), and 0,0.035,0.01,0.05,0.1 or 0.5 % FA (from formalin (37 %, w/v, 
formaldehyde) ACS reagent; Sigma) in PBS, pH 7.5 and were incubated at 37 °C for 48 
hrs. 
High FA-treated PT: The reaction mixture in PBS (2 mL final volume) consisted of 
1 µM PT (A280 nm = 0.12), 0.35 M lysine (0.383 g dissolved in the reaction mixture) and 
0.25,0.5,0.7 or 1.0 % (w/v) FA, and was incubated at 37 °C for 7 days. 
Reaction mixtures were prepared in 2 mL plastic cryo-tubes by first adding lysine to the 
PT then the FA and PBS and were mixed once gently, before incubation at 37 °C. 
Immediately after incubation, the FA-treatment samples were dialysed (section 2.2.4) 
extensively to remove the highly absorbing hydroxymethylated lysine and any other 
solution adducts. 
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2.2.4 Dialysis of PT samples 
Materials and methods 
The azide preservative was washed off the dialysis tubing by immersing in deionised 
water for 5 minutes and then rinsing with deionised water. Samples were transferred from 
the storage vials to the dialysis tubing using a glass Pasteur pipette and the ends of the 
tubing turned over before clipping. To remove storage buffer from PT samples, before 
use in experiments, dialysis was performed in 3 changes of 2L of PBS, pH 7.5 at 4 °C, 
the second change over night, with constant stirring. To remove the highly absorbing 
solution adducts formed during FA-treatment, more extensive dialysis was performed in 
at least 3 changes of 4L of PBS over 2-3 days, with constant stirring. 
2.2.5 Protein concentration technique 
Concentration of PT by Centricon-3 centrifuge concentration tubes (Amicon, 
Gloucestershire, UK) or vacuum dialysis gave poor recovery of protein. Newly dialysed 
PT samples were successfully concentrated by covering the sealed, sample-filled dialysis 
tubing with a sucrose polymer, Ficoll (Type 400-DL, Sigma), and leaving it to draw out 
the liquid. The sample-filled dialysis tubing was placed on a clean tray, covered to a 
depth of 0.5 cm with Ficoll and left at 4 °C. Ficoll was replenished every hour until the 
required volume reduction was achieved. This technique reduced the sample volume by 
1 mL every hour and gave - 90 % recovery. 
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2.2.6 Determination of protein concentration 
2.2.6.1 UV absorbance 
This technique was used routinely to check the concentration of PT preparations before 
analysis. PT samples were dialysed (section 2.2.4) in PBS, centrifuged in 1.5 mL plastic 
o-ring tubes (Sarsdedt, Leicester, UK) for 10 minutes at 13 000 rpm in a Sanyo-Micro 
Centaur microcentrifuge, (Sanyo, Illinois, USA) and the supernatant carefully taken off, 
with a Pasteur pipette, for protein determination. Absorbance spectra of PT samples were 
recorded between 190 nm and 370 nm with the PBS dialysate as the blank, in matching 
1cm path-length 1 mL quartz cuvettes (Hellma, Essex, UK), using a Cecil 6000 Series 
spectrophotometer. The maximal absorbance, which ranged between 271 nm and 280 nm 
for the different PT preparations, was recorded and used in equation (1) to calculate the 
protein concentration. According to the Beer-Lambert law the concentration, c (M), of a 
substance can be determined from the maximal absorbance, A, the path-length, d (cm), 
and the calculated molar absorption co-efficient, Eat maximal absorbance (Mach, 
Middaugh, and Lewis, 1992) which for PT is 126502 M'' cm'. Following FA-treatment, 
the highly absorbing lysine-FA intermediate (hydroxymethylated lysine A, abs) 
210 - 220 nm) interfered with the protein absorbance band. Therefore preparations were 
extensively dialysed (section 2.2.4) to remove as much of this adduct as possible for 
accurate protein determination. 
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2.2.6.2 Bicinchoninic acid (BCA) assay 
Materials and methods 
(1) 
The BCA assay was carried out to check for consistency with the UV absorbance method. 
Protein concentrations were determined for eight different preparations: untreated mutant 
PT (section 2.2.2), four FA-treated mutant PT samples (Low FA-treated, section 2.2.3) 
and commercial PT samples B, C and D (section 2.2.1) with concentrations in the range 
20 to 100 µg/mL'1. Results agreed very well (± 2.5 µg/mL'1) with absorbance-determined 
values. 
The Micro BCA Protein Assay Reagent Kit (Pierce and Warriner, Essex, UK) was used. 
Full instructions for preparation of the standard protein, bovine serum albumin (BSA), 
and BCA working reagent are described in the kit instructions. In brief, dilutions (0 - 
200 µg/mL) of the BSA standard protein solution were made in PBS, and 150 µL of each 
BSA dilution, PT sample or PBS (blank) were pipetted into wells of a 96-well microtitre 
plate (Falcon). The working reagent (150 µL) was added to each well and the plate was 
covered, mixed on a plate shaker for 30 seconds and incubated at 37 °C for 2 hours. The 
absorbance at 570 run was recorded, and the protein values corrected by subtracting the 
average blank value. A standard curve was prepared by plotting the corrected absorbance 
reading for each BSA standard against its concentration (µg/mL), and used to determine 
the protein concentrations of the PT samples. 
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2.3 Structural techniques 
Materials and methods 
2.3.1 Computer molecular modelling of the Si subunit of PT 
Three different models of the Si subunit of PT were generated: non-modified, `activated' 
and `activated' with NAD+-bound. 
2.3.1.1 Retrieving and visualising the S1 subunit model 
The X-ray crystal structure of PT used in the molecular simulations, was obtained from 
the Research Collaboratory for Structural Bioinformatics, Protein Data Bank (RCSB, 
PDB) ((Berman et al., 2000); http: //www. resb. orp/ndb/. ), PDB code: 1PRT (Stein et al., 
1994a). Visualisation and manipulation of the Si subunit of PT was performed using the 
insightlI programme (Molecular Simulations Inc, San Diego, California, see 
http: //www. accelrys. com) on a Silicon Graphics Octane workstation (SGI, Mountain 
View, California, USA). 
2.3.1.2 Molecular mechanics simulations 
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Energy minimisation calculations were carried out using the AMBER (Assisted Model 
Building with Energy Refinement) programme suite and forcefield (Cornell et al., 1995). 
The effect of solvent was modelled using a generalised Born approach (Srinivasan et al., 
1998). For `activation' and NAD+ docking, energy minimisation calculations were 
typically carried out using 500 steps of steepest descent before switching to a conjugate 
gradient method. 
Activation 
With the AMBER modelling programme, a neutral cysteine not involved in a disulphide 
bond is denoted by the residue name CYS. A cystine involved in a disulphide bond is 
denoted by the residue name CYX. Hence `activated' PT, in which the Cys-41 - Cys-201 
disulphide bond is broken, was modelled using the former residue name and non- 
`activated' PT using the latter. 
Docking of NAD+ 
Partial atomic charges for the nicotinamide ring of NAD+ were computed using the 
Jaguar quantum chemistry programme (Schrodinger Inc, Portland, Oregon, USA), 
following structure optimisation using a HF/6-31G* basis set. Partial atomic charges for 
other parts of the NAD+ molecule, and for the protein, were taken from those previously 
reported for known residues in AMBER (Cornell et al., 1995). 
Docking of NAD+ to PT (with Cys4l-Cys201 cleaved) was carried out on the basis that 
PT and diphtheria toxin (DT) share five homologous residues in their putative catalytic 
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sites (Stein et al., 1994a), together with the existence of an X-ray crystal structure for the 
DT-NAD+ complex (PDB ID: 1TOX; Bell and Eisenberg, 1996). An initial attempt was 
made to position NAD+ in the active site of PT by superimposing DT-NAD+ on PT using 
Ca atom coordinates of homologous amino acids. However, this led to part of a PT a- 
helix (amino acids 185 - 210) penetrating the ribose ring of the NAD+, which is a 
physically unrealistic artefact. 
A minimisation scheme to dock NAD+ into the PT catalytic site was therefore adopted, 
which allowed flexibility in both the protein and NAD+ molecules. A locally developed 
programme was used to find all atom-atom distances of less than 15A between the Ca 
atoms of the five conserved residues in DT and non-hydrogen atoms of NAD+, in the 
crystal structure of the complex. These distances were used to obtain distance restraints 
between the NAD+ atoms and the Ca atoms of the corresponding five conserved residues 
in PT. A total of 151 distance restraints were generated by this procedure. The restrained 
minimisation calculation was started from several different initial locations for the NAD+. 
The initial location giving the best agreement with the restraints was then used for any 
subsequent calculations. 
Analysis of models 
For all three Si models, the dihedral bond angles, 4 (defined by atoms N' -C- Ca - N), 
yr (defined by atoms C- Ca -N- C') and X1 (defined by atoms N- Ca - Cß - Cy etc) 
were measured for each residue using insightII. In addition, the relative percentage 
solvent accessibility of each amino acid side chain (relative to X-Gly-X) was determined 
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using the NACCESS programme (Hubbard and Thornton, 1993). The degrees of rotation 
of each dihedral bond angle, and the change in amino acid accessibility were calculated 
after `activation' and after NAD+ binding to `activated' PT. 
2.3.2 Reduction of PT and detection of free sulphydryls 
The number of free sulphydryls liberated with chemical reduction of mutant PT (section 
2.2.2), was determined based on the method of A. Habeeb (Habeeb, 1972). Ellman's 
reagent (5,5'-dithiobis(2-nitrobenzoic acid) or DTNB; Sigma) liberates 1 mole of 2-nitro- 
5-thiobenzoate (c = 14150 M"1cm 1,412 nm, in non-denaturing solution) from reaction 
with one mole of protein sulphydryl. The absorption, at 412 nm, of reduced PT in the 
presence of DTNB was measured to determine the number of disulphide bonds broken 
during reduction. Incubation of PT with a ten-times molar excess (260 PM) of 
dithiothrietol (DL-dithiothrietol (DTT), Sigma) at 4 °C overnight did not liberate any free 
sulphydryls, but the following more rigorous treatment with 4000 molar excess DTT was 
successful. 
A reaction mixture (2 mL), with a final concentration of 90 µg/mL PT (1.8 mL, 100 
pg/mL PT) and 100 mM DTT (200 µL, IM stock) in PBS, pH 7.5, was incubated at room 
temperature for 2 hours in a2 mL plastic cryo-tube. DTT was removed by dialysis in 
three changes, one overnight, of 4L0.1 M phosphate buffer (5.3 mL, 0.2 M NaH2PO4 + 
94.7 mL 0.2 M Na2HPO4 in 200 mL deionised water), pH 8.0. To determine the number 
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of free sulphydryls formed as a result of disulphide bond reduction, DTNB at a final 
concentration of 260 µM (from 2.6 mM stock solution) in 0.1 M phosphate buffer, pH 7.0 
(39.0 mL, 0.2 M NaH2PO4 + 61.0 mL, 0.2 M Na2HPO4 in 200 mL deionised water) was 
added to I mL of the dialysed PT solution. Absorbance at 412 nm of the PT plus DTNB 
solution was measured after 15 minutes and checked again after 1 hour, against a blank 
solution containing 260 µM DTNB in dialysate buffer in matching 1 mL, 1 cm path- 
length Hellma cuvettes. The concentration of 2-nitro-5-thiobenzoate, and thus the 
concentration of free sulphydryls, was determined. 
2.3.3 SDS-PAGE 
Commercially detoxified PT samples, B, C and E (section 2.2.1), and mutant PT 
untreated and treated with 0.035,0.1 and 0.5 % FA (section 2.2.3), were separated by 
SDS-PAGE, prior to Coomassie blue staining (as described in this section) or to Western 
transfer for immunoblotting with Mabs (section 2.4.6.1). Identical untreated mutant PT 
samples (five per gel) were also separated for immunoblotting with anti-PT mouse sera, 
in order to probe subunit-specific antibodies (section 2.4.6.2). Gels, buffers, molecular 
weight markers and power pack were from Novex (Invitrogen Ltd, Paisley, Scotland, 
UK). 
Procedures for setting up, running and removing the gel were carried out as described in 
the Novex pre-cast gel instructions booklet. For sample preparation, concentrated Tris- 
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glycine SDS sample buffer (five-times concentrate) and water were added to each PT 
sample (>_ 200 pg/mL) to give a final mixture (40 µL) containing - 6.5 µg PT, 0.05 M 
tris-HCI, 10 % (v/v) glycerol, 2% SDS and 0.05 % bromophenol blue; plus 2% (v/v) 
T Enercaptoethanol for reducing gels. This mixture was heated in a 0.5 mL "O"-ring tube, 
at 80 °C, for 10 minutes and 37 µL of the mixture (5 -6 µg PT) was applied to a pre-cast 
14 % tris-glycine acrylamide 10 well, 1.5 mm thick gel. The samples were subjected to 
electrophoresis in tris-glycine SDS running buffer (ten-times concentrate, diluted in 
deionised water to 1L to give 0.29 % w/v tris base, 1.4 % w/v glycine and 0.1 % w/v 
SDS), at a constant 125 V for about 90 minutes with an initial current of 30-40 mA, 
decreasing to 8-12 mA at the end of the run. 
For protein detection by Coomassie blue staining, the gel was immersed in stain (0.125 % 
(v/v) Coomassie Blue R-250,50 % methanol and 10 % acetic acid in deionised water) 
and shaken for one hour. The gel was shaken in destain I, (50% methanol, 10 % acetic 
acid) for 1 hour then destain II (7 % acetic acid, 5% methanol) until the required colour 
contrast was obtained. Images of the gels were taken using a UVP (Ultra Violet Products, 
Cambridge, UK) camera in a UVP white/UV transilluminator cabinet and visualised 
using Labworks analysis software for Windows. 
Generally two molecular weight marker protein mixtures, Markl2TM (myosin, 200 kDa; 
beta galactosidase, 116.3 kDa; phosphorylase b, 97.4 kDa; bovine serum albumin, 
66.3 kDa; glutamic dehydrogenase, 55.4 kDa; lactate dehydrogenase, 36.5 kDa; carbonic 
anhydrase, 31 kDa; trypsin inhibitor, 21.5 kDa; lysozyme, 14.4 kDa; aprotinin, 6 kDa; 
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insulin B-chain, 3.5 kDa; insulin A-chain, 2.5 kDa) or MultiMark TM (myosin; 
phosphorylase B; glutamic dehydrogenase; carbonic anhydrase; myoglobin, 30 kDa; 
lysozyme, aprotinin, insulin), were run on each gel. For the immunoblotting experiment, 
designed to probe murine sera for PT antibodies (section 2.4.6.2), five markers were run 
on each gel, arranged in alternation with five identical reference PT runs. 
A standard curve was prepared, by plotting the molecular weights of the marker proteins 
against their relative mobility (distance of marker protein migration/distance of tracking 
dye migration), and used to estimate the relative protein molecular weights (Mr, kDa) of 
the PT protein bands. 
2.3.4 Size exclusion chromatography with ultra-violet absorbance 
detection (SEC/UV) 
Commercial toxoids, A-E (section 2.2.1), high and low FA-treated mutant and native 
PT samples (section 2.2.3) were analysed by FPLC and the molecular weights of eluting 
species were determined. This technique was also used to check mutant and native PT 
samples for consistency before each new experiment. In addition, SEC fractions were 
collected for fluorescence analysis. 
The FPLC system (Pharmacia, Milton Keynes, UK) consisted of twin pumps, an injection 
valve (3-port solenoid) fitted with a 200 µL loop and a Superdex 200 or Superdex 75 HR 
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10/30 gel filtration column, separation ranges 10 - 600 kDa and 3- 70 kDa, respectively. 
PT samples were prepared for SEC by centrifugation in plastic "O"-ring tubes using a 
Micro Centaur microcentrifuge, at 13 000 rpm for 10 mins. Untreated PT and 0.035,0.1 
or 0.5 % FA-treated PT samples (containing 16.5 µg PT in a 220 µL volume) were 
loaded on to the column and eluted at ambient temperature in PBS, at a flow rate of 
0.5 ml/min. Absorbance was monitored at 214 nm, using a zinc lamp, and 280 nm, using 
a mercury lamp, and the data were collected using FPLC Director software for OS/2. 
The columns were calibrated using tyrosine (D, L-tyrosine, Sigma) plus a mixture of 
proteins from the Sigma molecular weight marker kit (carbonic anhydrase, 29 kDa; 
bovine serum albumin, 66 kDa; alcohol dehydrogenase, 150 kDa; beta-amylase, 200 kDa; 
apoferritin, 443 kDa; thyroglobulin, 669 kDa; and Blue Dextran, - 2000 kDa). Small 
quantities of each marker protein were mixed together in deionised water, dissolved, spun 
in a microcentrifuge, the supernatant aliquoted into 250 µL volumes in 0.5 mL eppendorf 
tubes, stored at -20 °C and used within 1 year. A calibration run was performed before 
each FPLC experiment, and the spectra compared with previous runs to check for 
variation. Only SEC data run on the same day, or which had superimposable calibration 
spectra, were collated and presented. A standard curve was prepared, by plotting the 
relative molecular weights of the standard proteins against their elution volumes, and 
used to determine the molecular weights (kDa) of the eluting PT protein species. The 
exclusion volume was 8 mL and the total volume was 21 mL for both the Superdex 200 
and Superdex 75 columns. 
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2.3.4.1 SEC fractions 
Materials and methods 
Fractions of FA-treated mutant PT (0.5 mL) were collected in 1.0 mL eppendorf tubes 
using a Pharmacia fraction collector linked up to the FPLC software. Fractions of the 
same peak were pooled and fluorescence measurements taken (section 2.3.8). 
2.3.5 Size Exclusion Chromatography/ Multi-angle Laser Light 
Scattering (SECIMALLS) 
Mutant PT samples, treated with 0.03 5,0.05 and 0.1 % FA (section 2.2.3), were analysed 
by SEC/MALLS and the molecular weights of eluting species were determined. 
The HPLC system consisted of a Waters 590 Solvent Delivery Module (Waters, Watford, 
UK), a Rheodyne injection valve (Model 7125) fitted with a 100 µL loop (Rheodyne, St. 
Louis, Mississippi) a guard column (GFC-Polysep P, 75x7.8mm; Phenomenex, 
Macclesfield, UK) and two analytical columns - TSK G3000PW + TSK G4000PW 
(Anachem, Luton, UK). Columns were eluted with PBS buffer, pH 7.5 (PBS tablets, 
Sigma). The eluent was pumped at a flow rate of 0.8 mUmin at ambient temperature. 
Samples were injected (100 µL) at a concentration of 478,505 and 525 µg/mL for 0.035, 
0.05 and 0.1 % FA-treated PT samples, respectively. Scattered light intensities of the 
eluted fractions were measured using a Dawn F multi-angle light scattering photometer 
(Wyatt Technology, Santa Barbara, CA) and concentrations were measured using an 
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Optilab 903 interferometric refractometer (Wyatt Technology, Santa Barbara, CA). The 
determination of molecular weights and molecular weight distributions by SEC/MALLS 
are described in (Wyatt, 1993) and were carried out using ASTRA software for Windows. 
Light scattering data from 12 detectors, at angles 44.6° -158.2°, were used in the 
analyses. The dn/dc value (specific refractive index increment) for a commercial 
formaldehyde-treated tetanus toxoid was determined to be 0.22 mL/g and used for the 
pertussis toxin molecular weight calculations in this experiment. 
2.3.6 Analytical ultracentrifugation (AUC) 
Mutant PT samples, untreated and treated with 0.05 and 0.1 % FA (section 2.2.3), were 
analysed by sedimentation equilibrium AUC. Solute distributions were examined and 
weight average molecular weights determined. 
Equilibrium solute distributions of PT samples were determined in a Beckman Optima 
XL-A analytical ultracentrifuge (Beckman Coulter, High Wycombe, UK) at 
4 °C, in a standard 1.2 cm path-length, 200 µL cell. Also in a 1.2 cm path length quartz 
cuvette, the concentrations of the samples were determined. Three different 
concentrations of each sample were analysed: untreated PT, 152,221 and 291 µg/ml 
(A271nm 0.22,0.32 and 0.42); 0.05 % FA-treated PT, 118,186 and 242 µg/ml (A27im 
0.17,0.27 and 0.35); and 0.1 % FA-treated PT, 69,173 and 228 pg/ml (A271nm, 0.10,0.25 
and 0.33) in PBS dialysate, pH 7.4. Distributions were recorded with scanning 
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absorbance optics (in radial step sizes of 0.001 cm) at three rotor speeds, 15 000,25 000 
and 35 000 rpm. A true optical baseline was determined by sedimenting the protein from 
the bulk of the solution volume at 47 000 rpm. 
The data were initially analysed using the data-fitting programme Origin, which uses 
models describing the sedimentation equilibrium process. Fits to the data with a1 or 2 
ideal species model were poor and therefore gave unreliable molecular weight estimates. 
The data were instead successfully analysed with the model-independent computer 
programme MSTAR (Cölfen and Harding, 1997) which calculates the M* parameter. At 
the cell base, M* is equal to the apparent weight average molecular weight (M,, , pp). 
2.3.7 Circular dichroism (CD) 
CD spectra, of native and mutant PT (section 2.2.2), were obtained using a Jasco J-720 
spectrapolarimeter and analysed using the Jasco software for Windows (Jasco, Great 
Dunmow, UK). Native (750 µg/mL) and mutant PT (382 µg/mL) samples were dialysed 
in 3 changes of 2 L, PBS buffer or 42 mM K2HPO4i 8 mM NaH2PO4 buffer, pH 7.6 (to 
obtain data from 180 - 195 nm, without the interference from chloride ions). They were 
analysed by near (250 - 320 nm) and far-UV (180 - 260 nm) CD in 1 cm and 0.02 cm 
path length cuvettes respectively. The sensitivity was set at 10 mega degrees for near UV 
and 50 mega degrees for far UV scans. The following settings were used: band width, 
1 nm; response time, 1 second; scan speed, 50 nm/min; and step resolution, 0.5 nm. 
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Spectra were corrected for dialysate buffer blank and molarity and were expressed as 
molar circular-dichroic absorption (i\c). The spectrapolarimeter instrument was calibrated 
according to the Jasco Instruction Manual. 
2.3.8 Fluorescence spectroscopy 
Commercially detoxified PT samples, A-E (section 2.2.1) and high and low FA-treated 
mutant and native PT samples (section 2.2.3) were analysed by fluorescence spectroscopy 
to analyse their protein secondary structure. This technique was used to check mutant and 
native PT samples for consistency with previous scans before each new experiment. 
NAD+ binding to PT, before and after reduction with DTT (2.3.2), was also studied using 
fluorescence. 
Intrinsic fluorescence of PT samples (10 - 50 µg/ml) was performed at 24 °C, using a 
Spex Fluoromax single photon-counting spectrofluorimeter (Jobin Yvon Ltd, Stanmore, 
UK). The temperature was kept constant at 24 °C with a water bath (model, Tempete TE- 
8D; Techne, Cambridge, UK), and the temperature inside the cuvette was measured 
before every fluorescence scan using a thermometer probe. The excitation wavelength 
was set at 280 nm or 295 nm and fluorescence emission was scanned in the range 260 - 
500 nm, in 1 nm increments, with a one second integration time. The samples were 
analysed in a1 cm path-length, 1 mL quartz cuvette (Hellma). The excitation band pass 
was set at 4.25 nm and the emission band pass at 4.50 nm. Data were recorded and 
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corrected using the Datamax software (Spex, Yobin Yvon Ltd) for Windows. 
Emission spectra were corrected by subtracting the spectrum of the PBS baseline. The 
inner filter effect (absorbance of excitation light by the sample) was minimal at these low 
protein concentrations and was therefore not corrected for. 
Water Raman excitation and emission spectra were recorded before each experiment and 
the fluorescence profile of the incident room light and/or of a fluorescent standard 
(NATA) were checked monthly according to the procedure detailed in the Spex 
FluoroMax Spectrofluorimeter instructions. 
2.3.8.1 NAD+ binding titrations 
The NAD+ binding affinities (Kd) of mutant PT, before and after reduction (section 
2.3.2), and of native PT were determined by measuring fluorescence quenching with 
increasing additions of NAD+. 
NAD+ (ß-NAD, non-reduced; Catalogue Number, N6522; Sigma) was added to the PT 
sample (1mL, 50 µg/mL) in the cuvette using a 10 µL glass syringe (Microlitre syringe, 
Hamilton Company). Volumes of 1-5 µL of a 0.002 M or 0.02 M stock solution of 
NAD+ in PBS, were added to give final concentrations of 2- 350 µM in 1 mL. After each 
addition of NAD+ the sample was mixed using a magnetic stirrer and fluorescence scans 
were performed exactly as described above. 
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The maximum tryptophan fluorescence intensity, in counts per second, was recorded for 
each scan. A titration using PBS was also carried out and the change in fluorescence 
intensity due to dilution of the sample or to photo-bleaching over the time course of the 
titration was found to be negligible. However, it was necessary to correct for the non- 
specific decrease in fluorescence intensity due to NAD+ absorbing the exciting light 
(inner filter effect). In a separate titration, the fluorescence intensity of a tryptophan 
derivative n-acetyl tryptophanamide (NATA), which fluoresces but does not bind NAD+, 
was recorded on each addition of NAD+ (as added to PT). Firstly, the fluorescence values 
for NATA were normalised so that the initial fluorescence intensity maximum of NATA 
was equal to that for PT (before any NAD+ addition). Secondly, the PT fluorescence 
intensities (F PT) at each NAD+ concentration were corrected (Fcorr PT) by multiplying 
them by the ratio of normalised initial fluorescence intensity for NATA with no NAD+ 
(Fo NATA) over the normalised fluorescence intensity for NATA at the corresponding 
NAD+ concentration (F NATA). That is, Fcorr PT =F PT * Fo NATA/F NATA. 
The Kd values for NAD+ binding were determined using the programme EqFit5 (kindly 
provided by Dr Stephen R. Martin, National Institute for Medical Research, Mill Hill, 
UK) which carries out a non-linear least squares fit of the corrected data to estimate the 
end point of the titration and thus the Kd. The programme also calculates the x2 values 
for each data fit. The % fluorescence quenching from the initial fluorescence, before 
addition of NAD+, to the final end point fluorescence was also calculated. 
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2.4 Immunological techniques 
Materials and methods 
The effect of FA and chemical toxoiding on the antigenic properties of PT was 
investigated. The PT preparations were analysed, before and after chemical treatment, to 
assess the quality and quantity of their subunit epitopes using mAbs in immunoblotting 
and ELISA. All of the PT preparations were also used to immunise mice to assess the 
effects of the various chemical treatments on the immune response. The immunogenicity 
of the preparations in mice was assessed by assaying the total IgG, IgGl and IgG2a 
response using ELISA. Immunoblotting was used to assess the presence of anti-subunit 
antibodies. In addition, the quality of antibody response was determined by assessing the 
ability of the sera to neutralise the toxic effects of an active reference PT on CHO-cells. 
The protective efficacy of the PT preparations was also assessed using an aerosol 
challenge assay. 
2.4.1 Sterile conditions 
Sterile assays and sample preparation were carried out in a Class 11 sterile cabinet using 
sterile plastics and reagents throughout, and 70 % ethanol solution in water was used 
regularly to disinfect surfaces. 
Buffers and media required for sterile assays and mice immunisations were sterilised in 
100 mL volumes in 150 mL glass bottles (unless otherwise stated) by autoclaving at a 
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minimum of 15 lbs at 121 °C for a minimum of 15 minutes, stored at 4 °C, and used 
within 1 '/2 years. 
PT and control samples used for CHO-cell assays and mice immunisations were sterile 
filtered, before dilution, through a low protein binding, 0.22 . tm pore size, syringe filter 
(polyethersulfone, 13 mm membrane diameter; Nalgene). 
2.4.2 PT preparations used 
Commercial toxoids and FA-treated mutant and native PT preparations are analysed in 
the experiments described in the following sections (sections 2.4.3. - 2.4.8) and have 
been described previously (sections 2.2.1 and 2.2.2). 
2.4.3 Reference PT and anti-serum 
In immunoblotting assays, untreated mutant PT (section 2.2.2) was used as the reference; 
in ELISA, an active PT preparation (code P57, in-house reference from a commercial 
source) was used; and in the CHO-cell toxicity, PT neutralisation, histamine challenge 
and leukocyte proliferation assays, another active PT preparation (code 90/518, NIBSC 
reagent) was used. 
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In all anti-PT serum assays, the serum raised against PBS or PBS plus alum was the 
negative control, and the 1st International Reference Preparation (IRP) of mouse anti-PT 
serum (code 97/642) was used as the positive control. 
2.4.4 Preparation of mAbs specific for PT subunits 
Murine mAbs specific for epitopes on Si - S5 were in the form of ascites fluid, or as 
supernatants produced from hybridoma cell lines (Sato et al., 1984b). 
2.4.4.1 mAbs in murine ascites 
For immunoblotting experiments, mAbs 1B7 (Si), 9G8 (S2), 7E10 (S3), 9C6 (S4) and 
7E3 (S5) were used in the form of concentrated murine ascites fluid, kindly donated by 
Dr Yuji Sato (National Institute of Health, Japan) (Sato and Sato, 1990; Sato, Sato, and 
Ohishi, 1991). 
2.4.4.2 Production of mAbs from hybridoma cell culture 
For ELISA, mAbs 1B7 (Si), 3A12 (S2), 7E10 (S3), 11E6 (S2/3), 7F2 (S4) and 7E3 (S5) 
were used as hybridoma supernatants produced from hybridoma cell lines. These 
antibodies are of the IgG isotype, and it is known that 1 B7 is of the IgG2a subclass. 
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Preparation of chemical stock solutions for cell culture: All chemicals used in the 
growth of hybridoma cell lines were from Sigma unless stated otherwise. Basic medium, 
consisting of 2.25 g NaHCO3,10 mL sodium pyruvate (Gibco, supplied as 100 mM 
solution) and 0.2 mL gentamycin (supplied as 50 mg/mL solution), made up to 1L with 
IMDM (Iscoves modified Dulbecco's medium), was filter sterilised using a vacuum 
sterile filter unit (0.22 µm pore size, 500 mL Stericup; Millipore). Solutions of insulin 
(2 mL of 8mg/mL solution in 0.05 N HC1 in deionised water) transferrin (2 mL of 1 
mg/mL solution in PBS) and glutamine (10 mL of 3% v/v solution in deionised water) 
were filter sterilised using a syringe filter (0.22 µm pore size, polyethersulfone, 13 mm 
membrane diameter; Nalgene). These stock solutions were all stored at 4 °C. 
Complete medium: The final medium consisted of 157 mL basic medium, 30 mL foetal 
bovine serum, 2 mL glutamine solution, 0.2 mL 2-mercaptoethanol (Gibco, supplied as 
50 mM), 0.2 mL insulin solution and 0.2 mL transferrin solution. The bulk complete 
medium was stored at 4 °C and appropriate amounts warmed in a water bath at 37 °C 
before use. 
Culture of hybridoma cells: Cell culture was carried out under sterile conditions. 
Hybridoma cell stocks were thawed in a water bath at 37 °C, added to 10 mL of complete 
medium in a centrifuge tube, spun at 80 g for 6 minutes and the supernatant carefully 
discarded. The cells were resuspended in 10 mL complete media, the suspension 
transferred into a 25 cm3 tissue culture flask and incubated at 37 °C in 50/0 CO2. When 
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cells were confluent (after 2-4 days), as checked under a light microscope with a 
magnification of 4- or 10-fold, 10 mL of cell suspension was transferred into a 75 cm3 
tissue culture flask with 30 mL of complete medium. This was incubated again until 
confluent (after 2-4 days) and the cell suspension was split into two 75 cm3 flasks with 
20 mL complete medium and incubated once more. Once these cells were confluent the 
suspension was transferred into 50 mL centrifuge tubes and spun at 80 g for 6 minutes. 
The supernatants were carefully removed, and those from the same hybridoma cell line 
were pooled, then aliquoted into 5 mL volumes and stored at - 20 °C. The mAb-binding 
was tested in each experiment by including a positive control on each ELISA plate. 
2.4.5 Preparation of anti-PT mouse serum 
Preparations of PT for immunising: Untreated mutant PT and FA-treated (0.25 - 1.00 
%, High FA -treated PT, section 2.2.3) mutant and native PT, at an initial concentration of 
50 µg/mL, were prepared with and without alum adsorption (0.3 mL of a2% stock 
solution, Alhydrogel Al(OH)3i Superfos, Denmark) in PBS under sterile conditions, to 
give 3 mL PT samples each of 10 µg/mL. 
Before immunisation, all of the PT samples were analysed by the CHO-cell toxicity assay 
(section 2.5.2) and were found to contain < 300 ng active PT per 5 µg dose. 
Immunisation: The mice (strain NIH, female, 5-6 weeks old; Harlem) were caged in 
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groups of five per sample and each mouse injected sub-cutaneously with PT sample 
(0.5 mL, containing 5 µg PT) or PBS (0.5 mL), with or without alum. 
At 5 weeks post immunisation each mouse was terminally bled, by cardiac pucture, into a 
1.5 mL eppendorf tube. The whole blood was left overnight at 4 °C for the erythrocytes to 
settle. The serum was then collected from the top of the tube and stored in a 0.5 mL 
eppendorf tube at -20 °C. 
Two mice from the 0.25 % FA (no alum) sample group and one mouse from the 0.5 % 
FA (no alum) sample group died, 10 days after immunisation, therefore their sera was not 
available for analysis. 
2.4.6 Immunoblotting 
This technique was used to analyse the effect of different FA-treatments or commercial 
toxoiding on both PT subunit-specific epitopes using mAbs, and on antibodies specific 
for PT subunits in anti-PT murine serum. 
Western transfer: Appropriate PT preparations had been subjected to SDS-PAGE by 
electrophoresis on Tris-glycine (14 %) acrylamide gels (described in section 2.3.3). 
Blotting apparatus, power pack and NuPage transfer buffer (20 x concentrate, diluted 
with deionised water to 1L to give 25 mM bicine, 25 mM bis-tris free base, 1.0 mM 
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EDTA, 0.05 mM chlorobutanol, pH7.2) were supplied by Novex. 
Western transfer was carried out according to the Novex NuPAGE electrophoresis system 
booklet, and is described in brief here. After electrophoresis, the gel was removed from 
its cassette and placed carefully onto nitro-cellulose membrane (Hybond-C super; 
Amersham Life Sciences) wet with transfer buffer. The gel and membrane were 
sandwiched between sheets of transfer buffer-soaked filter paper, cut to gel-size, and 
placed into the blotting module packed tightly with transfer buffer-soaked sponges. 
Protein transfer was carried out at a constant 25 V for 1 hour, with an initial current of 
-150 mA decreasing to -100 mA at the end of the run. Following transfer the membrane 
was rinsed with PBS four times then incubated, with 100 mL of 5% Marvel solution in 
PBS, at 37 °C for 1 hour with slight shaking and then washed with PBS at least 5 times. 
Immunoblot development: After the detection step, using mAbs or anti-PT serum 
(sections 2.4.6.1 and 2.4.6.2), each blot was washed thoroughly at least five times with 
15 mL PBS-Tween solution (0.05%, v/v, Tween 20 in PBS). Anti-mouse goat antibody 
peroxidase-conjugate (F,, specific, Sigma), diluted 1: 1000 in PBS-Tween, was then added 
and shaken for -2 hours. The membrane was washed thoroughly as before with PBS- 
Tween and developed using Sigma FAST DAB (3,3'- diaminobenzidine) tablets. Both 
tablets were dissolved in 15 mL deionised water, the membrane incubated in the solution 
at room temperature, with shaking, until the band colour developed (about 2 minutes) and 
washed with deionised water to stop the reaction. Care was taken not to over-develop the 
blot as this can cause a high background colour. Images of the blots were prepared as for 
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the SDS-PAGE gels (section 2.3.3). 
Materials and methods 
2.4.6.1 Detection of PT subunit-specific epitopes using mAbs 
To investigate the effect of different chemical treatments on PT subunit epitopes, blots of 
FA-treated PT preparations and toxoids were screened with mAbs 1B7 (Si), 9G8 (S2), 
7E10 (S3), 9C6 (S4) and 7E3 (S5) (section 2.4.4.1). 
Each blot, containing untreated mutant PT, 0.035,0.1 and 0.5 % FA-treated mutant PT or 
commercial toxoids, B, C and E, and untreated native PT, was placed in a petri dish, fully 
coated with 2 mL of one of the mAb concentrated ascites fluids (section 2.4.4.1), covered 
and incubated at room temperature overnight. The blots were developed as described 
above. 
2.4.6.2 Detection of antibodies specific for PT subunits in anti-PT 
murine serum 
To investigate the effect of FA on the anti-PT subunit specific antibodies produced, 
Western blots of reference PT (untreated mutant PT, section 2.4.3) were screened with 
murine serum, raised against different FA-treated PT preparations. 
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In this experiment, the nitrocellulose Western blots, of five alternating reference PT and 
molecular weight markers, were cut into five strips. Each strip contained one reference 
PT and one marker run. They were each placed in separate petri dishes and fully coated 
with 2 mL of one of the serum samples, raised against PBS or FA-treated (0.25 -1.00 % 
FA) mutant or native PT; or with the reference anti-PT serum preparation (all 1: 3 in 
PBS). The petri dishes were covered and incubated at room temperature overnight, with 
gentle shaking. The blots were developed as described above. 
2.4.7 ELISA 
This technique was used in two different experiments. A. The subunit-specific epitopes of 
PT in FA-treated PT preparations were quantitatively assessed by screening the 
preparations using subunit-specific mAbs. B. The PT-specific IgG antibody in murine 
serum raised against the FA-treated PT preparations or the commercial PT toxoids was 
quantitatively assessed by identifying serum-binding to reference PT. 
2.4.7.1 Preparation of ELISA plates 
Coating and blocking plates: A. To investigate the effect of different chemical 
treatments on the quantity of PT subunit epitopes, 96-well plates were coated with 
untreated or FA-treated (0.10 % FA) mutant or native PT, or reference PT (P57; section 
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2.4.3). B. To investigate the effect of chemical toxoiding or FA-treatment on the quantity 
of PT-specific IgG antibodies in murine serum, the plates were coated with reference PT 
(P57; section 2.4.3). 
The PT preparations for coating were diluted to 2 pg/mL with sodium carbonate coating 
buffer (from a1L stock containing 15 mM Na2CO3,350 mM NaHCO3,0.05 % w/v 
azide), pH 9.7. The coating solution (100 µL) was pipetted into the appropriate wells of 
96-well plates Plates (Nunc-Immuno plate, MaxiSorp surface; Nunc), the plates covered, 
incubated at room temperature overnight and then washed (described below). To block 
the plates, 100 µL of FCS diluent (10 % v/v foetal bovine serum, Life Technologies, in 
PBS-tween) was added to each well, incubated at room temperature, with gentle shaking, 
for 30 - 60 minutes and then washed. 
Plate washing: The solution filling the plate wells was shaken out, the plate immersed in 
a box of PBS-tween to fill all wells and the PBS-tween shaken out. This process was 
repeated four times and the plate was dried off with paper towels ready for the next 
solution addition. 
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2.4.7.2 Detection of subunit-specific epitopes in PT preparations by 
mAbs 
To investigate the effect of different chemical treatments on the quantity of PT subunit 
epitopes, plates coated with the different PT preparations (see A. section 2.4.7.1) were 
screened with PT subunit-specific mAbs 1B7 (Si), 3A12 (S2), 7E10 (S3), 11E6 (S2/3), 
7F2 (S4) and 7E3 (S5) (section 2.4.4.2). 
Primary antibody: The PT preparations were screened with mAbs, specific for epitopes 
on PT subunits (section 2.4.4.2), produced from hybridoma cell lines. Mab solutions, 
1B7,3A12 or 11E6 at a dilution of 1: 1000 or 7E10,7F2 or 7E3 at 1: 100, were pipetted, 
in duplicate, into the top well of a column, and each solution diluted 1: 2 down the plate in 
FCS diluent to give 100 µL in each well. The last well of each row was left containing 
diluent only in order to determine background variation between wells. The plate was 
incubated at room temperature, with gentle shaking, for two hours and then washed. 
Antibody-enzyme conjugate: Anti-mouse goat antibody peroxidase-conjugate (Fc 
specific, Sigma), 100 µL of 1: 1000 in PBS-Tween, was pipetted into each well, the plate 
incubated at room temperature, with gentle shaking, for two hours and then washed. 
Substrate reaction: The peroxidase substrate consisted of 1.25 mL of 1% 
3,3', 5,5'-tetramethyl-benzidine (TMB) in dimethylsulphoxide (DMSO; 0.015 g TMB in 
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1.5 mL DMSO; both Sigma) and 37 µL hydrogen peroxide (supplied as 30 %, w/w 
solution; Sigma), slowly mixed with 125 mL acetate buffer in deionised water (from a 
1 L, ten-times concentrate stock, 0.54 M NaCH3COOH. 3H20,0.16 % v/v glacial acetic 
acid; both BDH). This substrate solution was prepared immediately before use, as it is 
light sensitive. Substrate solution (100 µL) was pipetted into each well and incubated at 
room temperature, with gentle shaking, for 10 minutes. Dilute H2SO4 (50 µL; 1 M, in 
deionised water) was then added to each well, to stop the reaction, and the absorbance, at 
450 nm, of the solutions was read using a Multiskan MS plate reader and accompanying 
Genesis software for Windows (Labsystems). The data were subjected to statistical 
analyses (section 2.4.7.3). 
2.4.7.3 PT-specific immunoglobulins (Ig), total IgG, IgGI and IgG2a, 
in anti-PT mouse sera 
To investigate the effect of FA on the quantity of PT-specific total IgG, IgGI and IgG2a, 
in murine serum (see section 2.4.5) raised against different FA-treated PT preparations, 
plates coated with reference PT (see section 2.4.7.1 B) were screened with one of the test 
anti-PT serum or the reference anti-PT serum (section 2.4.3) and then anti-mouse IgG. 
Primary antibody: Reference PT was screened with anti-PT sera raised against 
untreated mutant PT, FA-treated (0.25,0.5,0.7 or 1.0 %) mutant and native PT and PBS 
(negative control) (all with and without alum). Serum from each mouse per sample group 
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was individually assayed. Anti-PT reference serum was assayed in duplicate on each 
plate. Anti-PT serum solutions were pipetted into the top well in FCS diluent at a dilution 
of 1: 1000, for total IgG and IgGI determination, or 1: 5, for IgG2a determination, and 
diluted in FCS diluent 1: 3 down the plate to give 100 µL in each well. The last well in 
each column was left containing diluent only to determine background variation between 
wells. The plates were incubated at room temperature, with gentle shaking, for two hours 
and then washed. 
Antibody-enzyme conjugate: Total IgG was detected using goat anti-mouse total IgG 
peroxidase-conjugate (1: 1000; Sigma) (as in section 2.4.7.1). IgG subclasses were 
detected using rat (strain LOU) anti-mouse IgGI or IgG2a (isotype, IgG 1, x) biotin- 
conjugates (1: 1000 or 1: 200 respectively; Pharmingen). Each well was filled with 100 µL 
of antibody conjugate at the appropriate concentration in FCS diluent. The plate was 
incubated at room temperature, with gentle shaking, for 1 '/i hours and then washed. 
Substrate reaction: For detection of total IgG, peroxidase substrate was used (as in 
section 2.4.7.1). For detection of the IgG subclasses, streptavidin-horseradish peroxidase 
conjugate (100 µL, 1: 1000 in diluent; Pharmingen), was added to each well, the plate 
incubated at room temperature, with gentle shaking, for 1 hour and then washed. The 
peroxidase substrate (Sigma Fast o-phenylenediamine dihydrochloride tablets, in 
deionised water), 100 µL, was pipetted into each well and the plate incubated in the dark, 
at room temperature, for 20 minutes. HCl (50 µL; 3M, in deionised water) was then 
added to each well to stop the reaction, and the absorbance, at 492 nm, of the solutions 
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was read using a Multiskan plate reader. The data were subjected to statistical analyses 
(section 2.4.7.3). 
2.4.7.4 Statistical analysis of ELISA data 
ELISA data was obtained from the Multiskan plate reader in the form of an absorbance 
titration curve, as absorbance (at 492 nm) against dilution. The linear portion of each 
titration curve, for the test samples and the reference preparation, was analysed by 
parallel line assay, using an in-house statistical analysis programme (PLATE RANDOM, 
NIBSC), which determines the sample titre relative to the reference, taking into account 
well-to-well variation. The negative controls were always found to give a titre of zero. No 
serum results were excluded from the statistical analyses. However, two serum samples 
from mice immunised with 0.25 % FA-treated PT (no alum) and one from the mice 
immunised with 0.5 % FA-treated PT (no alum) were not available for analysis, because 
these mice died ten days after immunisation. 
The geometric mean, GM, and geometric standard deviation, GSD, (equations 2- 4) were 
determined for duplicate mAb-binding titres (section 2.4.7.1) and for each group of five 
serum IgG titres (section 2.4.7.2). The GMwas calculated for each group of results, 
x, - xv, where N is the total number of values in the group (equation 2). From the 
geometric variance, GV, the GSD associated with each GM was determined (equations 3 
and 4). The difference between two groups of data was accepted as statistically 
significant if P <_ 0.1, as determined with Students t-Test. 
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N 
E (log x; ) 
log GM = `-' N 
(2) 
N 
(log x; - log GM)2 
logGV = '-' N 
(3) 
GSD = GV (4) 
2.4.8 PT-neutralising activity of anti-PT sera, using CHO-cells 
Biologically active PT, with both a functional binding B-oligomer and catalytic SI 
subunit (Pizza et al., 1989; Loosmore et al., 1993) affects the morphology of CHO-cells 
growing in a monolayer causing a characteristic clustering effect (Gillenius et al., 1985). 
The ability for anti-PT sera to neutralise the toxic effects of PT on CHO-cells was 
assayed. 
PT-neutralising activity of anti-PT sera was determined by pre-incubating a series of 
dilutions of the anti-PT sera with active reference PT (code 90/518; section 2.4.3) in a 
96-well plate, adding the CHO-cells and observing the dilution of sera which caused 
inhibition of the clumping effect. Three serum samples from each group of five raised 
against 0.25,0.5 and 1.0 % FA-treated PT (without alum) were randomly chosen for 
analysis. In addition, the positive control reference serum (see section 2.4.3) and negative 
control sera raised against PBS (without alum) were also analysed. 
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2.4.8.1 Preparation of CHO-cell suspension 
Materials and methods 
CHO-cell culture media: Complete RPMI medium was used for CHO-cell culture and 
consisted of 90 mL incomplete RPMI 1640,10 mL foetal bovine serum (Life 
Technologies) and 1 mL antibiotic antimycotic solution (from a 100 x solution containing 
10000 Units penicillin, 10 mg/mL streptomycin and 25 pg/mL amphotericin; Sigma). 
Preparing a confluent monolayer: CHO-cell culture was carried out under sterile 
conditions. CHO-cell (strain KI; ICN, Basingstoke, UK) stocks were stored in foetal 
bovine serum with 10 % (v/v) DMSO, in 2 mL cryo-tubes, in liquid nitrogen. A stock 
vial was removed from the liquid nitrogen, left at room temperature until only just 
thawed. The CHO-cells were immediately transferred into 20 mL complete RPMI 
medium in a 50 mL centrifuge tube and spun at 100 g, at 2-8 °C for 6 minutes. The 
supernatant was discarded and the cells resuspended in 50 mL complete RPMI medium, 
transferred to a 75 cm3 culture flask (Falcon) and incubated (2 -4 days) at 37 °C, in 5% 
CO2 until confluent as checked under a light microscope using a 4- or 10-fold 
magnification. 
Releasing and diluting cells: Following incubation, the medium was discarded and the 
cell layer carefully rinsed twice with PBS before releasing the cells from the flask surface 
by trypsination. Trypsin (5 mL, 0.25 %; Life Technologies) was added to cover the layer 
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of cells, the flask left at room temperature for 3 minutes, trypsin poured off and the flask 
incubated again at 37 °C for 5 minutes. Five mL of complete RPMI medium was added to 
the flask and the cells gently washed off the base of the flask. Cells in the suspension 
were counted using a haemocytometer and diluted with complete medium to a 
concentration of 2x 104 cells/mL. This cell suspension was prepared in the same way for 
both the CHO-cell toxicity assay (section 2.5.2) and the CHO-cell neutralisation assay. 
2.4.8.2 Preparation of neutralisation assay plates 
The preparation of neutralisation assay plates was carried out under sterile conditions. 
RPMI media (25 µL) was pipetted into all wells of a 96-well plate. Each serum sample 
(25 µL, 1: 10 in PBS), including negative (serum raised against PBS) and positive 
(97/642,1" IRP) controls, was pipetted into the first well of a row and diluted 1: 2 across 
the row. Active reference PT 90/518 (25 µL of a 16 ng/mL solution) was then added to 
each well, excluding one row. One row per plate was reserved to check the CHO-cell 
toxicity (section 2.5.2) of the active reference PT. In this row 25 µL, 64 ng/mL of active 
reference PT was pipetted into the first well and diluted 1: 2 across the row, and another 
25 µL of RPMI added to each well in the row instead of serum. The plate was gently 
shaken for a few minutes and then incubated at 37 °C for 3 hours. The CHO-cell 
suspension (200 µL) was then added to each well, the plate gently shaken for a few 
minutes and then incubated at 37 °C in 5% CO2 until there was sufficient level of cell 
growth to observe the morphological changes. This usually took 2 days and care was 
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taken not to over-culture the cells as they can recover from the toxin-induced changes 
(Gillenius et al., 1985). 
2.4.8.3 Interpretation of neutralisation assay plates 
The plate was removed from the incubator and viewed on a light microscope at 4- or 
10- fold magnification. The wells were examined across the plate for the presence of 
clustering as compared to the positive and negative controls. The titration end-point was 
taken as the highest serum dilution causing complete neutralisation of the toxin effect, 
resulting in unaffected cells (Gillenius et al., 1985). The reciprocal of the titration end- 
point dilution factor for each serum sample was taken as the neutralising titre. The 
neutralising titres for the test sera were corrected for variation between plates relative to 
the reference antiserum titration on each plate. However, the plates were consistent and 
varied occasionally only by one dilution factor. The geometric mean and geometric 
standard deviation of the neutralising titre for each group of three sera were determined. 
2.4.9 Aerosol challenge 
Procedure 
Groups of ten mice were immunised with one of the commercial toxoids (A - E), and 
subjected to aerosol challenge 30 days later using a live suspension of B. pertussis cells, 
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which were cultured on charcoal agar plates. The lungs from the mice were homogenised 
in lung tubes, plated out on charcoal agar plates and the number of viable cells per lung 
calculated. 
Mice immunisation 
Groups of ten mice (NIH) were immunised by the intraperitoneal route with 5 µg of one 
of the toxoids, A-E (described in section 2.2.1), or the positive control reference vaccine 
(in house reference, co-purified pertussis vaccine, code JNIH-3), in 0.5 mL saline (0.9 % 
NaCl, anhydrous), or with 0.5 mL saline alone, as the negative control. 
Charcoal agar plates 
A 5.1 % charcoal agar base (Oxoid, Hampshire, UK) solution (12.75 g in 250 mL water) 
was sterilised and allowed to cool to 50 °C. To this solution, 25 mL sterile defibrinated 
horse blood (Oxoid) was aseptically added, mixed and 15 - 20 mL aliquots were poured 
into 9 cm Petri dishes and stored at 4 °C for up to six weeks. 
Preparation of B. pertussis suspension 
B. pertussis cells (strain Wellcome 28) were stored in 200 µL aliquots, in a5% glycerol 
solution (v/v) in 1% casein solution, at -65 °C. Five days before aerosol challenge (day 
one), one aliquot of B. pertussis cells was taken from storage, allowed to thaw at room 
temperature and aseptically dropped onto two charcoal agar plates using a sterile glass 
Pasteur pipette. The plates were incubated for two days at 37 °C. On day three a visible 
amount of culture from these two plates were evenly streaked onto six fresh plates and 
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these were incubated at 37 °C for 18 - 24 hours. On day four, all of the culture was 
scraped from the six plates, resuspended in 3 mL of 1% casein solution and this 
suspension dropped and spread onto six fresh plates (0.5 mL per plate), and these plates 
were incubated at 37 °C for 18 hours. On day five, the day of the aerosol challenge, all of 
the bacterial culture was resuspended in 6mL 1% casein solution, 0.3 mL of this added to 
100 mL 1% casein solution and the suspension was adjusted to an optical density reading 
of 0.2 (absorbance at 625 nm), 40 000 bacteria/mL. This suspension was split between 
two 50 mL centrifuge tubes and kept on ice until required. This amount of suspension is 
sufficient to challenge 70 mice. 
Lung tubes 
Plastic O-ring conical tubes (Sarsdedt) were filled one third full with glass beads (BDH) 
and 1 mL of a1% casein solution (6 g NaCl (anhydrous) and 10 g casamino acid; BDH 
in 1L of distilled water). The filled and capped tubes were sterilised and stored at 4 T. 
Aerosol challenge apparatus and procedure 
The aerosol challenge apparatus and procedure were previously described by D. Xing and 
colleagues (Xing et al., 1999), and are described briefly here. The day before challenge, 
8 mL of 70 % ethanol solution was run through the aerosol system. This was repeated on 
the day of challenge, followed by 2x8 mL sterile water. A sterile nebuliser was then 
attached to the system for the start of the challenge. Each group of ten mice was placed in 
the metal restraint boxes, the nebuliser filled with 8 mL of challenge suspension and the 
airflow started. The mice were exposed to the aerosol challenge for five minutes. 
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Lung sampling 
Materials and methods 
Five saline control mice were sampled two hours after challenge to check that the aerosol 
challenge was successful. All other groups were sampled seven days after challenge. 
Lungs were removed following terminal anaesthesia intraperitoneal injection, and each 
lung placed in a lung tube. These were kept on ice until required. Each lung was 
homogenised in the lung tube using a mini beadbeater at a speed of 4600 rpm for 
ten seconds. The homogenate was placed on ice. 
Determination of viable counts 
A series of dilutions of each lung homogenate (neat, 10-, 100- and 1000-fold), were 
prepared in quadruplicate in a microtitre plate. Each was dropped (25 µL) onto a charcoal 
agar plate so there were 16 spots per plate (four dilutions, each in quadruplicate). At a 
countable dilution, the total number of colony forming units (CFU) in each of the 
quadruplicate drops were added up to give the number of CFU per 100 µL at that 
dilution. This count was then multiplied by the appropriate dilution factor and by 10 to 
give the total CFU count per lung (1 mL). 
The geometric mean CFU count and geometric standard deviation (equations 2-4, 
section 2.4.7.4) for each group of ten mice was determined. 
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2.5 Determination of PT toxic biological activities 
The toxic biological activities of 0.25 - 1.00 % FA-treated native PT preparations (High 
FA-treated PT, section 2.2.3) were determined using four different methods: CHO 
(Chinese hamster ovary)-cell toxicity assay, ADP-ribosylation assay and two murine in 
vivo tests, leukocyte proliferation and histamine sensitisation. These activities are all 
dependent on the functional B-oligomer (Loosmore et al., 1993) and ultimately the 
functional catalytic activity of the Si subunit (Nencioni et al., 1990). 
These FA-treated native PT samples were also incubated and examined for an increase in 
their toxic biological activities (toxicity reversion) by the CHO-cell toxicity assay and the 
ADP-ribosylation assay. 
2.5.1 Reference PT 
Reference PT used for the positive control in all four assays was an active PT preparation 
(code 90/518, NIBSC reagent). The negative controls used were PBS and mutant PT, 
which is devoid of catalytic activity and thus does not possess the toxic biological 
activities of CHO-cell toxicity, ADP-ribosyl transferase and leukocyte proliferation and 
histamine sensitisation (Nencioni et al., 1990). 
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2.5.2 CHO-cell toxicity assay 
Materials and methods 
Native PT causes a characteristic clustering effect of CHO-cells growing in a monolayer, 
(described in section 2.4.8). The concentration of biologically active PT in a FA-treated 
native PT preparation was determined by the CHO-cell toxicity assay by incubating 
CHO-cells with a series of concentrations of the sample, in a 96-well plate, and observing 
the end-point of the CHO-cell clumping effect. 
CHO-cells were grown to confluence and a cell suspension prepared to a concentration of 
2x 104 cells/mL as described in the PT neutralisation assay (section 2.4.8). 
2.5.2.1 Preparation of CHO-cell toxicity assay plates 
Assay preparation was carried out under sterile conditions. Incomplete RPMI medium 
(25 µL) was pipetted into all wells of a sterile 96-well plate (Microtest, flat bottom, tissue 
culture plate; Falcon). The active reference PT or FA-treated native PT preparations, neat 
and diluted 1: 10 (in sterile PBS), were pipetted (25 µL) into wells of the first column. 
Samples and control were tested in duplicate. These solutions were diluted 1: 2 across the 
plate using a multi-channel pipette. Two wells of every plate were left containing 
medium only, for the negative control. The CHO cell suspension (200 µL) was added to 
each well, the plate gently shaken for a few minutes, and then incubated at 37 °C in 5% 
CO2 until there was sufficient level of cell growth to observe the morphological changes. 
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This usually takes 2 days and care was taken not to over-culture the cells as they can 
recover from the toxin-induced changes (Gillenius et al., 1985). 
2.5.2.2 Interpretation of CHO-cell toxicity assay plates 
The plate was removed from the incubator and viewed on a light microscope at 4- or 
10- fold magnification. The wells were examined across the plate for the presence of 
clustering as compared to the negative and positive controls. The titration end-point was 
taken as the highest dilution to cause complete clustering (Gillenius et al., 1985). The 
minimum concentration (µg/mL) of active reference PT to cause clustering 
(cytopathogenic concentration) was calculated by multiplying its neat concentration 
added to the first column, by its titration end-point dilution. The concentration of 
biologically active PT (pg/mL) in the neat PT sample added to the first column, was 
determined by multiplying its end-point dilution factor reciprocal by the minimum 
cytopathogenic concentration. Average values for duplicate analyses are quoted as 
Tg active PT per 100 µg of total protein. 
2.5.3 ADP-ribosylation assay 
The ADP-ribosyl transferase activity of the FA-treated native PT preparations was 
determined by measuring the ribosylation of a fluorescent-tagged peptide substrate using 
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an enzymatic-HPLC coupled assay, based on the method of Dr Larry W. Whitehouse and 
co-workers (Cyr et al., 2001). The PT preparations were activated, prior to the enzymatic 
reaction, and then added to the fluorescent-tagged peptide substrate in the presence of 
ribosylating reagent containing NAD+ and ATP. The quantity of ADP-ribosylated 
fluorescent-tagged peptide substrate produced by each FA-treated native PT preparation 
was detected by HPLC, and the amount of active PT in each sample was calculated 
relative to the active reference PT. 
The following reagents were of analytical quality and obtained from Sigma, unless 
otherwise stated. 
PT activation buffer: Dithiothreitol (Aldrich) 200 mM in 0.5 M Tris HC1, pH 7.6. 
Ribosylating reagent: The ribosylating reagent contained equal volumes of i, ii, and iii: 
(i) 20 mM phenylmethylsulfonyl fluoride (PMSF, a serine protease inhibitor) containing 
1.5 mg/mL lysophosphatidylcholine (LPC) in a 2: 3 (v/v) solution of isopropanol and 0.1 
M Tris HCI, pH7.6. This solution was prepared using stock solutions of PMSF (100 mM, 
dissolved in isopropanol) and LPC (10 mg/mL LPC, in a 9: 1, (v/v) chloroform/methanol 
mix). When preparing the working PMSF/LPC solution, the organic solvent was removed 
from the LPC with a stream of nitrogen, prior to addition of the PMSF solution and Tris 
HCl buffer. The working PMSF/LPC solution was sonicated for one minute in an 
ultrasonic water bath before use. 
(ii) 18 mM ATP in 0.1 M Tris HCI, pH 7.6 
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(iii) 3 mM NAD+ (ß-NAD, as used in section in 0.1 M Tris HC1, pH 7.6 
The ribosylating reagent was sonicated for one minute in a water bath before addition to 
the assay reaction mixture. 
Enzyme substrate peptide: The enzyme substrate, a fluorescein caproic acid- (FAC) 
tagged Gai3 C20 peptide (FAC- VFDA VTD VIIKNNLKECGL Y-COOH), was a gift from Dr 
Larry W. Whitehouse (Cyr et al., 2001), and is referred to herein as the C20 peptide. 
Enzyme Assay 
A series of concentrations of active reference PT (0 - 0.4 pg/mL) were prepared in 
duplicate in 2 mg/mL ovalbumin solution, for preparation of a standard curve. Dilutions 
of each FA-treated PT preparation (from two to five-fold dilutions of the neat 50 pg/mL 
protein preparations), were made which kept the reaction within the linear range of the 
standard curve. The test PT preparations or references (20 µL), were incubated under 
nitrogen with 5 µL of PT activation buffer, for 10 minutes at 37 °C. To this mixture, 
ribosylating reagent (10 µL) was then added, vortexed, nitrogen added, and incubated at 
4 °C for 30 minutes. Then the C20 peptide substrate (5 µL) was added, the mixture 
vortexed, nitrogen added and further incubated at 21 °C for six hours. The reaction was 
stopped by adding 40 µL of a 1: 1 (v/v) solution of 0.5 M ammonium acetate buffer, 
pH8.5, and isopropanol. The reaction mixture was stored at -20 °C until HPLC analysis 
was performed. 
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Reverse-phase HPLC 
Materials and methods 
HPLC analyses were performed on a titanium and PEEK-lined Gilson binary pump 
system (Anachem), using a reverse-phase column (Shodex Asahipak, ODP50-4E 
(5 µ, 4.6 x 250 mm); Phenomenex). Detection was by a Gilson fluorescence detector, 
model 122 (Anachem). The HPLC system was operated, and data collected by the Gilson 
Unipoint software (Anachem). 
The HPLC mobile phase was aqueous acetonitrile buffered with 10 mM ammonium 
nitrate, pH 8.5. Solvent A contained 80 % acetonitrile and solvent B contained 0 
acetonitrile. The elution gradient (based on % of solvent B) was 0-1 min, 75%; 1-2 min, 
75-70%; 2-6 min, 70%; 6-8 min, 70-0%; 8-9 min, 0%; 9-11 min, 0-75 % and 11-20 min, 
75% and the flow rate was 0.8 mL/min. Elution was monitored by detection of FAC-tag 
fluorescence emission at 515 nm (excitation wavelength (Xex) 480 nm). The non-modified 
C20 peptide eluted at 11.1 minutes and the ADP-ribosylated C20 peptide eluted at 
7.8 minutes. 
The area under the ADP-ribosylated C20 peptide peak was calculated for each 
concentration of active reference PT and was used to compose a standard curve for active 
PT. This was used to determine the quantity of active PT in each FA-treated native PT 
sample. The results were calculated as the average for each duplicate experiment and are 
expressed as µg active PT/100 µg protein. 
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2.5.4 Leukocyte proliferation test 
Materials and methods 
Leukocyte proliferation activity of the FA-treated native PT samples, and active reference 
PT was studied by immunising mice with these PT preparations and counting the 
leukocytes in the resulting whole blood. 
Immunising preparations: Four different FA-treated (0.25,0.50,0.70 and 1.00 % FA) 
native PT preparations and an untreated mutant PT preparation (negative control), each of 
50 µg/mL, were diluted with PBSG (PBS with gelatin: 2g gelatin in 1L PBS, sterilised) 
to give 3 mL PT preparations with a final concentration of 10 pg/mL. The active 
reference PT, of 1 µg/mL, was diluted with PBSG to give a final concentration of 
200 ng/mL. 
Mice immunisation: The mice (strain NIH, male, 5-6 weeks old; Harlan) were caged in 
groups of five per sample and were each injected intra-peritoneally, using a5 mL syringe, 
with 0.5 mL of the FA-treated native or untreated mutant PT preparation (containing 
5 µg), the active reference PT (containing 100 ng) or of PBSG only. 
At three days post immunisation tail bleeds were taken from the mice. The mice were 
incubated at 35 °C for a few minutes prior to bleeding. The tail was pricked once with a 
sterile needle and approximately 100 µL of blood allowed to drip directly into an 
eppendorf tube containing 5 pL of 200 Units/mL heparin solution to give a final heparin 
concentration of - 10 Units/mL. The blood and heparin were mixed immediately and 
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leukocytes in the whole blood were counted, within 30 minutes of taking the blood, using 
a Coulter counter (Coulter Ac. T 8 Series Analyser; Beckman Coulter). The counts are 
expressed as the geometric mean for each group of five mouse serum samples, with 
geometric standard deviations (equations 2-4; section 2.4.7.4). The difference between 
two groups of data was accepted as statistically significant if P: 5 0.1, as determined with 
Students t-Test. 
2.5.5 Histamine sensitisation test 
Groups of five mice were immunised as for the leukocyte proliferation test (section 
2.5.4). 
Four days post immunisation the mice were challenged with histamine by intra-peritoneal 
injection of each mouse with 0.5 mL sterile histamine diphosphate solution (5.52 mg/mL; 
Sigma) in PBS. The mice were closely observed on injection, and the time of death, or 
culling of suffering mice, was recorded and regarded as positive for histamine 
sensitisation. 
2.5.6 Toxicity reversion study 
The toxicity reversion study was carried out on 0.5 and 1.0 % FA-treated native PT 
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preparations using CHO-cell toxicity and ADP-ribosylation assays. 
A proportion of each FA-treated native PT sample (200 µL of each at - 50 µglmL) was 
removed from storage at 4 °C for the toxicity reversion study. These were incubated in 
0.5 µL, in polypropylene screw-cap tubes tubes, at 37 °C for 11 days, and mixed 
manually twice every day. After incubation the preparations were stored at 4 °C 
overnight before performing the toxicity assays. The CHO-cell toxicity assay (section 
2.5.2) and ADP-ribosylation assay (section 2.5.3) were then performed, on both the 
incubated samples and on the non-incubated samples (which had remained in storage at 
4 °C), in duplicate. The quantity of active PT per 100 µg of protein was calculated, as 
determined in both techniques, for both the incubated and non-incubated PT preparations, 
as previously described (section 2.5.2 and 2.5.3). 
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Si subunit of PT 
3.1 Introduction 
The Si subunit of PT is an ADP-ribosyl transferase, which binds NAD+ and catalyses the 
transfer of the ADP-ribosyl moiety to the alpha subunit of host G-proteins. Si contains 
235 amino acids and has a molecular weight of 26 kDa with a secondary structure 
comprising 27 % a-helix and 24 % ß-sheet (Appendix 1) (see Figure 1.4). 
The known tertiary structures and sequences of ADP-ribosylating bacterial toxins, 
including PT, Escherichia coli heat-labile enterotoxins (LTI and LT2), cholera toxin 
(CT), Pseudomonas aeruginosa exotoxin-A (PAETA) and diphtheria toxin (DT) (Stein et 
al., 1994a; Sixma et al., 1991; Sixma et al., 1993; Allured et al., 1986; Choe et al., 1992) 
have been compared. In combination with site-directed mutagenesis these studies have 
highlighted a hydrophobic pocket predicted to bind NAD' (Domenighini et al., 1991; 
Domenighini et a!., 1994). In PT, several amino acids discovered to be important for 
assimilation of the NAD+ moiety in the catalytic action of Si, include Tyr-8, Arg-9, Phe- 
50, Thr-53, Glu-129 and Trp-26 (Pizza et al., 1988; Locht, Capiau, and Feron, 1989; 
Cortina and Barbieri, 1989). 
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Of these, Trp-26 of the Si subunit forms part of the predicted active site (Stein et al., 
1994a; Locht et al., 1990) and is essential for maximum catalytic activity (Locht, Capiau, 
and Feron, 1989; Cortina and Barbieri, 1989). It is positioned on the bend of a hydrogen- 
bonded turn, flanked on either side by an extended a-helix (Appendix 1), the first section 
of which is conserved between PT, LT1, LT2 and CT (PT residues 8- 25; Domenighini 
et aL, 1994). Analysis of the crystal structure (1PRT, Stein et al., 1994a) shows that Trp- 
26 protrudes into the Si molecule, and is only partially solvent exposed. 
Trp residues are largely responsible for protein intrinsic fluorescence which is sensitive to 
the Trp environment, making intrinsic fluorescence spectroscopy a useful probe of PT 
conformation. Upon excitation at 280 nm, PT typically displays intrinsic fluorescence 
with Trp fluorescence maximum (Fmax) of - 337 nm, and a shoulder from tyrosine 
fluorescence at - 305 nm (Lobban, Irons, and van Heyningen, 1991). This fluorescence 
was shown to be specifically quenched upon NAD+ binding, and the dissociation constant 
(Kd) of PT for NAD+ determined by NAD+ fluorescence quenching titrations (Kd µM) 
agrees well with both the Kd calculated by equilibrium dialysis, and the Michaelis 
constant for the NAD+-glycohydrolase activity of PT (Lobban, Irons, and van Heyningen, 
1991). The proximity of Trp-26 in the putative NAD+ binding site and its importance in 
the catalytic activity of PT suggests that it is Trp-26 fluorescence which is specifically 
quenched by NAD+, out of a total of six Trps in the holotoxin. 
Also important for enzymatic activity is the cleavage of the putative active site disulphide 
bond Cys-41 - Cys-201, or `activation', of the Si subunit. This has been implied from 
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findings that reducing conditions are required for full catalytic activity in vitro (Moss et 
al., 1986; Moss et al., 1983). In addition, it has been speculated from observations of the 
crystal structure that cleavage of this bond would be a physical requirement for opening 
up the putative active site (Stein et al., 1994a). 
Two distinct binding sites for the G-protein substrate have also been localised in the Si 
subunit, using recombinant SI deletion peptides. One is within the amino terminal 
180 amino acids (Finck-Barbancon and Barbieri, 1995) and the other is defined by 
residues 195 - 204 (Cortina and Barbieri, 1991). The residues 195 - 204 are part of an 
alpha-helix which is buried in the putative NAD-binding cleft (Stein et al., 1994a; 
Krueger and Barbieri, 1994). A structurally homologous `active site loop' has been 
purported to occlude the NAD+binding site of LT, CT (amino acids 47 - 56) and DT 
(amino acids 39 - 46) (Pizza, Masignani, and Rappuoli, 2001). Moreover, in DT it is 
known to change conformation upon NAD+ binding (Bell and Eisenberg, 1996). 
In the study of NAD+ binding to PT, predictions have been made from studying the 
crystal structure (Stein et al., 1994a), which is based on non-activated PT. Two previous 
groups attempted to model NAD+ binding in the active site of PT. However, only the 
amino terminal amino acids -2- 189 of PT, and NAD+ fragments, were used in the 
simulations (Cummings, Hart, and Read, 1998; Scheuring, Berti, and Schramm, 1998). 
Despite the requirement for activation and NAD+ binding in the toxic ADP-ribosyl 
transferase activity of PT, there was no model previously available for `activated' PT or 
the activated PT-NAD+ complex. 
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The aim of this study was to characterise the structural effects of `activation' and NAD+ 
binding on the Si subunit of PT, using fluorescence spectroscopy and computer 
modelling. Computer models for `activated' PT and the NAD+-bound `activated' PT 
complex are presented. 
3.2 Results 
3.2.1 Intrinsic fluorescence spectroscopy: Effect of `activation' and 
NAD+ binding on mutant PT structure 
Intrinsic fluorescence is a sensitive indicator of changes in protein conformation. Initially 
mutant and native PT structures, and their NAD binding properties, were compared by 
fluroescence. Mutant PT was then used in the remainder and majority of the study, for the 
investigation of changes in fluorescence upon `activation' and NAD binding. 
3.2.1.1 Comparison of native and mutant PT fluorescence 
Native and mutant PT (- 30 pg/mL) were subject to intrinsic fluorescence spectroscopy 
using a single photon-counting spectroflourometer at an excitation wavelength (A,, ) of 
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280 nm. The fluorescence was scanned from 260 to 500 nm and the base line 
fluorescence of the sample buffer (PBS, pH 7.5) was subtracted. To determine Kd values 
for the NAD+ binding of mutant and native PT, their fluorescence spectra were recorded 
with the addition of increasing concentrations of NAD+ (0 - 350 µM), and the 
fluorescence quenching titration data were corrected for the inner filter effect of NAD+ 
and analysed using the EquFit5 programme (kindly provided by Dr Stephen R. Martin, 
National Institute for Medical Research, Mill Hill). 
The fluorescence spectrum of mutant PT was found to be almost superimposable with 
that of native PT, both having an Fmax from Trp fluorescence at 337 nm and a shoulder 
from Tyr fluorescence at - 305 run (Figure 3.1). On NAD+ binding, the Trp fluorescence 
was specifically quenched and the Fmax remained unaltered, for both mutant (Figure 
3.2A and B) and native PT (not shown). Kd values of 52 µM for native PT and 63 µM for 
mutant PT were obtained (Table 3.1) and are in close correlation with that obtained by 
Lobban and co-workers, of 37 µM for native PT (Lobban, Irons, and van Heyningen, 
1991). These results demonstrate that mutant PT still binds NAD+, and with a similar 
affinity to native PT. On the basis of the similarity in protein structure and NAD+ binding 
between native and mutant PT, mutant PT was chosen rather than native PT for safety 
reasons for the `activation' and further NAD+ binding fluorescence experiments. 
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The dissociation constants (Kd) of different pertussis toxin (PT) preparations were determined 
by measuring the decrease in PT fluorescence spectroscopy with NAD concentration, at 24 °C. 
The data were corrected for the inner filter effect of NAD and analysed using the EquFit5 
programme (kindly provided by Dr Stephen R. Martin, National Institute for Medical 
Research, Mill Hill) to give the Kd values, % fluorescence decrease and errors of the data fit 
(x2). *Lobban and co-workers carried out the binding experiment at 23 °C, and the 
corresponding % fluorescence quenching value was given prior to correction for the inner 
filter effect. 
PT preparation Kd (µM) fluorescence 
quenching, % 
x2 
Mutant 63 23 0.54 
Native 52 36 1.72 
Native (Lobban et al., 1991 *) 37 -60 - 
Mutant, `activated' 21 44 1.53 
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Figure 3.1 Fluorescence of native and mutant PT 
Fluorescence spectra of native and mutant pertussis toxin (PT) (-30 µg/mL) 
in PBS, pH 7.4. An excitation, % of 280 nm was used with excitation and 
emission band passes of 4.25 and 4.5 nm respectively. 
134 
260 310 360 410 460 
1500000 
rn b 
aý o 
1000000 
Uy 
00 
, 
U. 
500000 
0 
260 310 360 410 460 
Wavelength (nm) 
Figure 3.2 (A) Quenching of fluorescence by NAD binding to PT 
Fluroescence spectra of mutant pertussis toxin (PT) before and after the 
addition of NAD+, 0- 40 µg/mL. The concentration of PT was 50 pg/mL 
in PBS pH 7.4, an excitation ?. of 280 nm was used and excitation and 
emission band passes were set at 4.25 and 4.5 nm respectively. 
The full quenching data for mutant PT is presented as fluorescence 
intensity maximum against NAD concentration in Figure 3.2 (B). 
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Figure 3.2 (B) Quenching of fluorescence by NAD binding to PT: 
Titration curve 
Comparison of fluorescence quenching of mutant pertussis toxin (PT) and the 
tryptophan derivative N-acetyl tryptophanamide (NATA), with the increasing addition 
of NAD+ (0 - 300 mM). In separate titrations, the maximum fluorescence intensity of PT 
or NATA was measured on each addition of NAD. NATA fluoresces but does not bind 
to NAD, and therefore was used to correct the PT titration data for the non-specific 
quenching of fluorescence due to absorbance of the exciting light by NAD (inner f ilter 
effect). The PT fluorescence intensities were corrected (not shown) for the reduction 
observed in NATA fluorescence, which is due to the inner filter effect of NAD. The 
dissociation constants (Kd) were calculated from the corrected titration data for native, 
mutant and 'activated' mutant PT, using the EquFit5 programme and are presented in 
Table 3.1. 
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3.2.1.2 Analysis of `activated' and NAD+-bound `activated' mutant PT 
fluorescence 
For `activation', mutant PT was treated with 100 mM dithiothreitol (DTT) at room 
temperature for two hours and the solution was extensively dialysed. Free sulphydryl was 
quantified immediately after `activation', and also after storage for one month at 4 °C, by 
the addition of Ellman's reagent and the measurement of absorbance by 
2-nitro-5-thiobenzoate at 412 nm. 
Intrinsic fluorescence spectroscopy was used, as described above (section 3.2.1.1), to 
analyse non-'activated' mutant PT, `activated' mutant PT, `activated' mutant PT after 
storage for one month at 4 °C and `activated' mutant PT with NAD+ added. The Kd 
values for NAD+ binding were also determined for mutant PT after `activation', by 
measuring intrinsic fluorescence intensity with increasing NAD+ concentration as 
described above (section 3.2.1.1). 
Analysis of `activated' mutant PT by fluorescence 
After reduction, or `activation', of mutant PT with 100 mM DTT for two hours at room 
temperature, 2.2 moles of free sulphydryl per mole of PT were detected (Table 3.2). This 
indicated that one out of a total of 13 disulphide bonds in the mutant PT molecule was 
broken. The reduction of this disulphide bond corresponded with a decrease in the Kd of 
mutant PT for NAD+, from a Kd of 63 to 21 µM (Table 3.1). These results implicated the 
cleaved disulphide bond as that of Cys-41 - Cys-201, in the putative active site. 
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Table 3.2 Disulphide bond cleavage by `activation' of mutant PT 
DTNB (5,5'-dithiobis(2-nitrobenzoic acid), or Eliman's reagent) liberates one mole of 2-nitro- 
5-thiobenzoate (A412nm) from reaction with one mole of free sulphydryl. On addition of 
DTNB, the absorbance (A412nm) of mutant pertussis toxin (PT) reduced with dithiothrietol 
(DTT) ('activated'), `activated' mutant PT after storage for 1 month and PT not reduced 
(negative control) was measured.. Reduced mutant PT was also examined for absorbance at 
412 nm without the addition of DTNB, as an additional control. The molar concentration of 2- 
nitro-5-thiobenzoate, was calculated according to the Beer-Lambert law and expressed as 
moles of free sulphydryl per mole of mutant PT. 
Mutant PT preparation Absorbance 
at 412 nm 
Moles of free sulphydryl 
per mole of mutant PT 
not reduced + DTNB 0.000 0 
reduced 0.000 0 
reduced, 1 month storage, +DTNB 0.000 0 
reduced + DTNB 0.022 2.19 
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Concomitant with the disulphide bond cleavage was a significant decrease in the band 
density for Si, relative to the other subunit bands, when `activated' PT was examined by 
SDS-PAGE under non-reducing conditions (data not shown). Further evidence implying 
the Si active site Cys-41 - Cys-201 as the cleaved disulphide bond, was that the 
concentration of DTT in this experiment was of the same order of magnitude as that 
necessary to produce almost full catalytic activity of native PT in vitro (Moss et al., 
1983). 
The `activation' of PT was accompanied by a2 nm red-shift in Trp fluorescence from 
338 to 340 nm (Figure 3.3). This suggested that cleavage of the Cys-41 - Cys-201 
disulphide bond promoted a structural modification causing exposure of nearby Trp to a 
more polar environment. The Trp-26 indole ring is located only 3.85 A from the Cys-41 - 
Cys-201 disulphide bond, suggesting that the reorientation of this Trp was responsible for 
the red-shift induced by `activation'. The reduction appeared to be reversible since after 
storing the `activated' mutant PT sample for one month at 4 °C, the free sulphydryls were 
no longer detectable (Table 3.1), the density of its Si band in SDS-PAGE was 
comparable with that of non-'activated' PT (not shown), and the Fmax was reversed back 
to 337 nm (Figure 3.3). 
Analysis of NAD+-bound `activated' mutant PT by fluorescence 
On addition of NAD+ to `activated' mutant PT a2 nm blue-shift in fluorescence from 340 
to 338 nm (Figure 3.3) was observed. This is in contrast to the unchanged Fmax observed 
with addition of NAD+ to non-`activated' mutant PT (Figure 3.2A). These results suggest 
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Figure 3.3 Effect of 'activation' and NAD binding on fluorescence spectrum 
Fluorescence spectra of non-activated pertussis toxin (PT), 'activated' PT, 'activated' PT after 
one month storage at 4 °C and 'activated' PT after addition of NAD (50 µM). The colours of 
the fluorescence spectra match those of the corresponding molecular models. The 
concentration of PT was 50 µg/mL, the excitation X used was 280 nm and excitation and 
emission band passes were set at 4.25 and 4.5 nm respectively. 
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that NAD+ causes a structural change in `activated' mutant PT near Trp 26 and/or 
interacts with Trp 26, shielding it from a polar environment. In addition they imply that 
`activation' allows NAD+ to come into closer contact with Trp-26 and thus move further 
into the binding site. 
3.2.2 Molecular modelling: Effect of `activation' and NAD+ binding 
on S1 subunit structure 
Models of the Si subunit were produced using the original crystal structure of PT (PDB 
number, 1 PRT (Stein et al., 1994a)). Initially a model was created for the mutated SI 
subunit of PT-9K/129G, which was used in the fluorescence studies. This was compared 
with the Si model of native sequence to identify possible structural differences. 
Secondly, in the majority of the study, molecular mechanics simulations were performed 
on the Si subunit of native sequence to produce three models: non-`activated', `activated' 
and NAD+-bound `activated', and their structures were analysed in detail. 
3.2.2.1 Comparison of mutant and native S1 subunit molecular models 
The majority of the molecular modelling studies were performed on the Si model of 
native sequence from the original crystal structure for PT, and compared with 
fluorescence the studies of mutant PT. Therefore, a mutant Si model was generated and 
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compared with the original Si model to identify any possible structural differences. 
Mutation of the Si subunit was simulated in insightII by changing Arg-9 to Lys and Glu- 
129 to Gly followed by energy minimisation. 
Superimposition of the native and mutant (Arg-9 to Lys, Glu-129 to Gly) Si subunit 
models demonstrated that their peptide backbones were almost completely aligned and 
that only small rotations in the 4, yr and xl angles occurred (data not shown). Most of the 
rotations were not significant compared to those observed after `activation' or NAD+ 
binding, with the exception of Thr-53, which rotated by more than 200. This result 
suggests that, in combination with the mutation of Arg-9 and Glu-129, the accompanying 
structural change in the catalytically important residue Thr-53 may further contribute to 
the catalytic inactivation of this mutant. Other than these changes, the mutant and native 
Si models were similar. The following modelling experiments were performed on the 
native Si subunit molecule, of the original crystal structure. 
3.2.2.2 Analysis of `activated' and NAD+-bound S1 subunit by 
molecular modelling 
From the original crystal structure of PT (PDB number, 1PRT Stein et al., 1994a) three 
models of the Si subunit were produced, and are presented: non-`activated' S 1, 
`activated' Si and NAD+-bound `activated' S 1. The Si subunit was `activated', by 
breaking and protonating the Cys-41- Cys-201 disulphide followed by energy 
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minimisation. In order to dock NAD+ into the `activated' Si molecule, distances 
measured between NAD+ and homologous amino acids (Table 3.3) in the DT-NAD+ 
complex (1TOX, Bell and Eisenberg, 1996) were applied as restraints during energy 
minimisation. The non-'activated' S 1, `activated' Si and NAD+-bound `activated' Si 
molecules were minimised using the AMBER force field and software (Cornell et al., 
1995) allowing flexibility in both the whole protein molecule and in NAD+. Rotation of 
the Si dihedral bond angles, 4 (defined by atoms N' -C- Ca - N), yl (defined by atoms 
C- Ca -N- C') and xl (defined by atoms N- Ca - Cß - Cy etc) (measured in 
insightII), and change in percentage solvent accessibility of amino acid side chains 
(determined using NACCESS, (Hubbard and Thornton, 1993)) were calculated both after 
`activation' of the Si molecule and NAD+ binding to the `activated' model. 
Analysis of the `activated' S1 subunit molecular model 
By cleaving the Cys-41 - Cys-201 disulphide bond ('activation'), there was significant 
movement of the Cys-201 and, more markedly, Cys-41 side chains (Figures 3.4A and 
3.4B). This movement, along with a significant rotation of the Trp-26 ti angle by 15°, 
positioned the indole ring of Trp-26 in much closer proximity to the Cys-41 residue. A 
1.9 A shift in the Ca atom of Trp-26 was measured. The indole ring shifted from a 
position 3.85 A from the Cys-41 S-S bond before `activation', to 2.03 A from the newly 
formed polar S-H bond after `activation'. This proximity to a polar group could 
account for the red-shift in Trp fluorescence maximum observed after reduction (Figure 
3.3). Additionally there was movement of a-helix amino acids 185 - 210 (Figure 3.4C), 
some becoming more solvent accessible and others more buried (Figure 3.4D). 
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Table 3.3 Homologous amino acids of PT and DT 
Homologous amino acids of pertussis toxin (PT) and diphtheria toxin (DT) obtained from 
sequence alignments of the structurally equivalent residues of pertussis toxin (PT), diphtheria 
toxin (DT), Escherichia coli heat-labile enterotoxin (LT) and Pseudomonas aeruginosa 
exotoxin-A (PAETA), taken from (Stein, 1994). 
PT Tyr-8 Gly-86 Glu-129 Tyr-130 Val-91 
DT Tyr-20 Gly-78 Glu-148 Tyr-149 Val-83 
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Figure 3.4 (A) `Activated' Si subunit model 
Superimposed models of the Si subunit before and after `activation', by cleavage 
of the Cys-41 - Cys-201 disulphide bond. Model minimised using AMBER 
software. 
Non-`activated' SI subunit - green; `activated' Si subunit - red. 
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Figure 3.4 (B) `Activated' Si subunit model (enlarged) 
Superimposed enlarged sections of the SI subunit models before and after `activation' 
by cleavage of the Cys-41 - Cys-201 disulphide bond. 
Non-`activated' SI subunit - green; `activated' Si subunit - red. 
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Figure 3.4 (C) `Activated' Si subunit, bond rotations 
Change in PT amino acid dihedral bond angles (4, y and x1) after 
`activation'. The bond angles for the 'activated' and NAD-bound 'activated' 
PT models were measured in insightII and the smallest absolute difference 
between them was calculated. 
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Analysis of NAD+-bound `activated' S1 subunit molecular model 
Trp-26 exists on a turn in a helix, and is partially solvent exposed, being 37 % accessible 
to solvent, as determined by a solvent accessibility programme (NACCESS, (Hubbard 
and Thornton, 1993)). On NAD+ binding, Trp-26 moves further into the molecule, into a 
less solvent accessible position by a 100° rotation of its side chain (3.5 A shift in the 
indole ring), compared with the average X rotation for all side chains of under 1011 
(Figures 3.5A - Q. Again this is in agreement with the blue-shift observed in intrinsic 
fluorescence spectroscopy upon addition of NAD+. 
The side chains of active site residues such as Tyr-8, Arg- 9 and Glu-129 also rotate 
significantly (Figure 3.5B) and their close proximity to the NAD+ molecule in the model 
was observed (Figure 3.5A). Other catalytically important residues, Phe-50 and Thr-53, 
did not appear to move significantly on NAD+ binding but the peptide backbone of the 
two residues between them, Val-51 and Ser-52, did move considerably. Further 
movement of a-helix amino acids 185 - 210 also occurred on NAD+ binding (Figure 
3.5B) and the a-helix moved out of the binding site (Figure 3.5A) into a more solvent 
accessible position, exposing the G-protein binding residues (195 - 204; Figure 3.5D). 
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Figure 3.5 (A) NAD-bound `activated' SI subunit model 
Model of the `activated' SI subunit after NAD binding. Model 
minimised using AMBER software. 
NAD-bound Si subunit - blue; NAD - yellow. 
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Figure 3.5 (B) NAD-bound `activated' SI subunit model (enlarged) 
Superimposed enlarged sections of the `activated' SI subunit models 
before and after NAD binding. 
`Activated' Si subunit before NAD binding - red; NAD-bound `activated' 
Si subunit - blue; NAD -yellow. 
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Figure 3.5 (C) NAD-bound `activated' Si subunit, bond rotations 
Change in PT amino acid dihedral bond angles (ý, yr and XI) after NAD 
binding. The bond angles for the non-'activated' and 'activated' PT models 
were measured in insightII and the smallest absolute difference between 
them was calculated. 
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3.3 Discussion 
`Activation' and NAD binding of Si subunit 
Many assumptions have previously been made about the binding of NAD+ to PT, from 
comparisons with other structurally and functionally homologous bacterial toxins 
(Domenighini et al., 1991). The present investigation has revealed models for both the 
`activated' and NAD+-bound forms of the Si subunit, which are wholly supported by 
results from fluorescence spectroscopy. These models also bear out some previous 
predictions and agree with active site mutagenesis experiments. 
Until now evidence for the physical requirements of catalytic activation has been 
speculative. From the original crystal structure of non-'activated' PT (Stein et al., 1994a), 
it was envisaged that `activation' or cleavage of the active site disulphide bond, Cys-41 - 
Cys-201, would be required to allow the NAD+ binding site to open up by movement of 
the amino acid sequence 184 - 203 (Stein et al., 1994a). The `activated' computer model 
of Si from this study illustrates that significant structural adjustment did occur within an 
a-helical region defined by amino acids 185 - 210. This model further illustrates 
movement of the catalytically important Trp-26 residue into the binding site, to a position 
close to the S-H bond of Cys-41, and this is supported by a red shift in intrinsic 
fluorescence spectroscopy of mutant PT upon reduction with DTT. It appears that 
`activation' by cleavage of Cys-41 - Cys-201 is required to release the a-helix (residues 
185 - 210) and orient the active site residues in preparation for subsequent NAD+ binding 
and catalysis. 
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The novel `activated' NAD+-bound PT model demonstrated that NAD+ docked into the 
putative binding site. This is a cleft defined by a motif composed of an a-helix and a 
ß-strand facing a large loop, which had been previously been predicted by homology 
studies of PT, LT1 and LT2, CT, PAETA and DT (Domenighini et al., 1991; 
Domenighini et al., 1994). Involvement of catalytically important residues, Tyr-8, Arg-9, 
Phe-50, Thr-53, Glu-129 and Trp-26 previously identified in mutagenesis experiments 
(Pizza et al., 1988), was also clearly illustrated by the model, as shown by significant 
rotation of 4, yr and yi angles upon NAD+ binding. 
The a-helix (185 - 210), observed to adjust upon `activation', moved significantly out of 
the active site cleft upon NAD+ binding. This model bears out the previous predictions of 
P. Stein and colleagues (Stein et al., 1994a), that this would be a physical requirement for 
NAD binding. It is fascinating that movement of the helix not only facilitates NAD+ 
binding but concomitantly reveals a G-protein substrate binding site (Figure 3.5D). The 
moving a-helix in this model is the predicted `active site loop' of PT, and homologous 
such `active site loops' have also been identified in LT, CT and DT (Locht and Antoine, 
1999). Attempts to model the active site using the crystal structure for PT have previously 
been carried out using only sections of the Si subunit, within the amino acid sequence 2- 
189, and the separated adenine and nicotinamide moieties of NAD+ (Scheuring, Berti, 
and Schramm, 1998; Cummings, Hart, and Read, 1998). Moreover, in these studies rigid 
docking schemes were employed (Scheuring, Berti, and Schramm, 1998). Therefore, 
these studies could not address the involvement of the a-helix occluding the active site. 
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The modelling studies also revealed that, upon NAD+ binding, Trp-26 moved to an even 
more buried position close to the nicotinamide moiety of NAD+. This was in agreement 
with the blue-shift in fluorescence observed upon addition of NAD+. Studies using 
fluorescence have previously failed to detect such a blue-shift (Seabrook, Atkinson, and 
Irons, 1991) due to the fact that non-'activated' PT was used. Results from the current 
study do corroborate findings of Cortina and Barbieri (Cortina and Barbieri, 1989) that 
Trp-26 is involved in NAD+ binding. This group also established the importance of an 
aromatic residue at this position for NAD+ binding. 
In addition to the blue-shift in PT fluorescence on NAD+ binding, fluorescence quenching 
was concomitantly observed. Past investigations of ADP-ribosylating toxins have 
highlighted several possible mechanisms for Trp fluorescence quenching with NAD+, 
including base-stacking of the indole ring with the nicotinamide or adenine moieties of 
NAD+ (Beattie, Prentice, and Merrill, 1996; Brandhuber et al., 1988). Aromatic stacking 
between nucleotides and the indole ring of Trp has been previously recognised as a 
common mechanism for protein-nucleotide binding (Nishikawa et ah, 1988; Khamis et 
al., 1987; Casas-Finet et al., 1988). However, our model for NAD+ binding does not 
support the mechanism of aromatic stacking of the Trp-26 indole ring. This may be partly 
due to the fact that the AMBER programme used for minimisation has no explicit force 
field term for aromatic stacking interactions. However, in agreement with our results, 
Cortina and Barbieri (1989) demonstrated that ADP-ribosyl transferase activity of PT was 
not fully maintained with any of the aromatic substitutions of Trp-26, and advocated that 
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the interaction between NAD+ and Trp-26 is more involved than aromatic base-stacking 
alone. 
An alternative explanation for the observed quenching of Trp-26 fluorescence is by an 
electron transfer mechanism, which has also been previously advocated in the 
fluorescence quenching of Trp-558 of PAETA (Beattie, Prentice, and Merrill, 1996). In 
the current NAD+-bound model of Si, the proximity of NAD+ to Trp-26 (nicotinamide 
ribose moiety of NAD+ is positioned only 2.45 A from the indole ring of Trp-26) may 
account for fluorescence quenching by electron transfer. 
The role of the active site Trp-26 of PT in the ADP-ribosyl transferase reaction is not yet 
known. Specific fluorescence quenching of active site Trps upon NAD+ binding has been 
found for several protein toxins including PAETA (Trp-558) and DT (Trp-50 and Trp- 
153; (Beattie, Prentice, and Merrill, 1996; Wilson et al., 1994; Lory et al., 1980). These 
results suggested that these Trp residues have a specific role in NAD+ binding. An 
alternative role for Trp residues in the assimilation of NAD+ may be in stabilising the 
hydrophobic NAD+-binding cavity, as found for Trp-350 of Bacillus-produced vegetative 
insecticidal protein-2 (VIP2) (Han et al., 1999). 
The `activated' NAD+-bound model for PT may form the basis for further research on the 
mechanism of ADP-ribosylation, common to a variety of bacterial protein toxins. The 
structural involvement of disulphide bond reduction and NAD{' binding in the action of 
PT, may be developed to explain the sequence of events following PT binding that lead to 
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catalysis in vivo including, vesicular trafficking, internalisation and G-protein targeting. 
The distinct roles of the A- and B-oligomer in the numerous biological properties of PT, 
including toxic and immunogenic properties, still require clarification. The use of toxins 
such as PT, CT and LT as vaccines, adjuvants and therapeutic products will depend on 
further such structural and functional investigation. 
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and murine immune response 
4.1 Introduction 
Clinical trials have revealed differences in the efficacy of acellular pertussis vaccines 
produced by different manufacturers (Hewlett and Cherry. J. D., 1997; Decker and 
Edwards, 2000; Edwards, 1998), and these discrepancies have been attributed to 
differences such as the study design of the trials and antigenic composition of the 
vaccines (Hewlett and Cherry. J. D., 1997). PT is the major toxic and immunogenic 
antigen of acellular pertussis vaccines (Pittman, 1979; Sato et al., 1980; Oda et al., 1984; 
Trollfors et al., 1995), and manufacturers employ a variety of detoxification protocols 
which involve different chemical treatments. Variations in the antigenic properties of PT 
toxoids could be one of the factors which contribute to the observed differences in the 
clinical efficacy of acellular pertussis vaccines. 
To investigate this possibility, five different PT toxoids were obtained from 
manufacturers of acellular pertussis vaccines for structural and immunological analysis. 
The toxoids are identified by letters A-E and were each produced under different 
manufacturing protocols using different toxoiding agents: A- genetically detoxified (PT- 
9K/129G) with low FA treatment (0.035 %, w/v, FA), B- glutaraldehyde plus 
formaldehyde treatment, C- glutaraldehyde treatment, D- tetranitromethane treatment, 
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and E- hydrogen peroxide treatment. The toxoids and the untreated native PT samples 
from each manufacturer were analysed by SEC/UV and fluorescence spectroscopy, to 
assess the effects of the different toxoiding procedures on the molecular structure and size 
of the resultant PT molecules. SDS-PAGE and Western blotting were carried out, using 
subunit specific monoclonal antibodies (mAbs), in order to investigate subunit cross- 
linking and epitope modification upon toxoiding. In addition, the relative 
immunogenicities of the toxoids were determined by assessing the induction of murine 
anti-PT total IgG by ELISA. IgGI and IgG2a subclass antibodies were also assayed, as 
markers for Th2- and Thl-type immune response respectively (Male et al., 1996). 
Furthermore, the protective efficacy of each toxoid was determined by aerosol challenge 
in the mouse model. 
4.2 Results 
4.2.1 The effect of different chemical toxoiding on the structure of 
PT 
The untreated native PT samples obtained from each manufacturer were all analysed by 
SEC/UV and fluorescence spectroscopy and gave comparable results. Therefore, the 
results from one native PT sample are presented. 
160 
Chapter 4 
Analysis of PT toxoids by SEC/UV 
PT toxoids 
The five different toxoids, A-E, and representative native PT sample were subject to 
SEC/UV using an FPLC system equipped with a Superdex 200 column, at a flow rate of 
0.5 mL/min in PBS buffer, pH 7.5. The elution of protein was detected both at 214 and 
280 nm, and the 214 nm trace is presented (Figure 4.1). 
The untreated native PT typically eluted as a single broad peak at 18 mL (Figure 4.1). For 
toxoid A, most of the protein eluted in an earlier peak at 16.7 mL, which was much 
broader and had a slight shoulder at about 18 mL. For the other aldehyde-treated toxoids, 
B and C, and the tetranitromethane-treated toxoid, D, the bulk of material eluted much 
earlier, starting at - 10 mL, as a series of non-uniform peaks. For these toxoids well 
defined peaks appeared at 12.3 mL for toxoid B, 17.1 mL for toxoid C and 14.9 mL for 
toxoid D. The hydrogen peroxide-treated toxoid E was quite different from the other 
toxoids, and eluted as a single peak at 19.4 mL, with a similar profile to the untreated 
native PT. 
The variety of profiles obtained for toxins A-E indicate that different toxoiding 
chemicals and procedures caused different modifications to the PT molecules, which 
became associated in different ways. Toxoid A, which is genetically detoxified and 
treated with 0.035 % (w, v) FA, appeared to contain slightly higher molecular weight 
material than the untreated native PT. For the formaldehyde plus glutaraldehyde-treated 
toxoid B, glutaraldehyde-treated toxoid C and tetranitromethane-treated toxoid D, the 
earlier-eluting, broad, non-uniform spectra suggest these toxoiding chemicals produced 
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Figure 4.1 Effect of different different toxoiding procedures on the size of PT 
Pertussis toxin (PT) toxoids obtained from five different manufacturers (A - E) and an 
untreated native PT sample (15 µg protein in 200 mL PBS, pH 7.5) were analysed using 
size exclusion chromatography with UV detection (SEC/UV). The FPLC system was 
equipped with a Superdex 200 column and samples were eluted in PBS, p117.5. Each 
manufacturer employed a different PT toxoiding agent: A- genetically detoxified plus low 
formaldehyde treatment, B- glutaraldehyde plus formaldehyde treatment, C- 
gluteraldehyde treatment, D- tetranitromethane treatment, E- hydrogen peroxide 
treatment. Elution positions of selected molecular weights (labelled in kDa) and of the 
exclusion volume (Vo) and total volume (Vt), as determined by calibration with protein 
standards, are indicated with arrows. Absorbance at 214 nm is shown. 
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heterogeneous species of higher molecular weight than the other toxoids. In addition, the 
early eluting, more defined peaks suggest that there were some high molecular weight 
molecules that were homogeneous in size. This implies that they may have been created 
from the favoured associations of holotoxin or oligomeric, dimeric or monomeric 
subunits. In contrast to the other toxoids, toxoid E eluted with a similar profile to the 
untreated native PT. Its slightly later elution may suggest that the charge or shape of the 
PT molecule had been modified to some extent by hydrogen peroxide. 
Analysis of PT toxoids by fluorescence spectroscopy 
PT contains six Trp residues and 62 Tyr residues, therefore intrinsic fluorescence of these 
environmentally sensitive aromatic side chains is potentially a sensitive indicator of 
changes in the molecular structure of PT. The PT toxoids, A-E, were subject to 
fluorescence spectroscopy by ,, e7, of 280 mn. The fluorescence was scanned from 260 to 
500 nm and the base line fluorescence of the sample buffer (PBS, pH 7.5) was subtracted. 
The untreated native PT displayed a typical fluorescence spectra with fluorescence 
emission wavelength maximum (Fmax) from Trp fluorescence at 337 nm and a shoulder 
from Tyr fluorescence at - 305 nm (Figure 4.2) (Seabrook, Atkinson, and Irons, 1991). 
Both toxoids A and B displayed a significantly red-shifted Fmax of 340 nm and 342 run 
respectively, but retained spectra of a similar shape to that of the untreated native PT 
(Figure 4.2). Toxoid C produced a fluorescence spectrum which also had a red-shifted 
Fmax of 345 nm (Figure 4.2). In addition, the intensity of fluorescence was significantly 
diminished with respect to the untreated native PT preparation, even though the same 
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concentration of protein was used. Toxoid D also exhibited a red-shifted Fmax and, like 
toxoid C, also gave lower fluorescence intensity than expected (Figure 4.2). The 
fluorescence of both toxoids C and D, even at three times the concentration (-. 90 µg/mL) 
of the native PT, resulted in half of the fluorescence intensity (not shown). Toxoid E 
produced a fluorescence spectrum which displayed a single peak at 305 nm but appeared 
to be devoid of any contribution from Trp (Figure 4.2). 
The very different fluorescence spectra obtained from PT toxoids illustrate that different 
chemical treatments cause a variety amino acid modifications, leading to an assortment of 
local conformational changes in the vicinity of aromatic residues and/or specific 
alterations of the aromatic residues. All of the toxoids, with the exception of toxoid E, 
displayed a red-shift in Fmax which can be indicative of Trp exposure to solvent, 
suggesting protein unfolding. Therefore, these results suggest that the FA treatment of 
toxoid A, the glutaraldehyde plus formaldehyde treatment of toxoid B, the glutaraldehyde 
treatment of toxoid C and the tetranitromethane treatment of toxoid D all caused protein 
unfolding. 
The results of toxoid E suggest that hydrogen peroxide modified the Trp residues, and 
thus altered their fluorescent properties. In addition, it is also credible that some specific 
Tyr and/or Trp modifications contributed to the marked reduction in fluorescence 
intensity of the glutaraldehyde and tetranitromethane treated toxoids, C and D. 
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Figure 4.2 Effect of different different toxoiding procedures on PT fluorescence 
Pertussis toxin (PT) toxoids (30 µg/mL) obtained from five different manufacturers (A 
E), and untreated native PT were analysed by fluorescence spectroscopy in PBS, pH 
7.5 with excitation at 280 nm. Fluorescence was scanned from 260 - 500 nm, and 
spectra corrected by subtraction of the PBS base-line spectra. Each manufacturer 
employed a different PT toxoiding agent: A- genetically detoxified plus low 
formaldehyde treatment, B- gluteraldehyde plus formaldehyde treatment, C- 
glutaraldehyde treatment, D- tetranitromethane treatment, E- hydrogen peroxide 
treatment. The different toxoids are labelled by letter along with their corresponding 
fluorescence maximum values (nm) which are marked with a cross on each spectra. 
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4.2.2 The effect of different chemical toxoiding on PT subunit cross- 
linking and epitope integrity 
Analysis of PT toxoids by SDS-PAGE and Western blotting 
Three different toxoids, B, C and E, and an untreated native PT sample (each of -5 µg) 
were subject to SDS-PAGE in tris-glycine SDS running buffer using a 14 % tris-glycine 
acrylamide gel, under non-reducing conditions. The gels were blotted onto nitrocellulose 
membranes and each screened with a mAb, specific for an epitope on the PT subunits Si 
- S5, or stained with Coomassie blue. Molecular weights were determined relative to 
protein molecular weight standards that were run on each gel. 
The Coomassie-stained gel illustrates the typical four-band pattern of untreated native PT 
(Figure 4.3), with distinct bands of relative molecular weights 26.5 kDa (Si), 24.1 (S2), 
22.2 (S3) and 13.4 (S4 and S5). The aldehyde-treated toxoids B and C, produced a smear 
of protein from close to the gel limit (250 kDa) to - 20 kDa, and protein bands 
corresponding to the molecular weight of subunits S4/5, SI and higher. Toxoid B 
produced denser higher molecular weight bands than toxoid C. The hydrogen peroxide- 
treated toxoid E did not produce any high molecular weight bands but produced a very 
faint band at - 32 kDa and slightly darker bands at 29 kDa, 24 kDa and 14 kDa. 
In direct correlation with the SEC/UV results, the results from SDS-PAGE suggested that 
aldehyde treatment of toxoids B and C promoted the production of heterogeneous high 
molecular weight aggregates, and in addition revealed that the high molecular weight 
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Figure 4.3 The effect of different chemical detoxification procedures on subunit 
cross-linking 
Chemically detoxified PT antigen from 3 different companies, B, C and E (lanes 3,4 
and 5 respectively), an untreated native PT sample (lane 2) and molecular weight 
standards (lane 1; labelled in kDa) were analysed by SDS-PAGE and stained with 
Coomassie blue stain, or blotted on to nitrocellulose and screened using one of five 
Mabs specific for epitopes on subunits S1- S5. Each manufacturer employed a 
different PT toxoiding agent: B- glutaraldehyde plus formaldehyde treatment, C- 
gluteraldehyde treatment, E- hydrogen peroxide treatment 
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species are associated by covalent cross-linking. In contrast, results from SDS-PAGE and 
SEC showed that the molecular weight and subunit association of PT in toxoid E 
remained relatively unchanged. The four bands of toxoid E detected by SDS-PAGE had a 
slightly shorter migration distance than untreated native PT, suggesting that hydrogen 
peroxide alters the charge, hydrophobicity or shape of the subunits. 
Western blotting showed that the high molecular weight products produced by 
glutaraldehyde plus formaldehyde treatment of toxoid B, contained combinations of 
subunit epitopes Si - S5. However, subunits S2, S3 and S4 appeared relatively sparse. 
The glutaraldehyde-treated toxoid C encompassed less dense Si epitopes and no 
detectable S2, S3 or S4 epitopes. These results suggest that S2, S3 and S4 epitopes were 
susceptible to chemical modification by aldehyde treatment which may be due to the 
covalent cross-linking. A large reduction in S2, S3 and S4 epitopes of these aldehyde- 
treated toxoids B and C was also observed by mAb-binding in ELISA (Dr D. Xing, 
unpublished work). In toxoid E, epitope Si was detected at a low density and all other 
subunit epitopes appeared to be absent, suggested that hydrogen peroxide-induced 
modifications are detrimental to the integrity of PT epitopes. In this toxoid E, a decrease 
in all subunit epitopes, Si - S5, was also observed by mAb binding in ELISA (Dr D. 
Xing, unpublished work). 
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4.2.3 The effect of different chemical toxoiding on murine anti-PT 
IgG antibody response and protective efficacy 
Analysis of anti-PT IgG antibody response by ELISA 
Sample groups of five mice (strain, NIH) were each immunised with one immunisation 
dose (5 µg) of the five different toxoids, A-E. After five weeks, the mice were 
terminally bled and serum samples prepared. The PT-specific total IgG, and IgG 1 and 
IgG2a subclass antibodies in the serum samples were quantified using ELISA. 
The genetically inactivated FA-treated toxoid A induced the highest IgG response (Figure 
4.4), followed by a two-fold lower response induced by the glutaraldehyde plus 
formaldehyde-treated toxoid B. The glutaraldehyde- and tetranitromethane-treated 
toxoids, C and D, induced similar total IgG responses, which were six-fold lower than for 
toxoid A. Finally, the hydrogen peroxide-treated toxoid E induced the lowest IgG 
response, 13-fold lower than for toxoid A. 
The decrease in total IgG response of toxoid C, compared with toxoid B, correlates with 
its diminished epitope density, as illustrated by results of Western blotting. In particular, 
toxoid C possessed less of the Si epitope, which is known to be a highly protective 
epitope of PT (Sato, Sato, and Ohishi, 1991; Sato and Sato, 1990). The low IgG response 
induced by hydrogen peroxide-treated toxoid E may also be a consequence of its 
exceptionally low density of subunit epitopes, as detected by Western blotting. 
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Figure 4.4 The effect of different PT toxoiding procedures on total IgG 
production 
Serum was collected from groups of five ºnice, each group immunised with 5 ig 
of a different pertussis toxin (PT) toxoid obtained from live different 
manufacturers (A - E). PT-specific total IgG was quantitated by F. LISA relative 
to a PT reference serum, and expressed as the relative geometric mean of the live 
serum samples with one geometric standard deviation, indicated by error bars. 
Each manufacturer employed a different PT toxoiding agent: A- genetically 
detoxified plus low formaldehyde treatment, B- glutaraldehyde plus 
formaldehyde treatment, C- glutaraldehyde treatment, 1) - tetranitromethane 
treatment, E- hydrogen peroxide treatment. 
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The IgG1 and IgG2a responses to the toxoids varied, and did not necessarily follow the 
trend of the total IgG (Figure 4.5). Toxoid A gave a high IgGl/IgG2a ratio (Figure 4.6) 
which is an indication that the immune response it induced was polarised towards a Th2 
type of response. Toxoid B had a very low IgGI/IgG2a ratio (0.4) indicating that it may 
have induced a relatively Thl polarised response. Toxoids C, D and E all gave an 
IgGl/IgG2a ratio much greater than 1 suggesting that these immune responses were also 
relatively Th2 polarised, but this was less significant than for toxoid A. 
Analysis of murine protective efficacy of PT toxoids using aerosol challenge 
Groups of five mice (strain, NIH) were each immunised with one of the toxoids A-E 
(5 µg/dose) as for the IgG assay, or with a negative control (PBS). After three weeks the 
mice were exposed to aerosol challenge for five minutes with a suspension of live B. 
pertussis cells. The lungs were sampled seven days after challenge, homogenized and 
plated out in four serial dilutions. The total viable count of B. pertussis cells per lung was 
determined and the geometric mean count per lung, and geometric standard deviation, for 
each sample group of five mice was calculated. 
The protective efficacy of the five different toxoids was in the order A, B, C, D and E 
(Figure 4.7). The genetic toxoid A treated with low FA was by far the most protective, 
and in this group of mice the bacterial count was 50-fold less than that detected in the 
negative control group. Protection provided by glutaraldehyde plus FA-treated toxoid B 
was four-fold lower than for toxoid A, and glutaraldehyde-treated toxoid C was ten-fold 
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Figure 4.5 The effect of different PT toxoiding procedures on IgGI 
and IgG2a production 
Serum was collected from groups of live mice, each group immunised with 5 Iºg 
of a different pertussis toxin (PT) toxoid obtained from five different 
manufacturers (A - E). PT-specific IgGI and lg(i2a subclasses were quantitated by 
ELISA relative to a PT reference serum, and expressed as the relative geometric 
mean of the five serum samples with one geometric standard deviation, indicated 
by error bars. Each manufacturer employed a different PT toxoiding agent: A- 
genetically detoxified plus low formaldehyde treatment, E3 - glutaraldehyde plus 
formaldehyde treatment, C- glutaraldehyde treatment, 1) - tetranitronmethanc 
treatment, E- hydrogen peroxide treatment. 
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Figure 4.6 The effect of different PT toxoiding procedures on 
on the IgGI/IgC2a ratio 
Five mice were each immunised with 5 pg of one of five different 
company's PT antigen (A - E). PT-specific Ig(i I and Ig(12a in the mice 
sera were quantitated by ELISA, relative to a PT reference, and the 
geometric mean potency of the five serum samples per group determined. 
The geometric means are expressed here as lgG t /lg(i2a ratio. Fach 
manufacturer employed a different PT toxoiding agent: A- genetically 
detoxified plus low formaldehyde treatment, 13 - glutaraldehyde plus 
formaldehyde treatment, C' - glutaraldehydc treatment, 1) - 
tetranitromethane treatment, E- hydrogen peroxide treatment. 
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Figure 4.7 Protective efficacy of PT toxoids 
Groups of live NIH mice were aerosol challenged with live R. fJertussi.,; cells three 
weeks alter immunisation with pertussis toxin (PT) toxoids, A- l`. (from five ditlerent 
manufacturers). Their lungs were sampled seven days after challenge, the number of 
colony forming units (CFU) per lung were determined and the geometric mean ('IU 
and geometric standard deviation (expressed as error bars) for each group of live mice 
were calculated. 100 0% infection is equivalent to 2.2 x 10" ('I U/lung. Fach 
manufacturer employed a different PT toxoiding agent: A- genetically detoxified plus 
low formaldehyde treatment, B- glutaraldehyde plus formaldehyde treatment, (' - 
glutaraldehyde treatment, D- tetranitromethane treatment, I. - hydrogen peroxide 
treatment. 
This experiment was carried out by Cathy Canthaboo, NIBS(', 1997. 
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lower. Tetranitromethane- treated toxoid D and hydrogen peroxide-treated toxoid E 
provided a relatively low level of protection - 25-fold lower than for toxoid A. 
The trend in protective efficacy of the toxoids A-E corresponds closely with the trend in 
total IgG response. Both the highest protection and the highest total IgG response were 
induced by toxoid A, and the protection and total IgG response provided by toxoid B 
were the next highest. The total IgG response induced by toxoids C and D was very 
similar but toxoid D provided slightly higher protection. Both the lowest protection and 
the lowest total IgG response of all the toxoids were provided by toxoid E. 
4.3 Discussion 
In order to address the role of toxoids in modulating the immune response, five 
commercial toxoids were analysed by structural and immunological techniques. 
Genetically detoxified PT with 0.035 % FA (toxoid A) 
Toxoid A encompassed heterogeneous PT species of slightly higher molecular weight 
than untreated native PT as illustrated in the SEC results. Since untreated mutant PT has 
been shown to be structurally similar to untreated native PT (Nencioni et al., 1990), it 
follows that it was the FA treatment which caused modification of the mutant PT toxoid. 
There appeared to be some unfolding of the toxoid species as determined by 
fluorescence. Although toxoid A was not analysed by Western blotting in this study, 
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mAb-binding was previously analysed by ELISA (Dr D. Xing, unpublished work) and 
showed that there was a high density of all subunit epitopes as compared with untreated 
native PT. In addition, toxoid A induced the highest total IgG response of all the toxoids 
tested, and the highest level of protection as determined by aerosol challenge. 
Glutaraldehyde plus formaldehyde-treated PT (toxoid B) 
Toxoid B was composed of species much more heterogeneous, and of considerably 
higher molecular weight than untreated native PT, as determined by SEC. Fluorescence 
spectroscopy also showed that at least a proportion of the toxoid species was unfolded 
compared to the untreated mutant PT. SDS-PAGE and Western blotting results of toxoid 
B confirmed the presence of high molecular weight species, and demonstrated that they 
were associated by inter-subunit covalent cross-linking. In addition, these results revealed 
that some subunit epitopes, in particular the protective epitope on S 1, were maintained in 
even the very highest molecular weight species. The presence of immune epitopes in 
toxoid B may account for its high immunogenicity, as illustrated by the relatively high 
IgG response and the high protection against aerosol infection, which was second only to 
toxoid A. 
Glutaraldehyde-treated PT (toxoid C) 
Toxoid C contained very high molecular weight material even compared to toxoid B, as 
told by the SEC spectra. As with toxoids A and B, the red-shifted intrinsic fluorescence 
implied that these high molecular weight species were composed of unfolded protein. In 
addition, intrinsic fluorescence intensity was unusually low, also suggesting that the 
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aromatic amino acids had been modified and their fluorescence properties were altered. 
Western blotting demonstrated that the high molecular weight species formed by 
glutaraldehyde treatment were associated by inter-subunit covalent cross-linking. 
However, toxoid C encompassed a lower density of epitopes compared with toxoid B. 
This correlates with the lower IgG response and decreased protectivity of toxoid C, 
compared with that of toxoid B. 
The variation of PT cross-linking, aggregation and epitope modification between the 
aldehyde-treated toxoids, A, B and C, may depend on differences in the detoxification 
protocol such as the concentration of aldehydes employed, the presence of amino acid 
additives, and the temperature and time of incubation. For example, toxoids B and C 
contained higher molecular weight material than toxoid A, which is very likely to be a 
consequence of the higher concentrations of aldehyde treatment required for 
detoxification of native PT. This proposal is in agreement with experiments which 
suggested that aldehydes such as formaldehyde and glutaraldehyde can cause an increase 
in the molecular weight of B. pertussis protein antigens, including PT and FHA 
(Bolgiano et al., 1999). In addition, FA-treatment has been shown to generate covalent 
cross-links in bovine serum albumin (Tome, Kozlowski, and Mabon, 1985). Also, in the 
present study, the more severely aldehyde-treated toxoids, B and C, had a lower 
immunogenicity and protective efficacy than toxoid A. In correlation with this, a previous 
study of mutant PT showed that increasing FA-treatment caused a decrease in its Si 
protective epitope recognised by mAb 1 B7, and a reduction in its ability to induce 
neutralising antibodies in vivo (Nencioni et al., 1991). 
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Tetranitromethane-treated PT (toxoid D) 
Toxoid D was composed of a large proportion of high molecular weight material as 
observed by SEC. In agreement with these results, tetranitromethane has previously been 
reported to cause aggregation in a variety of proteins including rabbit gamma-globulin 
and collagen (Doyle, Bello, and Roholt, 1968). As for the aldehyde-treated toxoids, the 
intrinsic fluorescence of toxoid D also suggested that it was composed of at least a 
proportion of unfolded protein. An additional possibility for the modified fluorescence 
spectra may be the chemical modification of Trp and Tyr residues by tetranitromethane, 
which may alter their fluorescence properties. This is very likely since tetranitromethane 
has been shown to react with both Trp and Tyr residues in proteins (Muhlrad, Corsi, and 
Granata, 1968; Riordan, Sokolovsky, and Vallee, 1967; Cuatrecasas, Fuchs, and 
Anfinsen, 1968). Previous analysis of this toxoid by mAb in ELISA showed a significant 
loss in the Si epitope and some decrease in the S3 and S4 epitopes (Dr D. Xing, 
unpublished work). These modifications of PT correspond to the reduction in 
immunogenicity and protective efficacy of toxoid D. 
Hydrogen peroxide-treated PT (toxoid E) 
Hydrogen peroxide treated PT was shown by SEC to be comprised of protein of similar 
molecular weight to untreated native PT. No additional peaks were observed, suggesting 
that the molecular association between the subunits had not been significantly altered. It 
is likely that slightly later elution time in comparison with untreated native PT is due to a 
difference in the molecular shape or charge of PT as a result of modification with 
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hydrogen peroxide. Toxoid E displayed a peculiar intrinsic fluorescence, compared with 
the other toxoids, showing no signs of Trp fluorescence, which suggested that the Trp 
residues of PT were chemically modified. These findings directly correlate with the 
known activities of hydrogen peroxide, which is a powerful oxidative agent of many 
organic compounds, and in proteins can attack cysteine, cystine, methionine, Trp and Tyr 
(Means. G. E. and Feeney. R. E., 1971b). It has also been previously shown to degrade Trp 
in Trp-containing peptides and in lysozyme (Simat and Steinhart, 1998). It is likely that 
the oxidative effects of hydrogen peroxide are detrimental to the integrity of PT epitopes, 
since only a low density of Si subunit epitopes, out of a total of five subunit epitopes 
screened, were detected by Western blotting. A previous study has also identified 
hydrogen peroxide-induced destruction of neutralising epitopes on the SI subunit and B- 
oligomer of the PT molecule (Ibsen, 1996). In correlation with these results the total IgG 
response induced by toxoid E was very low, 14-fold lower than that induced by toxoid A, 
and it gave the poorest protection against aerosol challenge. 
Correlates of immune response to combined vaccines 
Our results demonstrated that the antibody response to the different toxoids, starting with 
the highest, was in the order: mutant PT stabilised with FA, glutaraldehyde plus FA. 
treated PT, glutaraldehyde-treated PT/tetranitromethane-treated PT, hydrogen peroxide- 
treated PT. These results agree with those from a previous study of combined DTP 
vaccines containing acellular pertussis components (Edwards et al., 1995). The study 
showed that combined DTP vaccines induced antibody responses, starting with the 
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highest, in the order (referenced by PT toxoid): mutant PT stabilised with FA, 
glutaraldehyde-treated PT, FA-treated PT, tetranitromethane-treated PT. 
The results of this chapter illustrate that chemical toxoiding agents produce a variety of 
structural modifications of PT. Chemical detoxification is likely to be the result of a 
combination of specific chemical reactions causing local damage to functional groups, 
and more widespread non-specific cross-linking and aggregation which possibly masks or 
conformationally alters functional groups of PT. The detoxifying modifications of PT 
also affect the epitopes of the toxoid, the extent and type of immune response they induce 
and ultimately their ability to protect against infection. These results give proof that 
modifications of PT molecules are influenced by both the chemical toxoiding agent and 
the toxoiding method, and this is likely to affect the overall efficacy of acellular pertussis 
vaccines. This study prompted more in-depth investigations into the effects of 
formaldehyde on the structure and immunogenicity of PT (described in Chapters 5 and 
6). 
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5.1 Introduction 
Pertussis toxin (PT) is a major virulence factor of the whooping cough bacterium B. 
pertussis (Monack et al., 1989). It belongs to the AB class of ADP-ribosylating protein 
toxins, which are characterised by their distinct functional binding and catalytic domains. 
The PT holotoxin, of molecular mass 105 kDa (Stein et al., 1994a) comprises a catalytic 
A (S1)-subunit (26 kDa), which ADP-ribosylates certain G-proteins, disrupting cell- 
receptor signalling, and a pentameric B-oligomer (79 kDa), for binding to the tracheal 
epithelium. The B-oligomer is composed of five subunits, S2, S3, two copies of S4 and 
S5, which have molecular weights of 22,22,12 and 11 kDa respectively (Stein et al., 
1994a). These subunits are primarily assembled as two dimers, S2-S4 and S3-S4, and the 
contacts forming these dimers are extensive anti-parallel beta-sheet interactions, forming 
the most extensive interactions of the PT molecule. The dimers are associated together 
with S5 mainly through antiparallel ß-sheet interactions, to form a pentameric 
asymmetric ring structure with a central pore. The catalytic S1-subunit penetrates the 
pore with its carboxyl terminal tail positioning it on top of the ring structure. 
PT in a chemically or genetically detoxified (PT-9K/129G) form is the primary 
component of all current acellular whooping cough vaccines. Formaldehyde (FA) is used 
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in some acellular pertussis vaccine preparations to detoxify native PT (Edwards et al., 
1995; Sato, Kimura, and Fukumi, 1984), and is also used in lower concentrations to 
stabilise the genetically detoxified PT (PT-9K/129G), herein referred to as mutant PT 
(Edwards et al., 1995; Nencioni et al., 1991). Most studies on the effects of FA on PT 
have been carried out on mutant PT and have largely focused on changes in 
haemagglutinating activity and mitogenicity (Nencioni et al., 1991) as well as effects on 
T- and B-cell epitopes (Nencioni et al., 1991; Di Tommaso et al., 1994; Cropley et al., 
1995; Ibsen, 1996; Nencioni et al., 1990). 
Preliminary structural studies suggest that FA treatment of a variety of protein antigens 
may cause the production of high molecular weight species (Bolgiano et al., 1999; 
Bolgiano et al., 2000; Fowler et al., 2000; Manetti et al., 1997). The chemistry of amino 
acid side chain modifications arising from FA treatment has also been explored 
(Means. G. E. and Feeney. R. E., 1971a; Tome and Naulet, 1981; Petre et al., 1996). 
However, there is little understanding of the effect of FA on secondary, tertiary and 
quaternary protein structure despite its widespread use in vaccine preparations. A 
thorough understanding of the molecular forms produced by FA-detoxification is a 
necessary prelude to determining the roles of different molecular forms in directing the 
immune response. In addition, guidelines by the World Health Organisation have 
emphasised the importance of physico-chemical testing for the standardisation of 
acellular pertussis vaccines (Arciniega et al., 1998). The advantages of establishing 
molecular correlates of immunogenicity or protection also extend to the development of 
physico-chemical procedures as alternatives to animal experiments. 
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In the present study, a detailed physico-chemical characterisation of the effects of FA on 
PT was undertaken. Firstly, mutant and native PT were compared, before and after FA- 
treatment, using SEC/UV, fluorescence spectroscopy and CD. In this analysis the native 
and mutant PT were treated with relatively high concentrations of FA (0.25 - 1.00 % FA) 
using a long incubation time of 7 days at 37 °C, due to the putative toxicity of the native 
PT preparations. For safety reasons mutant PT preparations were used for the remainder 
and majority of the study, and were treated with lower FA concentrations (0.01 - 0.50 % 
FA), and a shorter incubation time of 48 hours, in order to characterise the effects of FA 
from low stabilising concentrations to higher toxoiding concentrations. The effect of FA 
on size and subunit association of PT was assessed using SDS-PAGE, SEC/UV, AUC 
and SEC/MALLS. In addition, the effects of FA on the protein conformation of PT were 
explored using fluorescence spectroscopy. 
5.2 Results 
5.2.1 Comparison of the effect of FA on native and mutant PT 
SEC/UV of FA-treated native and mutant PT 
Mutant and native PT preparations, untreated and treated with 0.25 and 1.00 % FA (high 
FA-treatment, Chapter 2, section 2.2.3) were subject to SEC/UV using an FPLC system 
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equipped with a Superdex 200 column, at a flow rate of 0.5 mIJmin in PBS buffer, pH 
7.5. The elution of protein was detected both at 214 and 280 nm, and the 214 Mn trace is 
presented (Figure 5.1) 
For both untreated mutant and native PT preparations comparable SEC spectra were 
obtained and the majority of protein eluted from the SEC column as a main broad peak at 
18.0 mL, with a trailing shoulder (Figure 5.1). For both 0.25 % FA-treated mutant and 
native PT preparations, the main peak became broader and eluted significantly earlier at 
14.2 mL, and an additional peak for both preparations appeared at 11.8 mL. Increasing 
FA treatment to 1.00 % caused the main peak of both mutant and native PT preparations 
to elute even earlier at 13.4 mL. The increasingly early elution of the mutant and native 
PT molecules suggests that FA treatment caused the PT molecules to associate together to 
form much larger species. The broadening of the main peak and appearance of another 
distinct peak illustrate the increasing heterogeneity of protein species size with increasing 
FA. Moreover, the mutant and native PT preparations had very similar elution patterns, 
indicating that they were structurally similar and were modified in the same way with FA 
treatment to form analogous molecular assemblies. 
Fluorescence spectroscopy of native and mutant PT 
Mutant and native PT preparations, untreated and treated with 1.00 % FA (high FA- 
treatment, Chapter 2, section 2.2.3) were subject to fluorescence spectroscopy using a 
single photon-counting spectrofluorimeter by Xex of 280 nm. 
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Figure 5.1 The effect of FA on the size of native and mutant PT 
Samples (15 µg protein in 200 µL PBS, pH 7.5) of native (black trace) and mutant 
(grey trace) pertussis toxin (PT), untreated and treated with 0.25 and 1.0 % 
formaldehyde (FA) were analysed using size exclusion chromatography with UV 
detection (SEC/UV). The FPLC system was equipped with a Superdex 200 
column and samples were eluted in PBS, pH7.5. Absorbance at 214 nm is shown. 
185 
Chapter 5 Effect of FA on structure of PT 
The fluorescence was scanned from 260 to 500 nm and the PBS, pH 7.5 buffer base line 
fluorescence was subtracted. 
Untreated mutant and native PT displayed superimposable fluorescence spectra (Figure 
5.2) with a characteristic Trp fluorescence emission wavelength maximum (Fmax) at 
337 nm and a shoulder from Tyr fluorescence at - 305 nm (Seabrook, Atkinson, and 
Irons, 1991). With FA-treatment the Fmax for both the untreated and mutant PT 
preparations shifted to longer wavelengths (red-shift), displaying an Fmax of 345 nm 
(Figure 5.2). The fluorescence red-shift observed with FA treatment of both mutant and 
native PT may be indicative of protein unfolding leading to solvent exposure of Trp 
residues, but specific chemical modification of Trp residues with altered fluorescence 
properties can not be ruled out. The similarity of the corresponding FA-treated mutant 
and native PT preparations suggests that the mutant and native PT molecules have the 
same conformation and that their molecular structures are altered in a similar way with 
FA treatment. CD was subsequently employed as a complementary tool to fluorescence. 
CD of native and mutant PT 
Both native (750 pg/mL) and mutant (382 pg/mL) PT preparations were analysed by near 
(250 - 320 nm) and far (180 - 260 nm) UV CD, in 2x1 cm and 1x0.01 cm cuvettes, for 
respective wavelength ranges, using a Jasco J-720 spectrapolarimeter. The spectra were 
each corrected for dialysate buffer blank (PBS, pH 7.5) and molarity, and are expressed 
as molar circular-dichroic absorption (A E). 
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Figure 5.2 The effect of FA on the conformation of native and mutant PT 
Native (black trace) and mutant (grey trace) pertussis toxin (PT) preparations (10 - 
30 µg/mL) in PBS, pH 7.5, untreated or treated with 1.0 % (w/v) formaldehyde 
(FA), were excited at 280 nm and their fluorescence recorded from 260 - 500 nm. 
Spectra were corrected by subtraction of the PBS base-line spectra. Lower traces - 
untreated preparations; upper traces - 1.0 % FA-treated preparations 
187 
260 310 360 410 460 
Chapter 5 Effect of FA on structure of PT 
Circular dichroism is a chiroptical method, which measures the difference in absorbance 
of left and right circularly polarised light. In the near UV, CD bands are dominated by 
absorption from the aromatic side chains and disulphide linkages. CD in this range can be 
a sensitive indicator of changes in tertiary structure. Mutant and native PT display very 
similar near UV CD spectra (Figure 5.3), possessing a broad band presumably caused by 
the 13 di-sulphide bonds of PT. There is also particuarly negative dichroic absorption 
caused by the large numbers of tyrosine residues present. Trp features at around 283 - 
285 nm (Strickland, 1974) but this Ac is unusually negative for proteins containing Trp. 
The large negative dichroic absorption may be due to the high tyrosine content of PT. 
Far UV CD can be used to interpret the extent and type of secondary protein structure. 
Both mutant and native PT display very similar far UV CD spectra (Figure 5.3). These 
are typical of previous spectra obtained for PT, having a minimum at about 208 nm 
(Seabrook, Atkinson, and Irons, 1991; Bloemendal and Johnson, Jr., 1995), and are 
characteristic of a+ß protein. The same native PT sample analysed in a chloride-free 
buffer gave a comparable far UV CD spectrum (not shown), which included data down to 
180 nm. Analysis of this spectrum using the Varslc programme (variable selection 
method of protein secondary structure estimation) (Manavalan and Johnson, Jr., 1987) 
determined a secondary structure composition of 15 % a-helix and 39 % ß-sheet. This is 
compatible with that determined from the crystal structure of PT (Stein et al., 1994a), of 
16 % a-helix and 37 % ß-sheet (Appendix 1). 
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Figure 5.3 CD of untreated native and mutant PT 
Circular dichroism (CD) was performed on native (750 µg/mL; black trace) 
and mutant (382 µg/mL; grey trace) pertussis toxin (PT) by measuring near 
(250 - 320 nm) and far (195 - 260 nm) UV CD, in 2x1 cm and 1x0.01 cm 
cuvettes, for respective wavelength ranges, using a Jasco J-720 
spectrapolarimeter. The spectra were each corrected for dialysate buffer blank 
(PBS, pH 7.5) and molarity, and are expressed as molar circular-dichroic 
absorption (A c). 189 
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Overall the SEC, fluorescence spectroscopy and CD studies comparing mutant and native 
PT demonstrate that the untreated molecules are of similar molecular structure and 
quality. Furthermore the SEC and fluorescence spectroscopy results demonstrate that 
both mutant and native PT molecules undergo similar molecular association and 
conformational changes with FA treatment. To more thoroughly assess the effect of FA 
on PT, mutant PT preparations treated with stabilising concentrations through to 
toxoiding concentrations of FA (0.01 - 0.50 % FA) were analysed. 
5.2.2 Effect of FA on the size and subunit association of PT 
Mutant PT untreated and treated with 0.01 - 0.50 % FA (Low FA-treatment, Chapter 2, 
section 2.2.3) were analysed by four different sizing methods: SDS-PAGE, SEC/UV, 
SEC/MALLS and AUC. 
SDS-PAGE of FA-treated PT 
Mutant PT, untreated and treated with 0.035,0.1 and 0.5 % FA (each of -i 5 µg), were 
subjected to SDS-PAGE in tris-glycine SDS running buffer using a 10 well, 14 % tris- 
glycine acrylamide gel, under non-reducing and reducing conditions. Molecular weights 
were determined relative to protein molecular weight standards that were run on each gel. 
Under non-reducing conditions, untreated mutant PT produced the typical 4-subunit 
band-pattern (Nencioni et al., 1990) with relative molecular masses (Mr) of 25.6 kDa 
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(Si), 22.8 kDa (S2), 20.3 kDa (S3), and 9.6 kDa (S4 and S5) (Figure 5.4). In addition to 
this pattern, mutant PT treated with increasing FA concentrations yielded a series of 
defined bands of progressively higher Mr with smearing between them. Above 0.035 % 
(w/v) FA treatment species as large as 200 kDa were observed, which is the resolving 
limit of the gel. All of these features were also observed in the reducing gel (Figure 5.4). 
Together the results provide evidence that FA treatment of mutant PT induces the 
formation of large species, some of which exceed holotoxin molecular weight. 
Furthermore, they reveal that the molecules are associated by stable covalent cross- 
linking, which is independent of disulphide bonding. The defined bands of molecular 
weights higher than those of monomeric subunits are indicative of homogeneous species 
likely to be formed by favoured covalent cross-linking between neighbouring subunits in 
the native structure. The smearing effect represents many species of heterogeneous size, 
which may encompass an array of protein species that are randomly cross-linked and/or 
have various side-chain modifications including decoration to different extents by lysine 
from the reaction mixture. It is known that in reaction with FA, a variety of amino acids, 
including lysine used as the FA quencher during treatment, are capable of cross-linking 
via their side-chain groups (Tome and Naulet, 1981). 
In order to characterise any larger species that exceed the limit of the SDS-PAGE gel, or 
that are not irreversibly associated, the mutant PT preparations were subsequently 
analysed by SEC/UV. 
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Figure 5.4 SDS-PAGE of mutant PT treated with different concentrations of FA 
Mutant pertussis toxin (PT) samples (5 µg) electrophoresed in non-reducing sample buffer were 
treated with 0 (lane 1), 0.035 (lane 2), 0.1 (lane 3) and 0.5 (lane 4) % (w/v) lormaldehyde (FA). 
Two of the PT samples were electrophoresed on a second gel in reducing sample hohler. 0.5 
(lane 5) and 0.035 (lane 6) % (w/v) FA. The gels were stained with ('oomassie blue. Molecular 
weight standards ('Markers', kDa) were run in non-reducing conditions. 
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SEC/UV of FA-treated PT 
Effect of FA on structure of PT 
Mutant PT untreated and treated with 0.035,0.10 and 0.50 % FA were subject to 
SEC/UV using a Superdex 200 column as described above. In addition untreated mutant 
PT was also analysed using a Superdex 75 column. 
The bulk of untreated mutant PT eluted as a broad peak in PBS, pH 7.5 at 18.0 mL 
(M1 10 kDa) from the Superdex 200 column (Figure 5.5). This was significantly later than 
the expected elution volume for a protein of 105 kDa and implies that the toxin may be 
eluting as individual subunits. However, fractions of the peak run on an SDS-PAGE gel 
were found to contain all five PT subunits (results not shown). The untreated mutant PT 
sample was also analysed using a Superdex 75 column (Figure 5.5), which has an 
exclusion range suitable for resolving molecular weights of subunit size. Again the 
protein eluted as a single peak, at 10.6 mL (Mr 32 kDa), which had a slight trailing edge 
to -18 mL (Mr 5.5 kDa), and there was no resolution of peaks corresponding to subunit 
size (Figure 5.5). Together these results illustrated that the untreated toxin was not eluting 
at the expected volume, possibly due to its different hydrodynamic volume in comparison 
to the molecular weight standards. Another possibility is that PT could have been 
retarded on the SEC columns possibly due to column interactions. 
As can be seen from Figure 5.5, the 0.035 % FA-treated sample eluted at 16.0 mL (Mr 23 
kDa) with a slight leading shoulder around 14 mL (Mr 57 kDa) and a trailing shoulder 
around 17 mL (Mr 15 kDa). With 0.1% FA-treatment the main peak eluted at 15 mL (M, 
37 kDa) with a leading shoulder again around 14 mL (Mr 57 kDa) and there was 
193 
0.6 
0.5 
0.4 
10.3 
0.2 
03 0.1 
0 
Retention Volume (mL) 
0.06 
0.05 
0.04 
cu ö 0.03 
cn 
0.02 
0.01 
0 
Figure 5.5 SEC/UV profiles of PT 
Size exclusion chromatography with UV detection (SEC/UV) of mutant pertussis 
toxin (PT) preparations using an FPLC system equipped with a (A) Superdex 200 
column, for analysis of untreated (under control conditions) and 0.035,0.1 or 0.5 
% (w/v) formaldehyde-treated samples or (B) Superdex 75 column for analysis of 
untreated mutant PT (not incubated). Running buffer was PBS, pH7.5, the samples 
applied were 15 µg protein in 200 gL PBS, pH 7.5. Elution positions of selected 
molecular weights (kDa) and of the exclusion volume (Vo) and total volume (Vt), 
as determined by calibration with protein standards, are indicated with arrows. 
Absorbance at 214 nm is shown. 
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development of an additional, low amplitude, high molecular weight peak at 12 mL 
(M, 132 kDa). With 0.5 % FA there was an even earlier eluting peak at - 10 mL 
(M, 300 kDa), followed by the peak at 12 mL (Mr 132 kDa) and main peak at 13.5 mL 
(Mr 72 kDa). Absorbance traces, at 280 nm, mirrored those obtained at 214 nm. Solution 
salts eluted as a large peak at 20 mL, just before the total volume of the column. 
'These results demonstrate that FA-treatment caused an increase in mutant PT relative 
molecular mass and an increase in the heterogeneity of mutant PT species. Estimates of 
molecular mass may not be accurate by this method since the untreated mutant PT 
holotoxin was shown to elute later than expected for its molecular mass. This may have 
been due to weak binding of the B-oligomer of PT to the polysaccharide moieties of the 
column. FA-induced changes in the B-oligomer may have prevented this association and 
thus cause the observed decrease in retention time. In addition, changes in conformation 
and charge could also be partly responsible for small shifts in elution time. However, the 
FA-dependent step-wise increases in molecular weight are of significance. Some of the 
elution volumes were common between preparations (Figure 5.5) demonstrating discrete 
increases in mutant PT molecular weight, as would be the case if certain subunits or 
multimers were associating or cross-linking to form favoured combinations. This is in 
agreement with the evidence of subunit cross-linking from SDS-PAGE. The largest 
species observed by SEC/UV had an estimated molecular mass of 300 kDa, which is 
nearly three times the mass of the holotoxin, indicative of multimeric structures larger 
than the limit of the SDS-PAGE gel. In order to confirm the presence of such large 
species these analyses were followed by SEC/MALLS. 
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SEC/MALLS of FA-treated PT 
Effect of FA on structure of PT 
A combination of SEC coupled to refractive index and MALLS is a sensitive method for 
detection and more precise sizing of large molecules. This method obviates the need for 
column calibration with standards, which may not be similar in size and conformation to 
the sample. Mutant PT samples, treated with 0.035,0.05 and 0.1 % FA were subjected to 
SEC/MALLS using an HPLC system equipped with two analytical columns (TSK 
G3000PW + TSK G4000PW), at a flow rate of 0.8 mL/min in PBS buffer, pH 7.5. 
Scattered light intensities of the eluted fractions were measured using a light scattering 
photometer and concentrations were measured using an interferometric refractometer. 
Twelve angles were used for measuring light scattering intensities and those at 9011 are 
presented (Figure 5.6). 
The low FA-treated sample (0.035 %) yielded a molecular mass of 367 kDa for peak 1, 
121 kDa for peak 2, which was just slightly higher than the expected holotoxin molecular 
mass, and of -7 kDa for peak 3 (Figure 5.6 and Table 5.1). Further FA treatment caused 
the molecular mass of these species to increase by amounts corresponding to holotoxin 
and dimeric and monomeric subunits. With 0.05 % FA the species in peak 1 increased to 
423 kDa, in peak 2 increased to 140 kDa and in peak 3 increased to 66 kDa. Aggregates 
as large as 1 000 kDa were detected in the 0.1% FA sample. 
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Figure 5.6 SEC/MALLS of FA-treated PT 
Mutant pertussis toxin (PT) preparations (- 500 µg), which had been treated 
with 0.035,0.05 and 0.1 % (w/v) formaldehyde (FA), were subjected to size 
exclusion chromatography (SEC) in PBS, pH 7.5, with detection by multi- 
angle laser light scattering (MALLS; 90° detector response shown) and 
refractive index (not shown) for determination of protein molecular masses 
(Table 1). 
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Table 5.1 SEC/MALLS of FA-treated PT 
Mutant pertussis toxin (PT) preparations (- 500 pg/mL), which had been treated with 
0.035,0.05 and 0.1 % (w/v) formaldehyde (FA) were subjected to size exclusion 
chromatography (SEC) in PBS, pH 7.5, with detection by multi-angle laser light 
scattering (MALLS; Figure 5.6) and refractive index monitoring (not shown). 
Molecular mass values are quoted for PT species eluting in the selected volumes. The 
error for each molecular mass estimate is associated with the statistical fluctuations in 
each detector signal. 
PT sample, Peak elution (mL) Molecular mass 
FA-treatment (kDa) 
%, w/v 
0.035 11.32-12.33 Peak 1: 367.1 ± 60 
12.43-14.89 Peak 2: 120.7 ± 30 
17.36-20.59 Peak 3: 6.7 ±3 
0.05 11.26-12.44 Peak 1: 423.3 ± 30 
12.53-14.28 Peak 2: 140.3 ± 20 
14.79-18.70 Peak 3: 65.8 ±9 
19.03-20.21 Peak 4: 5.4 ±1 
0.1 11.31-12.49 Peak 1: 1004.0 ± 30 
12.63-14.09 Peak 2: 270.0 f8 
14.23-14.79 Peak 3: 91.9 ± 10 
14.89-15.78 Peak 4: 48.6 ± 10 
198 
Chapter 5 Effect of FA on structure of PT 
These results support those from SEC /UV and in addition give an indication of the sizes 
of the very largest species, which were not detected by UV-detection possibly because 
they were present in very small concentrations. 
AUC of FA-treated mutant PT 
AUC was used in order to analyse the protein in solution, rather than associated with a 
gel matrix. Mutant PT preparations, untreated and treated with 0.05 and 0.1 % FA were 
analysed by AUC to determine their equilibrium solute distributions. Three different 
concentrations of each sample were analysed in PBS dialysate, pH 7.4. Molecular weight 
distributions were recorded with scanning absorbance at three rotor speeds, 15 000, 
25 000 and 35 000 rpm. A true optical baseline was determined by sedimenting the 
protein from the bulk of the solution volume at 47 000 rpm. Using the MSTAR 
programme (Cölfen and Harding, 1997) the value of M* at the cell base, which is equal 
to the apparent weight average molecular weight (Mw,, app) (kDa) of the whole sample, was 
calculated for each concentration of mutant PT preparation at each rotor speed (Figure 
5.7 A). 
The M,,,, app of untreated mutant PT at low rotor speed (15 000 rpm) was - 70 kDa (Figure 
5.7 A). This decreased to - 20 kDa at 35 000 rpm. Since the observed molecular weight 
represents the average across the radial distribution of sample solute, these results suggest 
that mutant PT exists in solution partly as unattached B-oligomer (79 kDa) and A-subunit 
(26 kDa), which have markedly different equilibrium distributions owing to their 
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Chapter 5 Effect of FA on structure of PT 
different molecular masses. That is, at 15 000 rpm the observed molecular weight is an 
average of that for A-subunit, B-oligomer and holotoxin, while at 35 000 rpm the 
holotoxin and B-oligomer have sedimented out of the main solute column giving an 
average observed molecular weight corresponding to that of the A-subunit. 
Mutant PT treated with 0.05 % FA had an increased observed molecular weight of 
80 kDa at low rotor speed and - 40 kDa at 35 000 rpm (Figure 5.7 A), suggesting there 
was a greater proportion of holotoxin or larger molecular weight species in this sample 
than in the untreated sample. For the 0.1 % FA-treated sample the observed molecular 
weight increased to - 100 kDa at low rotor speeds which suggests an even larger 
proportion of holotoxin or larger molecular weight species in this preparation. 
The plot of M* versus the radial distance from the centre of rotation (Figure 5.7 B), 
shows that M* increased more steeply towards the cell base with increasing FA 
treatment. These data are indicative of high molecular weight species sedimenting out of 
the solute column. 
These results indicate that untreated mutant PT exists in solution partly dissociated into 
its A-subunit and B-oligomer. They imply that FA treatment reinforces the association of 
native subunit contacts preventing holotoxin dissociation. In addition there is further 
inter-subunit association to form much larger species for which molecular weights cannot 
be assigned at these rotor speeds. Overall these results support the data from the three 
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other sizing methods. In order to characterise the effect of FA on the molecular 
conformation of PT fluorescence spectroscopy was subsequently performed. 
5.2.3 Effect of FA on the molecular conformation of PT 
Fluorescence spectroscopy of FA-treated PT 
PT contains six Trp residues distributed in the S1, S2, S3 and S5 subunits and also 62 Tyr 
residues distributed throughout all of the subunits. Therefore, intrinsic fluorescence of the 
environmentally sensitive aromatic side chains is potentially a sensitive indicator of 
changes in the local, molecular protein structure of PT. Mutant PT, untreated and treated 
with 0.035,0.05,0.1 or 0.5 % FA, were subject to fluorescence spectroscopy as described 
previously (section 5.2.1). 
Untreated mutant PT displayed fluorescence typical of PT (Seabrook, Atkinson, and 
Irons, 1991) with an Fmax at 337 nm from Trp and a shoulder at - 305 nm from Tyr 
(Figure 5.8 A). With FA treatment the Fmax (Xe,, 280 nm) of mutant PT gradually red- 
shifted, from 337 nm for untreated mutant PT to 342.5 nm for 0.5 % FA-treated mutant 
PT (Figure 5.8 A). These results are in agreement with the experiment above, which 
showed a large red-shift (7 nm) after more severe FA treatment (Figure 5.2). A red-shift 
of 3 nm was also seen at XX 295 nm (Figure 5.8 B), from 347 nm for untreated mutant PT 
to 350 run for 0.5 % FA-treated mutant PT. A red-shift in fluorescence at both of these 
excitation wavelengths can be indicative of protein unfolding. 
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The emission spectra (Xex 280 nm) also changed shape with FA-treatment due to changes 
in the relative intensities of Trp and Tyr fluorescence (Figure 5.8 A). Normalising the 
spectra at 305 nm (not shown) exemplifies the gradual increase in Trp fluorescence with 
respect to Tyr as FA-treatment increased. Taken together with the red-shifts, these 
changes in Trp intensity are indicative of a change in protein folding. 
It was also possible that the formation of Trp derivatives was responsible for the modified 
fluorescence emission of mutant PT. Trp is accessible to N-hydroxymethylation by 
formaldehyde and can undergo cross-linking reactions with other side-chains (Tome and 
Naulet, 1981; Kitamoto and Maeda, 1980; Means and Feeney 1971a). Known Trp 
derivatives, which may be formed by reactions with FA, tend to absorb light at 
wavelengths longer than those absorbed by native Tip. The tryptophan derivatives, 
norharman and kynurenine, have maximal absorbance in the range 315 - 375 nm and 
corresponding maximal fluorescence in the range 440 - 490 nm (Udenfriend, 1962; 
Morton, 1975). Neither absorbance nor fluorescence at these wavelengths was observed 
for any of the mutant PT preparations suggesting that such modifications were not 
responsible for the observed fluorescence changes with increasing FA. We conclude that 
the red-shifts and increasing Trp intensity observed are most likely due to increasing 
exposure of Trps to solvent due to protein unfolding. 
Fluorescence spectroscopy of FA-treated PT SEC fractions 
Mutant PT, untreated and treated with 0.5 % FA, were subjected to SEC using an FPLC 
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Figure 5.8 (A) Intrinsic fluorescence of PT treated with different 
concentrations of formaldehyde (A. ex280 nm) 
Mutant pertussis toxin (PT) samples (10 - 30 pg/mL) in PBS, pH 7.5, which had 
been treated with 0,0.035,0.05,0.1 and 0.5 % (w/v) formaldehyde (FA), were 
excited at 280 nm, their fluorescence scanned from 260 - 500 nm, and spectra 
corrected by subtraction of the PBS base-line spectra. 
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Figure 5.8 (B) Intrinsic fluorescence of PT treated with different 
concentrations of formaldehyde (hex 295 nm) 
Mutant pertussis toxin (PT) samples (- 50 pg/mL) in PBS, p117.5, which had 
been treated with 0,0.01,0.10 and 0.50 (w/v) formaldehyde (FA), were excited 
at 295 nm, their fluorescence scanned from 260 - 500 nm, and spectra corrected 
by subtraction of the PBS base-line spectra. 
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system equipped with a Superdex 200 column, as described above, and 0.5 mL fractions 
were collected. For each preparation, fractions of the same peak were pooled and 
fluorescence measurements taken. 
It can be seen that the main SEC peak of untreated mutant PT had an Fmax of 336 - 337 
TT'IITex 280 nm) (Figure 5.9), which is typical of whole non-fractionated PT (Figure 5.8 
A). The latest-eluting fraction of the 0.5 % FA-treated sample had an Fmax of 339 nm, 
which is significantly red-shifted compared to untreated whole PT. Increasingly earlier 
eluting fractions of 0.5 % FA-treated mutant PT exhibited decreasingly red-shifted Fmax 
values. The highest molecular weight species (Fmax, 336 nm) is likely to be an 
aggregated version consequently with more buried Trps. 
Together these findings indicate that FA is altering the native folding of the protein 
initially causing unfolding followed by re-association of the non-native species to form 
aggregates leading to an increase in molecular weight. 
5.3 Discussion 
The ultimate goal in vaccine development is to produce a non-toxic immunologically 
efficacious product. The use of FA in the detoxification of bacterial toxins to produce 
vaccine components is cheaper and simpler to employ than protein-engineering methods 
and is still used by manufacturers of tetanus, diphtheria and pertussis vaccines 
worldwide. Moreover, non-toxic antigens and genetically inactivated proteins often 
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Figure 5.9 Intrinsic fluorescence analysis of SEC-fractionated PT 
Mutant pertussis toxin (PT) preparations (15 µg PT in 200 µL PBS, pH 7.5), 
untreated (faint trace) and 0.5 % (w/v) formaldehyde (FA)-treated (bold trace), 
were subjected to size exclusion chromatography (SEC) using an FPLC system 
with a Superdex 200 column, and eluted in PBS with detection at 214 nm. 
Column fractions, indicated by the T-bars, were analysed by fluorescence 
spectroscopy (A-ex 280 nm) and for each fraction the Fmax values (nm) are 
labelled. 
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require FA treatment for stabilisation (Nencioni et al., 1990; Petre et al., 1996). There is a 
need to characterise the heterogeneous mixtures that can be produced by formaldehyde. 
The application of biochemical and biophysical techniques is enabling the manufacture of 
products that are increasingly well-defined in terms of purity, component size and 
molecular association. 
Primarily, it was shown by SEC and fluorescence that mutant and native PT have the 
same structural characteristics and are modified in the same way with FA treatment. 
Untreated and FA-treated mutant PT preparations were then analysed in more detail using 
a variety of sizing techniques to characterise the heterogeneous species that could arise 
from FA treatment of an oligomeric protein. AUC provided evidence that untreated 
mutant PT exists in solution as a proportion of holotoxin, B-oligomer and A-subunit. All 
of the sizing techniques gave complementary evidence to support the conclusions that 
low FA treatment of mutant PT stabilises native subunit contacts and further FA 
treatment causes additional subunit association, cross-linking and aggregation. Some of 
the mechanisms involved in this association can now be discussed in detail. 
Untreated PT 
The AUC results suggest that mutant PT in solution is made up of a proportion of 
holotoxin, A-subunit and B-oligomer. It is known that full activation of PT holotoxin 
requires binding of ATP to the B-oligomer to destabilise the A-subunit and B-oligomer 
(Moss et al., 1986; Burns and Manclark, 1986). Residual activity has been found in PT 
without ATP added (Moss et al., 1986; Burns and Manclark, 1986) also suggesting that 
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PT exists partially as separate A and B domains. There may be an equilibrium between 
the associated and non-associated states. Comparison of the crystal structures of PT 
before and after ATP binding, which is distant from the S 1B-oligomer interface, shows 
that there are only minor side-chain movements and no extensive changes in the protein 
backbone (Hazes et al., 1996). It may be that this is enough to switch the equilibrium to 
the non-associated state. It was suggested that the triphosphate moiety of ATP may 
sterically repel the C terminus of the Si subunit, thus dissociating it from the B-oligomer 
(Hazes et al., 1996; Kaslow eta!., 1987). It is feasible that this mechanism does not 
operate by `pushing' the Si subunit out of the B-oligomer pore, but by the ATP 
molecules occupying the free B-oligomer population and preventing their re-association 
with Si subunits. 
FA-treated PT 
Cross-linking 
The results of SDS-PAGE, SEC-MALLS and AUC collectively substantiate the 
hypothesis that, with small concentrations of FA, covalent cross-linking occurs between 
amino acids on neighbouring subunits causing an increase the number of species of 
holotoxin size, perhaps by preventing subunit dissociation. This study also demonstrates 
that higher FA treatment produces molecules exceeding holotoxin molecular weight 
providing novel evidence of cross-linking between holotoxins or large multimeric 
species. Studies on FA-treatment of the oligomeric VacA protein, of Helicobacter pylori, 
have provided some evidence, from SDS-PAGE, of covalent, inter-monomer cross- 
linking (Manetti et al., 1997). Presumably intra-subunit cross-links also occur. Following 
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FA-treatment, the S l-subunit band on SDS-PAGE gels is preserved for longer periods of 
incubation at 37 °C (Nencioni et al., 1991). These findings are in accordance with the 
known cross-linking reactions of FA with amino acids. 
In reaction with FA, certain amino acids become modified forming a reactive 
hydroxymethyl derivative. Hydroxymethylated amino acids can react in a variety of 
ways, with each other or with non-modified amino acids, to form different chemical 
cross-links. FA cross-links were analysed in FA-treated bovine serum albumin using 
nuclear magnetic resonance (NMR) spectroscopy (Tome, Kozlowski, and Mabon, 1985). 
Lys, the most FA-reactive amino acid, in solution can link to protein amino acids via its 
hydroxymethylated epsilon amino group to form a methylene bridge (Tome and Naulet, 
1981) (Tome, Kozlowski, and Mabon, 1985). These were found to be primarily between 
lysine and arginine, asparagine, glutamine or tyrosine, via their reactive hydroxymethyl 
derivatives. Secondary reactions between amino acids other than lysine, namely, tyrosine, 
tryptophan, histidine, asparagine and glutamine were also implicated (Tome, Kozlowski, 
and Mabon, 1985). In addition, amino acid derivatives such as methyllysine and 
formyllysine were detected. These FA products can be divided into three types: stable, 
acid labile or reversible (Bizzini and Raynaud, 1974; Tome et al., 1979). 
The laddering and smearing effect on SDS-PAGE gels, above 0.035 % (w/v) FA, is likely 
to be due to various side-chain modifications, including decoration of the protein with 
lysine from the reaction mixture. Free lysine linked to the protein via its 
hydroxymethylated epsilon amino group (Tome and Naulet, 1981; Tome, Kozlowski, and 
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Mabon, 1985) has an exposed protonated alpha amino group. FA treatment of pertactin 
protein from B. pertussis showed that increasing the lysine concentration caused an 
increase in the isoelectric point of the protein (Ceccarini et al., 2000), in accordance with 
our proposal of lysine decoration. Moreover, previous results from amino acid analysis of 
FA-treated PT, found an increase in the lysine content of PT (Nencioni et al., 1990). In 
order to confirm specific subunit-subunit cross-linking and further characterize the 
subunit composition of FA-induced multimeric structures, Western blotting using subunit 
specific mAbs was subsequently performed and these results are described in the next 
chapter (Chapter 6). 
Unfolding 
The red-shifts in fluorescence spectroscopy with increasing FA-treatment suggest that FA 
also causes an increase in the unfolding of mutant and native PT. These results agree with 
a previous study which showed a significant red-shift in the fluorescence spectra of 
aldehyde-treated PT (Bolgiano et al., 1999). Unfolding occurs regardless of the covalent 
cross-links. Unfolding may be due to intra-molecular charge effects caused by FA, intra- 
molecular lysine additions and/or inter-molecular covalent cross-links or other 
interactions disrupting and opening up the native, and methylene cross-linked, subunit 
structures. The largest species appear to have masked, Trps compared to the bulk of the 
sample suggesting that they are formed by aggregation of the unfolded material. A series 
of electron micrographs of FA-treated VacA protein illustrate the loss of its shape and 
definition during the formation of aggregates (Manetti et al., 1997). 
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The high molecular weight species detected by SEC/UV, SEC/MALLS, AUC and SDS- 
PAGE could represent specifically associated subunits or holotoxins (oligomers), or less 
uniform association of subunits of non-native structure (aggregates). Since oligomers and 
aggregates could not be absolutely differentiated in this study, the high molecular weight 
species are generally referred to as aggregates. Aggregates as large as 1000 kDa were 
observed by SEC/MALLS. Species up to 900 kDa have been previously observed in a 
commercial pertussis toxoid (Bolgiano et al., 1999). 
A proportion of the aggregates was comprised of stable structures, as confirmed by their 
detection with SDS-PAGE. In addition, there was evidence of some dissociation, 
suggesting that less stable structures were also formed. In the 0.035 % FA treated 
preparation, large species exceeding 100 kDa were detected by SEC/MALLS, while 
species only as large as 50 kDa were detected with SDS-PAGE. 
Taken together, the results demonstrated that stable and reversible interactions are 
involved in subunit association, oligomerisation and aggregation of PT. This is in line 
with the known cross-linking reactions of FA (see above; Cross-linking). In addition the 
amino acid derivatives produced are likely to change the charge and hydrophobicity of 
the molecule, which could facilitate non-covalent associations between subunits. The 
next chapter (Chapter 6) will assess the integrity of the epitopes in these cross-linked 
species. 
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It is known that protection against B. pertussis is dependent on both antibody specificity 
and cell-mediated immunity (Mahon et al., 1997; Redhead et al., 1993; Mills et al., 1993; 
Ryan et al., 1998a; Mahon et al., 1996). Therefore structural changes in the immunogenic 
PT molecule, including changes in its conformation, charge and cross-linking, which 
could alter antigen processing or surface structural epitopes, are of significance. 
Physico-chemical methods have provided a detailed description of the molecular forms 
comprising FA-treated PT, and now their significance in the immune response can start to 
be realised. Subunit cross-linking and epitope integrity will be studied in the next chapter 
(Chapter 6). The immune response to FA-treated mutant and native PT will also be 
assessed. Obtaining structural correlates of protection and developing reliable alternatives 
to animal experiments are priorities in the pertussis field. Detailed physico-chemical 
characterisation of PT and other vaccine components will drive the development of 
better-defined and potentially more immunogenic vaccines. 
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6.1 Introduction 
FA was the one of the first chemicals accepted for the detoxification of vaccine products, 
and is still used to toxoid bacterial protein toxins for use in vaccines licensed around the 
world. FA-detoxified PT is commonly used in acellular pertussis vaccines. However, the 
effects of FA treatment on the immunological properties of the antigen are poorly 
understood. There have been no direct studies on the effect of FA on the immunology of 
native PT to our knowledge, and only limited studies on mutant PT (PT-9K/129G) have 
been reported (Nencioni et al., 1990; Cropley et al., 1995; Di Tommaso et al., 1994; 
Nencioni et al., 1991). 
Mutant PT is stabilised with a relatively low concentration of FA (0.035 %, w/v) for use 
in one of the acellular pertussis vaccines. In order to decide the stabilising concentration 
of FA, some immunological studies were performed on a series of FA-treated mutant PT 
preparations. The effect of FA on anti-PT antibody recognition of mutant PT epitopes 
was assessed, using competitive radioimmunoassay, and it was shown that the affinity of 
polyclonal anti-PT serum for mutant PT was reduced by 16-fold with 0.21 % (w/v) FA 
(Nencioni et al., 1991). In addition, the affinity of anti-S1 mAb, 1B7, for mutant PT was 
reduced to undetectable levels with 0.052 % (w/v) FA-treatment (Nencioni et al., 1991). 
However, in the same study, screening with the 1 B7 mAb in Western blotting generated 
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dense Si bands for even the highest FA-treated sample (0.42 %, w/v, FA). It was 
suggested that the 1B7 epitope may have been masked in solution and unmasked with the 
denaturing technique of Western blotting. 
T-cell epitope studies showed that recognition of mutant PT by T-cell clones specific for 
the wild-type SI subunit was not affected by treatment of mutant PT with 0.42 % (w/v) 
FA (Nencioni et al., 1991). Another study showed that a much higher concentration, of 
3.5 % (w/v) FA, destroyed the ability of mutant PT to induce proliferation of SI-specific 
T-cell clones (Di Tommaso et al., 1994). 
The effect of FA on the immunogenicity of mutant PT has also been researched. Serum 
was raised in guinea pigs, against the 0-0.42 % (w/v) FA-treated mutant PT 
preparations, and were analysed by ELISA for levels of IgG antibodies specific for PT 
holotoxin or B-oligomer (Nencioni et al., 1991). The level of PT-specific IgG antibody 
was not significantly affected by FA-treatment of the mutant PT antigen. However, the B- 
oligomer-specific IgG response progressively increased with increasing FA-treatment (0 
- 0.42 %/ w/v). This study also found a decrease in the serum neutralizing titre with FA- 
treatment of mutant PT, as determined by CHO-cell assay, which corresponded with the 
increase in B-oligomer specific IgG antibodies. They concluded that the overall level of 
PT-specific IgG antibody response is not affected by FA-treatment but that the fine 
specificity and neutralising properties of the antibodies obtained are altered. 
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Such changes in the immunogenicity between FA-treated PT toxoids may contribute to 
the differences observed in the immunogenicity of acellular pertussis vaccines. For 
example, it has been shown that different acellular vaccines induce Thl and Th2 
responses to different extents (Ausiello et al., 1997; Mills et al., 
1998; Ryan et al., 
1998a). However, the effect of FA on the immunogenicity of both native and mutant PT, 
used in acellular pertussis vaccines, has not yet been fully characterised. 
In this chapter, the aim was to study the effect of a series of FA concentrations on the 
immunogenic properties of both mutant and native PT. The effect of FA on the epitope 
characteristics and on the PT-specific murine antibody response was assessed. This study 
design permitted the novel investigation of the immunogenic effect of FA on the toxic 
native PT with respect to the catalytically inactive mutant PT. 
6.2 Results 
Mutant and native PT treated with 0 -1.0 % (w/v) FA (High FA -treated PT, section 
2.2.3), which covers the concentration range used in commercial toxoiding, were used 
throughout this study. 
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6.2.1 Characterisation of PT subunit cross-linking and epitope 
integrity after FA-treatment, by immunoassay 
The effect of 0-0.1 % FA on PT epitopes was analysed using PT subunit-specific mAbs 
to screen PT preparations in ELISA and immunoblotting. ELISA was performed to 
quantitatively assess the subunit epitopes, and immunoblotting was chosen to provide 
additional information on the subunit cross-linking of the antigen preparations. 
PT epitope recognition by murine mAbs in ELISA assay 
In the ELISA analysis, 96-well plates were coated with untreated and 0.1 % FA-treated, 
mutant and native PT preparations and an in-house reference PT (P57) in duplicate, and 
then screened with mAbs specific for subunits Si - S5. The geometric mean potencies of 
mAb binding to each preparation were calculated by parallel line analysis relative to the 
reference PT. 
All of the subunit-specific mAbs showed good binding to both untreated native and 
mutant PT (Figure 6.1). Binding of the anti-S1, S4 and S5 mAbs to both native and 
mutant PT treated with 0.1 % FA was significantly lower, by 50 to 100%(P , -, 0.1), 
compared with the untreated antigens (Figure 6.1). After 0.1 % FA-treatment, there was a 
significantly greater decrease in the S 1-specific mAb binding to native PT (59 % 
decrease) than to mutant PT (44 % decrease) (PS 0.1). There was also a significantly 
greater decrease in the S5-specific mAb binding to native PT (100 % decrease) compared 
with mutant PT (83 % decrease) (P S 0.1) after 0.1 % FA-treatment of the antigens. For 
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Figure 6.1 The effect of FA on PT epitopes as determined hN m. mh-binding 
Mutant (grey bars) and native (black bars) pertussis toxin (I'"I ), treated with U and U. I ".. 
(w/v) formaldehyde (FA) , were used to coat 
96 well plates and screened with monoclonal 
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both mutant and native PT, the effect of 0.1 % FA-treatment on the anti-S2/3 mAb 
binding was not significant (P > 0.1) (Figure 6.1). 
The reduction in epitopes available for mAb binding in ELISA (Figure 6.1) may have 
been due to specific alteration of amino acids in the epitopes by reaction with FA and 
lysine, such as lysine cross-linking. The difference in the effect of FA on the Si subunit 
of mutant compared with native PT is likely to be due to the difference in the Si amino 
acid sequence of these molecules, leading to different amino acid modification. 
Differences in stability of the two PT preparations due to different manufacturers' 
production, storage and handling procedures also cannot be ruled out. This may also have 
accounted for the variations between mutant and native PT epitopes on the S5 subunit. 
Immunoblotting experiments were subsequently performed in order to identify any 
subunit epitopes in the high molecular weight species detected in SEC and SDS-PAGE 
(Chapter 5) and to characterise the inter-subunit covalent cross-linking. In addition, this 
technique was used for comparison with ELISA, and to address the possibility of epitope 
depletion via masking within reversibly associated complexes. 
PT epitope recognition by murine mAbs in immunoblotting assay 
Untreated and 0.035,0.05 and 0.1 % FA-treated mutant PT preparations were separated 
by SDS-PAGE and blotted onto a nitrocellulose membrane. Each membrane was 
screened with one of the five mAbs specific for subunits S 1- S5. 
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The five immunoblots (Figure 6.2 A), with the aid of the summary plot (Figure 6.2 B), 
illustrate the typical bands corresponding to the five subunits of untreated mutant PT 
(11 - 26 kDa). With FA treatment up to 0.1 %, all monomeric subunits were still detected 
and in addition combinations of subunits were detected in higher molecular weight bands 
(Figure 6.2 A and B). 
The first high molecular weight band was a distinct band detected at Mr 37 - 45 kDa in 
all of the FA-treated mutant PT samples by all five subunit-specific mAbs. This could 
correspond to a combination of dimeric and trimeric cross-linked subunits. Initially these 
are likely to be S2/3 + S4 (Mr 34 kDa) and/or S2/3 + S4 + S5 (Mr 45 kDa), since S2 - S4 
and S3 - S4 dimers have the most extensive native interactions of the PT molecule (Stein 
et al., 1994a). Cross-linked Si + S5 (Mr 37 kDa) were also likely to have existed in this 
band. With FA-treatment above 0.035 % FA, another band was detected at 
M, 57 - 65 kDa, by all of the mAbs, and is likely to correspond to the cross-linking of 
another dimeric subunit or of another subunit, perhaps Si or S5, to the dimeric and 
trimeric complexes. 
In samples treated with more than 0.035 % FA, bands of higher molecular weight, above 
Mr 60 kDa were observed. These high molecular weight bands were more frequent, 
broader and were joined by smears. Broad bands indicate that protein species were no 
longer homogeneous. In this case they may suggest that there was an array of lysine- 
decorated, and perhaps differently modified proteins, which could still be recognised by 
221 
SI S2 S3 
250 
60 ± 
42 -º . ý... ''ýr'... ' 
22-º 
Lanes 12345 12345123 
S4 
60 -* 
42 
22 
Lanes 12345 
S5 
54 
1? 34 
Figure 6.2 (A) Effect of FA on PT subunit cross-linking 
Mutant pertussis toxin (PT) samples (5 µg) treated with 0 (Lane 4), 0.035 (Lane 1), 0.05 (bane 
2) and 0.1 (Lane 1) % (w/v) formaldehyde (FA), or molecular weight standards (labelled in 
kDa) (Lane 5) were subjected to SDS-PAGE, blotted onto nitrocellulose membranes and then 
screened with one of five monoclonal antibodies (mAb) specific fier ehitohes on the five Iv I 
subunits Sl-S5, as indicated. 
ýftft *"Mrrw 
ý,.... am* 4w dumb 
ý» 
200 
  
180 
160 
Q 
140 x 
120 
r 
100 
 . 
  
Z 
O 
80 { 
60 
40 
20 1 1 0. r ' 
SIC x 0 
0 0.035 0.05 0.1 
FA concentration (%, w/v) 
Figure 6.2 (B) PT subunit cross-linking with FA; summary 
A plot of relative molecular mass as a function of % (w/v) FA for PT 
bands resulting from immunoblotting or Coomassie blue staining of 
SDS-PAGE gels. Band detected by subunit-specific mAb binding: 
Sli; S21 ; S3 4; S4XandS5+ 
Coomassie blue band  ; Coomassie blue smear: (vertical 
line) 
223 
Chapter 6 Effect of FA on PT immunogenicity 
the mAbs. However, fewer epitopes were detected at high molecular weights in the 0.1 % 
FA-treated sample compared with the 0.05 % FA-treated sample. The largest species in 
the 0.1 % FA-treated sample were detected by the S2 and S3-specific mAbs, in bands of 
molecular weight -140 and 120 kDa (Figure 6.2 A and B). 
Together, observations of the immunoblots confirm that FA causes inter-subunit cross- 
linking to form multimeric structures, in agreement with the previous sizing methods 
(Chapter 5). Furthermore, there is evidence that low concentrations of FA cause cross- 
linking between neighbouring subunits, and, higher FA concentrations produce less 
uniform subunit association with possible loss of epitopes. 
6.2.2 Assessment of murine anti-PT antibody response to FA-treated 
PT 
To investigate the effect of FA on the immunogenicity of mutant and native PT, groups 
of five mice (strain, NIH) were immunized once, sub-cutaneously with mutant or native 
PT treated with 0.25 - 1.00 % FA, or untreated mutant PT; each administered with and 
without alum. Five weeks later, the mice were terminally bled and serum samples 
prepared. Two serum samples raised against 0.25 % FA-treated native PT and one against 
0.5 % FA-treated native PT were not available for analysis because these mice died 10 
days after immunization. This suggests that with low FA-treatment the native PT samples 
may still have residual toxicity and/or have reverted to toxicity in vivo. 
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The total IgG and IgG subclass response was investigated by assaying the PT-specific 
total IgG, IgGI and IgG2a subclass antibodies in the serum samples using ELISA, and 
the effect on the antibody response of adsorbing the antigens to alum was also assessed. 
The binding specificity of these sera for different subunits of PT was also assessed, by an 
immunoblotting assay using a native PT reference preparation. In addition, the 
neutralizing capacity of these sera for PT was determined using the CHO-cell 
neutralization assay. 
6.2.2.1 Total IgG response 
To assess the PT-specific total IgG antibody response in mice immunised with different 
FA-treated mutant and native PT preparations, 96-well plates were coated with reference 
PT (P57), screened with the different serum samples or anti-PT reference serum (97/642, 
1 S` International Reference Preparation (IRP)) followed by a secondary antibody, goat 
anti-mouse total IgG antibody. The geometric mean potency for each serum sample was 
calculated by parallel line analysis, relative to the anti-PT reference serum. 
Mutant PT 
Untreated mutant PT generated a lower total IgG response than all of the FA-treated 
mutant PT preparations (P <_ 0.1) (Figure 6.3). The 0.25 % FA-treated sample generated 
relatively high levels of total IgG in murine sera and there was a slight decreasing trend 
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in this response with increasing FA treatment. IgG levels decreased by 22 %, from a 
relative geometric mean titre of 1.52 for the 0.25 % FA-treated mutant PT to 1.19 for the 
1.0 % FA-treated mutant PT, although this was not statistically significant (P > 0.1). 
These results demonstrate that FA-treatment of mutant PT does not cause a significant 
decrease in the total IgG production compared with the untreated mutant PT, and in fact 
may cause a slight increase in the total IgG response. This may be due to FA-induced 
cross-linking causing stabilising of the antigen, or to effective presentation of epitopes to 
the immune sysem on the high molecular weight complexes. 
Native PT 
Untreated native PT could not be used to immunise mice for the production of antibodies 
due to its toxicity. Native PT treated with 0.25 % FA generated a very low total IgG 
response which increased dramatically with FA treatment (Figure 6.3). In response to the 
0.25 % FA-treated native PT, the relative geometric mean titre for total IgG was 0.57, 
which is much lower than that of the corresponding mutant PT (P: 5 0.1). With 0.7 % FA- 
treated native PT the total IgG antibody increased significantly by 89 % to 5.21 (P: 5 0.1). 
With 1.0 % FA-treated native PT the antibody level dropped off slightly compared with 
the 0.7 % FA-treated, but this was not statistically significant. Both the 0.7 and the 1.0 
FA-treated native PT preparations induced total IgG responses which were significantly 
higher than the total IgG levels induced by the corresponding mutant PT preparations (P 
<_ 0.1). 
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Serum was collected from roues of live mice each immunised v III) lý of 
mutant or native pertussis toxin (PT) treated with 0.25,0.70 or I . 
00 " (w/v) 
formaldehyde (FA); or untreated mutant PT. PT-specific total Ig(i was 
quantitated by FLISA relative to a Pl reverence serum, and expressed as the 
relative geometric mean of the five serum samples with one geometric 
standard deviation, indicated by error bars. These results are representative 
of three separate immunogenicity experiments. 
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These results imply that putative residual toxicity in the 0.25 % FA-treated native PT 
inhibited the IgG response, with respect to the non-toxic mutant PT. The mice immunized 
with this preparation looked very ill and two of them died. The IgG response increased 
dramatically with FA-treatment, suggesting that the immune response was no longer 
inhibited, which may be indicative of a decrease in the toxicity of the native PT antigen. 
The 0.7 and 1.0 % FA-treated native PT appeared to augment the total IgG response in 
comparison to the corresponding mutant PT preparations. 
6.2.2.2 IgG subclass response 
The PT-specific IgG I and IgG2a responses to the FA-treated mutant and native PT 
preparations were determined by ELISA as described for the total IgG response, except 
that the secondary antibody employed was rat anti-mouse IgG 1 or IgG2a antibody. 
Mutant PT 
The trend in the IgGI and IgG2a response (Figure 6.4) was very similar to that of the 
total IgG response (Figure 6.3) with respect to FA. With 0.25 % FA-treatment of the 
antigen both the IgGI and the IgG2a response increased, although this was only 
statistically significant for the IgGI response (P: 5 0.1) (Figure 6.4). Compared with 0.25 
% FA treated mutant PT, the 0.7 % FA-treated preparation induced a much lower IgGI 
and IgG2a response (P: 5 0.1) (Figure 6.4). With further FA treatment (1.0 % FA) there 
was no further decrease in IgG 1 and IgG2a (Figure 6.4). 
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Figure 6.4 The effect of FA on anti-PT IgC subclass response 
Serum was collected from groups of five mice each immunised with 5µg of 
mutant or native pertussis toxin (PT) treated with 0.25,0.70 or 1.00 °., (w 'v ) 
formaldehyde (FA). PT-specific Ig(Il and fg(I2a was quantitated by f. 1A 
relative to an anti-PT reference serum, and expressed as the relative geonuctric 
mean of the five serum samples with one geometric standard deviation, 
indicated by error bars. These results are representative of three separate 
immunogenicity experiments. 
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The increase observed in the IgGl/IgG2a ratio with FA treatment (Figure 6.5) indicates 
that there may have been a shift towards a Th2-type immune response with increasing 
FA-treatment of the mutant PT antigen. The large difference between the immune 
response to the experimentally produced FA-treated mutant PT in this experiment and the 
analagous commercially produced toxoid A (Figure 4.6, Chapter 4) may be due to real 
differences in antigen treatment. The experiment in Chapter 4 may merit repeating to 
confirm this. The slight increase in IgGI and IgG2a response to mutant PT with 0.25 % 
FA-treatment agrees with results of the total IgG response and may indicate FA-induced 
cross-linking and stabilisation of the mutant PT antigen. The decline in IgGI and IgG2a 
response with increasing FA treatment may be an indication of damage to immune 
epitopes. However, the epitopes do not continue to decline with further FA treatment 
suggesting the molecules may be stabilised. 
Native 
The trend in the IgGI and IgG2a response (Figure 6.4) was very similar to that of the 
total IgG response (Figure 6.3) with respect to FA. The IgGI and IgG2a antibody 
responses to the 0.25 % FA-treated native PT were very low, and considerably lower than 
the responses to the corresponding mutant PT (P 5 0.1) (Figure 6.4). From 0.25 % FA- 
treatment to 1.0 % FA-treatment, the IgG2a potency increased by 93 % (P S 0.1) to a 
level comparable with that induced by the corresponding mutant PT preparation (Figure 
6.4). However, the IgG 1 response to native PT did not significantly increase with FA 
treatment, and with 1.0 % FA-treatment was only 50 % of that induced by the 
corresponding mutant PT preparation. 
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Figure 6.5 The effect of FA on the lg(: 1/Il; (: 2a ratio 
Serum was collected from groups of li%e mice each immunised with 5 Its; 
of mutant or native Pertussis toxin (PT) treated with 0.25,0.70 or 1.00 ";. 
(w/v) formaldehyde (FA). PT-specific IgGI and Ig(i2a were quantitated by 
F. LISA relative to an anti-PT reference serum, and the geometric mean 
Ig(i I and IgG2a titres of the five serum samples tier each group were 
expressed a ratio of Ig(i 1 /IgG2a. 
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The 0.25 % FA-treated preparation induced a strong Th2 profile, as indicated by the high 
IgGI/IgG2a ratio; five-fold greater than for the corresponding mutant PT preparation 
(Figure 6.5). With increasing FA treatment of the native PT antigen, the IgGl/IgG2a ratio 
decreased dramatically (Figure 6.5), suggesting that FA-treatment of native PT caused a 
polarization towards a Thl-type response. Further cytokine studies would be required to 
confirm this. 
Effect of alum 
Most acellular pertussis vaccines are adsorbed to aluminium hydroxide (alum) or 
aluminium phosphate for immunisation. To investigate the effect of alum, antibody 
responses were also determined for mutant and native PT preparations adsorbed to alum. 
Total IgG data is presented for 0.25 and 1.00 % FA-treated mutant and native PT 
preparations both administered with and without adsorption to alum (Figure 6.6). Alum 
caused a significant increase in total IgG response to the FA-treated native and mutant PT 
preparations (P<_ 0.1), with the exception of the response to 1% FA-treated native PT, 
which was not significantly increased (P > 0.1). This may have been due to the fact that 
the IgG antibody response was already close to its upper limit. The effect of alum on the 
response to the 0.25 % native PT was not as great as the effect on the response to the 
corresponding mutant PT, which may be another result of the stress and immune 
suppression experienced by this group of mice, as previously discussed. The overall trend 
in total IgG antibody response with increasing FA-treatment was the same for the 
samples administered with alum (data not shown) as for those without alum (Figure 6.3). 
The trend in IgGI and IgG2a with increasing FA-treatment was also similar with (data 
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Figure 6.6 The effect of alum on total lg(: production when 
administered with native or mutant PT 
Serum was collected from groups o[' five mice each immniunised with S pg of 
mutant or native pertussis toxin (PT), treated with 0.25 or I. (X) ° (w/v) 
formaldehyde FA, with (block bars) or without (hatched bars) alum. PT-specific 
total lgG was quantitated by ELISA relative to it PT reference scrim, and 
expressed as the geometric mean of the live serum samples with one geometric 
standard deviation, indicated by error bars. These results are representative of 
three separate immunogenicity experiments. 
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not shown) and without alum (Figure 6.4). Exceptionally, for mutant PT the IgG2a 
response decreased with FA treatment to an even greater extent when administered with 
alum, demonstrating the effect of alum as a Th2 adjuvant. It is also worthy to note that for 
native PT there was not such a marked trend towards Thl response with increasing FA- 
treatment when administered with alum, again demonstrating the Th2 adjuvanticity of 
alum. 
Overall the results in this section illustrate that, even with the highest FA treatment, the 
mutant PT antigens could still induce higher levels of PT-specific IgG antibodies 
compared with untreated mutant PT. However, the type of immune response changed 
with FA treatment, demonstrating a trend towards a Th2-type response. The results also 
suggested that native PT treated with 0.25 % FA seemed to inhibit the production of IgG 
antibodies. With increasing FA-treatment (0.7 and 1.0 % FA) the total IgG response 
exceeded that of the corresponding mutant PT preparation and this appeared to be 
polarized towards a Thl-type response. Alum caused an increase in the IgG antibody 
production but did not effect the overall FA-induced changes on mutant and native PT 
immunogenicity. 
6.2.2.3 Binding specificity of antisera for PT subunits in immunoblots 
To assess the binding specificity of the antisera for PT subunits, identical preparations of 
reference PT (untreated mutant PT) were subject to SDS-PAGE and blotted onto 
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nitrocellulose membranes. These were cut into strips encompassing one reference PT and 
one molecular weight marker, and each strip was screened with the sera raised against 
0.25 - 1.00 % FA-treated mutant and native PT preparations, or with anti-PT reference 
serum (97/642,1S` IRP), and the results of the 0.25 and 0.70 % FA-treated preparations 
are presented (Figure 6.7). 
Screening of PT blots with the anti-PT reference serum produced dense bands 
corresponding to subunits S1, S2 and S3, and a faint band corresponding to S4/S5 (Figure 
6.7). Similar dense bands for Si, S2 and S3 were detected with serum from mice 
immunized with 0.25 - 1.0 % FA-treated mutant PT, and results from the 0.25 and 0.70 
% FA-treated preparations are representative of these. Dense bands corresponding to S 1, 
S2 and S3 also developed with serum against 0.50,0.70 and 1.0 % FA-treated native PT, 
and the result for 0.7 % FA-treated native PT is presented (Figure 6.7). In contrast, serum 
from mice immunized with 0.25 % FA-treated native PT produced S 1, S2 and S3 bands 
of distinctly lower intensity than the other samples (Figure 6.7). The S4/S5 band could 
not be detected by any of the test sera at the concentrations applied, suggesting that there 
was a very low density of anti-S4 and S5 antibodies in the sera, which may reflect the 
FA-induced damage to the epitopes on S4 and S5, as previously detected by ELISA 
(Figure 6.1). Alternatively, the anti-S4/S5 antibodies may have been abundant, but the 
immune epitopes may have been conformational epitopes susceptible to denaturation 
during SDS-PAGE; in which case the anti-S4 or S5 antibodies could not be detected by 
this method. 
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Figure 6.7 The effect of FA treatment on the quality of anti-PT serum 
Serum was collected from groups of five mice each immunised with 5 tg of mutant 
or native pertussis toxin (PT) treated with 0.25 or 0.70 % (w/v) formaldehyde (FA). 
The pooled sera from each group of five or an anti-PT reference serum were used to 
screen nitrocellulose membrane SDS-PAGE blots of reference PT. 
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These results suggest that the highest level of FA used did not seem to be deleterious to 
the production of subunit-specific antibody production. In addition, the 0.25 % FA- 
treated native PT induced the lowest quantity of subunit-specific antibodies, suggesting 
that the possible toxicity of this sample had an inhibitory effect on antibody production in 
the mice. These data support the results of IgG assays (Figure 6.3). 
6.2.2.4 Assessment of neutralising antibodies by CHO-cell assay 
A CHO-cell assay was designed in order to assess the PT-neutralising capacity of the 
antisera. Serum samples raised against FA-treated native and mutant PT preparations and 
the anti-PT reference serum (97/642,1s` IRP) were titrated on a 96-well plate, incubated 
with reference PT (90/518, NIBSC standard; 25 µL, 16 ng/mL) for three hours and then 
the CHO-cell suspension added and incubated for a further 2 days. The plates were 
assessed for neutralization of the toxic clumping effect of PT on the CHO-cells. The 
neutralisation titres were corrected for variation between plates relative to the reference 
serum titre and were expressed as the geometric mean for each group of serum samples. 
Mutant 
The neutralization capacity of murine serum induced by 0.25 % FA-treated mutant PT 
was relatively high, and this decreased with increasing FA treatment of the mutant PT 
antigen, declining by 60 % (Ps 0.1) with 1.0 % FA (Figure 6.8). 
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Native 
Effect of FA on PT immunogenicity 
The neutralising capacity of murine serum induced by 0.25 % FA-treated native PT was 
much lower than that for the corresponding mutant PT preparation. In direct contrast to 
mutant PT results, the neutralizing capacity increased with FA-treatment of the native PT 
antigen, and had increased by 80 % (P <_ 0.1) with 1.0 % FA (Figure 6.8). 
Comparison with total IgG 
The trend in the neutralizing capacity of the sera with increasing FA-treatment of the 
antigen, mirror the trend in the IgG antibody response. From 0.25 - 1.00 % FA-treatment 
of the native PT antigen, there is an 84 % increase in total IgG potency and an 80 % 
increase in the neutralization capacity. Therefore, the increased population of lgG 
antibodies consisted of neutralising antibodies. With 0.25 - 1.00 % FA-treatment of the 
mutant PT antigen, there is a 21 % decrease in the total IgG titre but a much larger 
decrease of 60 % in the neutralizing capacity. This suggests a large decline in the 
neutralizing population of IgG antibodies, with 1.00 % FA-treated mutant PT antigen. 
6.3 Discussion 
Characterisation of antigens 
Immunoblotting results showed that with low FA-treatment (0.035 %) of mutant PT, 
cross-linking occurred between neighbouring subunits in the holotoxin structure. With 
higher FA-treatment, above 0.035 % FA, molecules exceeding holotoxin molecular 
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Figure 6.8 The effect of FA on anti-PT neutralising capacity 
Serum was collected from groups of three mice each immunised with 5 pg of mutant 
or native pertussis toxin (PT) treated with 0.25,0.50 or 1 . 
00 (/,, ) (w/v) lormaldchydc 
(FA). Each serum sample was titrated, incubated with active PT reicrence and further 
incubated with CHO-cells. The neutralisation titre was taken as the reciprocal of the 
highest serum dilution causing complete neutralisation of ('I IO-cell clumping. Results 
are expressed as the geometric mean of three senun samples and geometric standard 
deviation is denoted by error bars. 
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weight were produced demonstrating cross-linking between multimeric species. In 
addition, the cross-linking became more random, and with 0.1 % FA loss of epitopes was 
observed in the higher molecular weight bands over - 100 kDa. These results support 
those from the previous sizing experiments (Chapter 5). The evidence for inter-subunit 
and inter-multimer cross-linking, reveals at least part of the mechanism for the FA- 
induced production of the large aggregates which were previously observed (see Chapter 
5). In addition, the cross-linking may explain the stabilising properties of low FA- 
treatment which have been previously reported. This was demonstrated by SDS-PAGE, 
in that FA-treated mutant PT retained its subunit integrity for a longer period of storage 
than untreated mutant PT (Nencioni et al., 1990). 
The results from both ELISA and immunoblots implied there was some loss in the 
density of S 1, S4 and S5 epitopes with 0.1 % FA-treatment. In contrast, both techniques 
demonstrated that abundant S2 and S3 epitopes prevailed in this preparation. Although 
some correlations can be made between the results of ELISA and immunoblotting, the 
same significant reduction in Si, S4 and S5 subunit epitopes measured by ELISA was not 
observed by immunoblotting. The immunoblot bands for all subunits remained dense, 
even with the highest FA-treatment. This could be an indication that there was masking 
of the S 1, S4 and S5 epitopes in ELISA, and unmasking with the denaturing technique of 
immunoblotting, presumably as the result of reversion of FA-induced modifications. In 
addition, the pattern of mAb-binding in immunoblotting confirmed that FA caused the 
formation of inter-subunit covalent cross-links and perhaps the cross-linking of Lys from 
the reaction mixture. 
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These results provide evidence for two possible mechanisms of epitope loss. One 
mechanism is by specific FA-induced modification of amino acids that comprise the 
subunit epitopes, and the other is by masking of intact epitopes within aggregated 
molecules. Chemical cross-linking between Lys from the reaction mixture and specific 
epitope amino acids, or intra-molecular cross-linking, could be responsible for direct 
epitope modification. Additionally, association of molecular surfaces by covalent cross- 
linking or non-covalent interactions could be responsible for epitope masking. 
As previously described (section 5.3, Chapter 5), certain amino acids form reactive 
intermediates during reaction with FA, and these can form methylene cross-links in 
proteins. Lys in solution can also cross-link with protein amino acids (Tome and Naulet, 
1981). The I B7 epitope on the SI subunit is known to reside within the amino acid 
sequence 8- 15 (Sato et al., 1984) and this sequence harbours four primary FA-reactive 
amino acids (Cieplak et al., 1988). For native PT these are Tyr-8, Arg-9, Tyr-10 and Arg- 
13, and in mutant PT Arg-9 is changed to Lys, which is known to be the most FA- 
reactive amino acid (Tome, Kozlowski, and Mabon, 1985). This may account for the 
difference in the FA-induced modification of 1 B7-binding in ELISA, observed between 
mutant and native PT (Figure 6.1). Some FA-induced cross-links and other modifications 
produced by FA have been found to be reversible (described in section 5.3, Chapter 5) 
(Bizzini and Raynaud, 1974; Tome et al., 1979; Tome, Kozlowski, and Mabon, 1985). 
The occurrence of reversible interactions correlates with the mechanism of epitope 
unmasking. In the immunoblotting experiment it is likely that reversion of some 
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interactions led to unfolding or dissociation of large multimers, allowing mAbs to bind. 
Similar evidence of B-cell epitope unmasking in vitro has previously been presented 
(Nencioni et al., 1991) and specific T-cell epitopes have also been shown to be restored 
after heat denaturation (Di Tommaso et al., 1994). 
In contrast to the other subunit epitopes, ELISA and immunoblotting experiments showed 
that the S2/3 epitope was not significantly altered. This may be due to low modification 
of this particular S2/3 epitope due to its amino acid sequence, and/or it may be that the 
these subunits are presented on the surface of the cross-linked molecules. 
Immune response 
Mutant and native PT preparations, treated with increasing concentrations of FA, 
produced totally different trends in antibody response, even though the corresponding 
mutant and native PT preparations were found to be physico-chemically similar (Chapter 
5). In the characterisation of FA-induced changes in PT immunogenicity, it seemed that 
the most influential factor controlling the immune response to the FA-treated native PT 
preparations may have been their putative residual active PT. The mutant PT studies 
addressed the influence of structural changes alone. 
The IgG response induced by 0.25 % FA-treated mutant PT preparations was higher than 
for the untreated mutant PT. This may be attributed to the stabilising effects of FA due to 
covalent cross-linking within or between mutant PT molecules as discussed above. 
Increasing FA-treatment did not cause the IgG titres to decline significantly, as also 
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observed by Nencioni and co-workers (Nencioni et al., 1991). This was despite the fact 
that FA-treated mutant PT preparations were extensively cross-linked and aggregated 
with a reduced number of epitopes (section 6.2.1 and Chapter 5). These results suggest 
that although there was some damage to epitopes, the epitopes that were intact may be 
efficiently presented on aggregates to the immune system in vivo. It is also conceivable 
that the FA-aggregated structures became partly unfolded or dissociated with incubation 
in the body, providing a slow release of immune epitopes. 
The type of antibody response induced by mutant PT may have changed with increasing 
FA-treatment however. This is demonstrated in that the neutralising capacity of the anti- 
PT antibodies declined to a greater extent than the total IgG. This suggests that FA 
affected the quality of the antibody response induced. This is in line with the proposal 
that there are local modifications to the surface protective epitopes by FA-induced cross- 
linking, as shown with mAb binding in ELISA and immunoblots. In addition, the relative 
potencies of IgGI and IgG2a subclasses suggest that the class of immune response is 
shifted towards a Th2-type response. An explanation for this shift may be due to FA- 
induced cross-linking which could potentially alter binding to and/or processing by 
antigen presenting cells, thus altering the cytokine environment. This explanation is in 
line with evidence, from in vitro studies of T-cell proliferation, that FA-treatment of 
vaccine antigens alters their proteolytic processing by antigen presenting cells (Di 
Tommaso et al., 1994). 
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Antibody production induced by the 0.25 % FA-treated native PT was significantly lower 
than the response induced by the corresponding mutant PT preparation. The 0.25 % FA- 
treated native PT was potentially the most toxic of the native PT preparations, and 
concurrent with this there were in fact two fatalities in this group of mice and the 
remaining mice appeared stressed. Therefore, it may be that the potentially higher 
toxicity in this preparation was inhibitive to the immune response. With 0.7 and 1.0 % 
FA-treatment of native PT, a huge increase in the IgG antibody response was observed, 
suggesting that the antibody response was no longer inhibited by the toxicity of these 
preparations. These results provide some evidence that a FA concentration greater than 
0.25 %, under the current conditions of preparation, is required to detoxify native PT. 
It is particularly interesting to note that the total IgG response for the 0.70 and 1.00 
FA-treated native PT preparations was even higher than that for the corresponding mutant 
PT preparations. This implies that these FA-treated native PT preparations actually 
enhanced the IgG response. Although it has been suggested that the putatively high 
toxicity of the 0.25 % FA-treated PT inhibited the total IgG response, it may be that much 
lower residual activity can have the opposite effect. 
Concomitant with the augmented total IgG levels, the quality of the antibody response 
was altered. The differential induction of IgGI and IgG2a suggests that the enhanced 
response was Thl polarised. In addition, the large number of antibodies was also found to 
consist mainly of effective neutralising antibodies (Figure 6.8). 
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In line with the augmented antibody responses observed, native PT has been shown to 
have adjuvant properties. PT coadministered with immunologically inert antigens can 
augment murine antibodies and cytokines specific for that antigen (Ryan et al., 1998b; 
Wilson et al., 1993; Shive et al., 2000). Additionally a residual amount of native PT can 
induce enhanced protection against B. pertussis infection in mice when co-administered 
with other B. pertussis antigens and cause a corresponding increase in the nitric oxide 
production of macrophages (Robinson and Irons, 1983; Xing, Canthaboo, and Corbel, 
2000). These factors can be indicative of a Thl-polarised response, which is concurrent 
with the augmented immune response found in this study. Specific cytokine studies 
demonstrated that the adjuvant response was a mixed Thl/Th2 response (Ryan et al., 
1998b). There is still controversy over the mechanism of PT adjuvanticity. The results of 
this study, which have provided a parallel comparison of structurally similar non-toxic 
and partly toxic native PT preparations, suggest that the immune enhancing properties of 
PT are dominated by the ADP-ribosyl transferase-dependent effects. 
It is interesting to note that the structurally related toxins, cholera toxin (CT) of Vibrio 
cholerae and heat-labile enterotoxin (LT) ofEscherichia coli, also have potent adjuvant 
activity (Williams, Hirst, and Nashar, 1999). However, CT augments predominantly a 
Th2-type immune response (Wilson et al., 1993), and LT a mixed Thl/Th2 response 
(Takahashi et al., 1996). Differences in the immunogenicity of CT, LT and PT could be 
due to their different host cell receptors, and in the case of PT, different host G-protein 
substrate. The current experimental evidence suggests roles for both the A- and the B- 
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domains of CT and LT in their adjuvant activity (Williams, Hirst, and Nashar, 1999; 
Rappuoli eta!., 1999). 
Overall it appears that FA-induced structural changes can influence epitope presentation, 
the inhibition or enhancement of the immune response, the neutralising quality of the 
antibody response and the differential induction of Thl and Th2 cells. Variations in PT 
antigens such as these may help to explain the large differences in immunogenic 
properties between different acellular pertussis vaccines (Ausiello et al., 1997; Mills et 
al., 1998; Ryan et al., 1998a). This work provides the basis for tailoring a protective 
immune response against B. pertussis by the inclusion of different quantities of molecular 
aggregates/cross-linked species. In addition, it suggests that ADP-ribosylating activity 
may affect the magnitude and class of immune response induced by PT. To corroborate 
the role of toxicity in the immune responses obtained in this chapter, the toxic biological 
activities of the native PT preparations are assessed in the next chapter (Chapter 7). 
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7.1 Introduction 
PT has been characterized over the decades under many different aliases, owing to its 
diverse and numerous biological activities. Some of these activities include its ability to 
sensitise animals to histamine, promote elevated levels of circulating lymphocytes, 
enhance insulin release, augment the immune response to coinjected antigen and, 
amongst its abundant in vitro effects, cause CHO-cells growing in a uniform mono-layer 
to morph and clump together (Munoz, 1985). 
PT is of the AB class of protein toxins, which encompass two functionally distinct 
domains. The B-oligomer facilitates host-cell binding and entry of PT into the cell, and 
there it exerts its toxic effects via its catalytic A-domain, which ADP-ribosylates host G- 
proteins. The toxic biological activities of histamine sensitization, leukocyte promoting 
activity and CHO-cell toxicity all require functional A and B-domains and have been 
found to be ultimately dependent on the catalytic activity of the A-domain, that is, they 
cannot be caused by B-oligomer binding alone (Nencioni et al., 1991). The distinct roles 
of A- and B-domains in the adjuvant activity of PT is unclear. 
FA is commonly used to toxoid PT, namely to remove the toxic biological activities of 
PT, for its inclusion in acellular pertussis vaccines. Existing studies on the effects of FA 
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on the toxicity of native PT were carried out over a decade ago, generally on combined 
antigens or crude PT preparations. The Japanese DTP vaccine containing the acellular 
pertussis component, which encompasses 0.4 % FA-treated PT, was reported to have one- 
tenth of the toxicity of the whole cell vaccine as determined by mouse-body-weight- 
decreasing activity, leukocyte promoting activity and histamine sensitising tests (Sato, 
Kimura, and Fukumi, 1984). Studies of a partially purified PT extract after treatment with 
0.05 - 0.2 % FA for 24 hrs at 37°C demonstrated a reduction in CHO-cell toxicity, 
leukocytosis and histamine sensitisation with increasing FA treatment (Gupta et al., 
1991). It was noted that, even with 0.2 % FA-treatment, high residual activity of PT still 
remained in the preparation. 
In the previous chapter (Chapter 6), the effects of increasing FA treatment on the 
immunogenicity of PT were assessed, and opposite trends in IgG response were observed 
for native and mutant PT antigens. In comparison with the corresponding mutant PT 
preparations, the lowest FA-treated native PT seemed to inhibit the immune response, 
while the highest FA-treated native PT augmented the response. It was noted that there 
were some fatalities after 10 days, in the groups of mice inoculated with 0.25 and 0.50 % 
FA-treated native PT. This suggested that these lower FA-treated native PT preparations 
may have had residual toxicity or have reverted to toxicity in vivo. Accordingly, the large 
differences observed in the immune response induced by the native PT preparations, 
compared with mutant PT preparations, were attributed to their putative toxicity. 
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Although native PT detoxified with FA is still being used in pertussis vaccines 
worldwide, no new efforts have been made to characterize the detoxification process. In 
particular, the specific effects of FA on the functional domains of native PT, to our 
knowledge, have not yet been explored. In addition, the role of toxicity in the immune 
responses previously observed (Chapter 6) must be addressed; therefore a detailed 
investigation of the toxic properties of the FA-treated native PT preparations is required. 
The aim of these experiments was to assess the toxic properties of the FA-treated native 
PT preparations and to test for reversion to toxicity. 
Native PT was treated with 0.25,0.50,0.70 and 1.00 % FA (as used in Chapter 6), which 
covers the range of FA concentrations used to treat PT for use in commercial pertussis 
vaccines. The effect of FA on the toxic biological activities of native PT was assessed 
using four different assays. These were, an in vitro ADP-ribosylation assay in a cell-free 
system, a CHO-cell toxicity assay, and two murine in vivo tests, of leukocyte 
proliferation and histamine sensitisation. Reversion to toxicity was also tested by 
analysing the toxicity of the preparations before and after incubation for 1l days at 37 °C, 
using the ADP-ribosylation and CHO-cell toxicity assays. 
249 
Chapter 7 
7.2 Results 
Effect of FA on PT toxicity 
7.2.1 Effect of FA on the toxic activities of native PT 
Histamine sensitisation test 
Five mice per group were each immunised with 5 µg/dose of one of the 0.25 - 1.0 % FA- 
treated native PT preparations, 100 ng/dose of the positive control active PT (90/518, 
NIBSC reagent) or one of the negative controls, PBS and non-toxic mutant PT 
(5 µg/dose). After five days each mouse was challenged with histamine diphosphate 
solution and the reaction of the mice was recorded. 
After histamine challenge, all of the mice inoculated with PBS or mutant PT and two out 
of five mice inoculated with 100 ng of reference PT survived. In contrast, none of the 
mice from the groups inoculated with any of the FA-treated native PT preparations 
survived (Table 7.1). The groups injected with 0.25 and 0.5 % FA-treated native PT died 
more rapidly than those injected with the 0.7 and 1.0 % FA-treated native PT (Table 7.1). 
From comparison with the reference PT (100 ng/dose), the results from this assay suggest 
that all of the FA-treated native PT samples, contain more than 100 ng of active PT per 
dose. This may explain the fatalities and illness of the mice that were immunised with 
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Table 7.1 Effect of FA treatment of native PT on histamine sensitization 
Five mice per group were immunised with 0.25 - 1.00 % (w/v) formaldehyde (FA)-treated 
native pertussis toxin (PT) (5 µg), positive control (100 ng reference PT, code 90/518, NIBSC 
reagent) or negative controls (untreated mutant PT (5 µg); or PBS). The histamine sensitivity 
of each group was assessed and expressed as the number of fatalities per group of five. 
Immunising preparation Formaldehyde 
treatment (%, w/v) 
Number of mice, out of 
five, dead after 
histamine sensitisation 
Native PT 0.25 5 (at 10 mins) 
" 0.50 5 (at 10 mins) 
0.70 5 (at 15 mins) 
1.00 5 (at 15 mins) 
PBS - 0 
Mutant PT 0 0 
100 ng reference PT 0 3 
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0.25 and 0.5 % FA-treated native PT, observed in the immunogenicity study in the 
previous chapter (Chapter 6). 
Leukocyte proliferation test 
Mice were immunised as described for the histamine sensitisation test. Three days after 
immunisation, tail bleeds were taken from each mouse and the number of leukocytes in 
each whole blood sample was counted. 
A base-line number of leukocytes (- 6 000) was counted in the whole blood from mice 
inoculated with the negative control, PBS (Figure 7.1). The same level of leukocyte 
proliferation was obtained in response to the mutant PT sample. There was a 1.6 times 
greater number of leukocytes in the mice immunised with 100 ng of the reference PT than 
those with the base-line number. An even greater rise in the leukocyte count to 
> 30 000, more than 5 times higher than the base-line number, was observed in mice 
inoculated with the 0.25 and 0.5 % FA-treated native PT preparations (Figure 7.1). The 
leukocyte proliferation declined with increasing FA treatment of the native PT and was 
reduced by 55 % with the highest FA-treatment. 
All of the FA-treated native PT preparations induced a higher leukocyte count than 
100 ng of reference PT. In agreement with the histamine sensitisation test, this suggests 
that they all contained over 100 ng of active PT, which may explain the fatalities and 
illness observed in the two groups of mice in the immunogenicity study (Chapter 6). 
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Figure 7.1 Effect of FA on leukocyte proliferation activity of nativ c PT 
°.. Iwýý l fiºrm. ºIdehv. k' (I .x) Five mice per group were immunised with 0.2; 1.00 
treated native pertussis toxin (PT) (5 µg), positive control (100 ng ret'. I' f, code 
90/518, NIBSC reagent) or negative controls (untreated mutant P'1 or PUS). "I he 
geometric mean leukocyte counts per nil- of whole blood tür each group of I ive mice 
were determined, and are presented with error bars indicating one standard 
deviation. 
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CHO-cell toxicity assay 
Effect of FA on PT toxicity 
Each FA-treated PT preparation, the positive control active PT (90/518, NIBSC reagent) 
or PBS negative control were titrated on a 96-well plate, the CHO-cell suspension was 
added to each well and the plate incubated at 37 °C. Unaffected CHO-cells grow in a 
uniform mono-layer (Figure 7.2 A), while those in the presence of toxic PT change 
morphology and clump together (Figure 7.2 B). After three days the wells were checked 
under the microscope for CHO-cell clumping and the quantity of toxic PT in each sample 
was determined relative to the reference PT. 
The CHO-cell toxicity of native PT progressively decreased with increasing FA 
treatment. The 0.25 % FA-treated native PT contained 1 pg of active PT per 100 µg of 
protein and this declined by 95 % with 1.00 % FA treatment, to 0.053 pg of active PT 
(Figure 7.3). 
The reduction in CHO-cell toxicity with increasing FA concentration could be as a result 
of alterations within the CHO-cell binding sites of the B-oligomer, which could prevent 
initial binding of the PT molecule to the CHO-cell. There may also or alternatively have 
been modifications to the amino acids of the catalytic site in the A-domain, thus 
inactivating the ADP-ribosyl transferase activity of the toxin. In order to address the 
question of the site of FA-induced detoxification, the FA-treated native PT samples were 
also analysed by a cell-free ADP-ribosylation assay. ' 
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Figure 7.2 (A) CHO-cells 
ý %T \Rß r-o 
CHO-cells growing in a confluent monolayer. CHO-cells were 
grown in complete RPMI medium for 3 days at 37 °C, in 5 ON, CO,. 
They were stained with Coomassie blue and visualised with a light 
microscope at 10-fold magnification. This photograph is courtesy 
of Dr D. Xing. 
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Figure 7.2 (B) CHO-cells exposed to native PT 
CHO-cells were grown in complete RPMI medium, in the presence of 
16 ng/mL reference PT (90/518, NIBSC reagent) for 3 days at 37 °C, 
in 5% CO,. They were stained with Coomassie blue and visualised 
with a light microscope at 10-fold magnification. This photograph is 
courtesy of Dr D. Xing. 
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Figure 7.3 The effect of FA on ('IIO-cell toxicity 0f native P'1' 
The quantity ofpertussis toxin (PT) with ('110-cell toxicity, in native 
PT preparations treated with 0.25 - 1.00 "o (w/v) fornmaldchydc (I- A), 
was determined. The CHO-cell toxicity assay measured the ability of 
the preparations to cause CHO-cell clumping, performed according 
to Gillenius et al., 1985. The amount of active PT (pig) in each 
preparation was determined relative to retcrcnce PT (code 90/5 I K, 
NII3SC reagent) and presented as a proportion of 100 pg ot'total 
protein in the sample. The C'HO-cell toxicity assay was repeatable to 
one dilution factor. 
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ADP-ribosylation assay 
Effect of FA on PT toxicity 
The FA-treated preparations were assayed for ADP-ribosyl transferase activity by 
measuring their ability to ADP-ribosylate the C20 peptide in a cell-free system. This 
reaction is explained diagrammatically (see Figure 7.4). The C20 peptide is a 
fluorescently tagged peptide homologous to the 20 carboxyl-terminal amino acids of the 
alpha-subunit of the Gi3 protein. After incubation of the PT preparation with the C20 
peptide, ADP-ribosylated C20 peptide was detected and measured by HPLC, and the 
activity of the PT preparation calculated relative to the PT reference (90/518, NIBSC 
reagent). 
The ADP-ribosyl transferase activity of native PT progressively decreased with 
increasing FA treatment (Figure 7.5). There was 5.72 µg of active PT per 100 pg protein 
in the 0.25 % FA-treated native PT preparation, and this was reduced by 74 % to 1.48 µg 
active PT with 1.00 % FA treatment. 
These results confirm that at least part of the FA-induced modification occurs within the 
active site of the A-domain. In order to assess whether FA-induced modifications also 
specifically affect the function of the B-oligomer, the results from the CHO-cell toxicity 
assay and ADP-ribosylation assay were directly compared. 
The quantity of active PT determined by the CHO-cell toxicity assay was lower than that 
determined by the ADP-ribosylation assay for all of the PT preparations (Figure 7.6). 
From 0.25 to 1.00 % FA-treatment, the CHO-cell toxicity decreased by 95 %, which was 
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Figure 7.4 ADP-ribosylation of C20 substrate by PT 
A diagrammatic representation of the pertussis toxin (PT)-catalysed ADP-ribosyl 
transfer from NAD+ to the fluorescein-tagged (FAC TAG) C20 peptide (Cyr, T. D., 
et. al., 2001). The C20 peptide is homologous to the 20 carboxyl-terminal amino acids 
of the alpha-subunit of the Gi3 protein. 
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Figure 7.5 The effect of FA on ADP-ribosylation activity of native PT 
The quantity of pertussis toxin (PT) with ADP-ribosyl transferase activity was 
determined, for native PT preparations treated with 0.25 - 1.00 % (w/v) 
formaldehyde (FA), . The ADP-ribosylation assay quantitated the ribosylation 
of a fluorescent- tagged peptide substrate using an enzymatic-HPLC coupled 
assay (Cyr et al., 2001). The amount of active PT (µg) in each preparation was 
determined relative to reference PT (code 90/518, NIBSC reagent) and 
presented as a proportion of 100 µg of total protein in the sample. The ADP- 
ribosylation assay was repeatable to ± 0.15 µg active PT/100 pg protein. 
These assays were performed by Dr C-T Yuen. 
260 
100 
Q ADP-ribs assay 
Z., 
10 
0.1 
0.01 
0 0.25 0.5 
" ('1 I( )-ccII I) 
0 
bA 
0 
0 
H 
0. 
aý 
U 
Cý 
b4 
%, FA (w/v) 
0.7 
Figure 7.6 The effect of FA on ADN-rihosv lation actin itity and 
0110-cell toxicity of nati%e N'1' 
The quantity of pertussis toxin (PT) with CI IO-cell toxicity and Al)1'- 
ribosyl transferase activity in native PT prcparatiuns treated with 0.25 
1.00 °/0 (w/v) formaldehyde (FA), was determined and presented as 
described for Figures 3 and 5 respectively. An arbitrary value of' I00 
. tg active 
PT/ 100 i. g protein has been entered For 0 "o FA,, for 
comparison. 
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more marked than the 74 % decline in ADP-ribosyl transferase activity. In particular, 
from 0.5 to 0.7 % FA-treatment the CHO-cell toxicity of native PT decreased 
dramatically by 86 %, compared to the ADP-ribosylation activity, which fell by only 32 
%. The CHO-cell toxicity is dependent on both a functional A and B-domain, while the 
ADP-ribosyl transferase activity in this assay only requires a functional A-domain. 
Therefore these results suggest a FA-induced decrease in both the B-oligomer binding 
activity and in the catalytic activity of the A-domain. 
It is interesting to note that, relative to the same reference PT, the quantity of active PT 
determined by the CHO-cell assay was lower than that determined by the histamine 
sensitising and leukocyte proliferation tests. The in vitro CHO-cell toxicity assay 
indicated that all of the FA-treated native PT preparations had 1 µg, or less, of 
biologically active PT per 100 pg of protein. However, the in vivo tests suggested that all 
of the FA-treated preparations contained much more than 2 µg per 100 µg of protein (i. e. 
more than 100 ng per dose: the quantity of reference PT used). A possible explanation for 
the discrepancy between these assays is that FA treatment may cause a higher degree of 
modification to the moieties on PT required for CHO-cell toxicity, than to the moieties 
required to produce histamine sensitisation and leukocyte proliferation in vivo. Another 
likely explanation is that the preparations reverted to toxicity in vivo. This has previously 
been demonstrated in FA-treated PT (Quentin-Millet et al., 1988), and is in agreement 
with the observation that there were fatalities in the groups of mice immunised with 0.25 
and 0.5 % FA-treated mice ten days after immunisation. A toxicity reversion study was 
subsequently carried out to address this. 
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7.2.2 Reversion to toxicity of FA-treated native PT 
A quantity of each of the 0.5 and 1.0 % FA-treated native PT preparations was incubated 
at 37 °C for 11 days with manual shaking twice every day, and the remaining sample was 
left in storage at 4 °C. The incubated and the 4 °C samples were analysed by the CHO- 
cell toxicity assay and ADP-ribosylation assay (described in section 7.2.1). 
Of the FA-treated native PT preparations tested, both the CHO-cell toxicity and the ADP- 
ribosyl transferase activity significantly increased after incubation at 37 °C for 11 days 
(Figure 7.7). The CHO-cell toxicity of the 0.5 and 1.0 % FA-treated preparation increased 
by 99 % and 83 % respectively, while the ADP-ribosyl transferase of these preparations 
increased by 33 % and 45 % respectively. These results imply that there is reversion of 
FA-induced detoxification. In addition, since the CHO-cell toxicity increases to a greater 
extent than the ADP-ribosyl transferase activity, the results suggest that there was 
reversal of FA-induced modifications in both the A- and B-domain. 
7.3 Discussion 
The results from ADP-ribosylation, CHO-cell toxicity, leukocyte proliferation and 
histamine sensitization tests all provided evidence that FA causes a decrease in the toxic 
biological activities of a purified preparation of native PT. In addition, the results show 
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Figure 7.7 Reversion to toxicity of FA-treated native PT 
The quantity of PT with ADP-rihusyl transtcrase actin it,, and ('I I( )-cell 
toxicity, in native pertussis toxin (PT) preparations treated v% ith (). 5 and 
1.00 °/o (w/v) FA, was determined beli>re and after incubation tier 
days at 37 °C. The AI)P-ribosylation assay measured the ribusylatiun of 
a fluorescent- tagged peptide substrate using an enzymatic- 
Coupled assay (Cyr et al., 2001 ). The ('I 1O-cell toxicity assay measured 
the ability of the preparations to cause ('I I( )-cell clumping, performed 
according to Gillenius et at., 1095. The amount of active r l' (pg) in 
each preparation was determined relative to reference PT (code 91)/5 18, 
NIESC reagent) and presented as a proportion of 100 1ºg total protein in 
the sample. 
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that FA-treated native PT, under the conditions of preparation in this study, contains 
residual activity and is subject to reversion to toxicity. The level of residual activity 
harboured by the FA-treated native PT preparations, the ability of the preparations to 
revert to toxicity and the mechanism by which the native PT preparations are detoxified 
are now discussed in detail. 
It should be clearly noted that, although the concentrations of FA used to treat native PT 
in the present study were in the range used for commercial toxoiding, the detoxification 
protocols used in this study could be quite different to those employed by the vaccine 
manufacturers. Buffer reaction mixture, molar ratio of FA and PT, intervals of FA 
additions, mixing, periods and temperature of incubation can all vary between 
commercial PT preparations and these experimental PT preparations. Therefore, toxicity 
measurements obtained in this study are unlikely to be indicative of the toxicity of 
commercial PT antigens prepared with the same final concentration of FA. 
Residual toxicity 
The present study revealed that all of the FA-treated native PT preparations harboured 
measurable residual activity as detected by both the in vivo and in vitro tests employed. 
The histamine sensitisation and leukocyte proliferation tests, both suggested that there 
was over 2 µg of active PT per 100 µg of protein in even the highest FA-treated (1.0 %) 
PT preparation. The lowest FA-treated (0.25 % FA) preparation retained 1 µg of CI10. 
cell toxic PT and 5.72 µg of ADP-ribosylating PT, and the highest FA treated PT (1.0 % 
FA) still harboured 0.053 µg CHO-cell toxic PT and 1.48 µg ADP-ribosylating PT per 
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100 pg protein. In addition, the higher toxicity measured with in vivo compared with in 
vitro assays may also suggest that there was reversion to toxicity in vivo. 
Toxicity reversion 
Reversion to toxicity of the FA-treated native PT samples was indicated by both in vivo 
and in vitro studies. The first clue of reversion was from observations of mice fatalities in 
the low FA-treated native PT preparations, ten days after immunisation. Subsequently it 
was found that leukocyte proliferation and histamine sensitisation activities were much 
higher than would be expected from comparison with the in vitro assays, which had used 
the same reference PT. After incubation at body temperature for 11 days, the in vitro 
assays detected a much higher toxicity than before incubation, providing direct evidence 
for toxicity reversion. 
The reversion data supports previous results from a model for reversion to toxicity 
(Quentin-Millet et al., 1988). The progression of leukocytosis was measured in nude 
mice, which are incapable of producing neutralising antibodies that may delay or mask 
the effects of reversion. It was found that the maximum leukocyte count induced by a 
FA-treated native PT preparation was not detected at 3 days as for untreated native PT 
(Munoz and Bergman, 1977) but at six days post-immunisation, and that a considerably 
elevated count was still observed for 16 days after the maximum leukocyte count. This 
study concluded that there was reversion to toxicity of the PT preparation and that there 
may have been slow release of the native toxin, which prolonged the leukocytosis. 
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In overall analysis, it is conceivable that in vitro assays may not reveal the full in vivo 
toxicity of some PT toxoids, highlighting a potential problem in the sole use of in vitro 
tests for the realistic assessment of the toxicity of pertussis vaccine toxoids in humans. 
Mechanism of detoxification 
The present study further uncovered that the FA-induced decrease in the in vitro and in 
vivo toxic properties of native PT was due to modifications in both the Si catalytic site 
and the B-oligomer cell-binding domain. The observed reduction in the ADP-ribosyl 
transferase activity (by cell-free assay) established that there was specific FA-induced 
modification of the Si catalytic site. The greater decrease in CHO-cell toxicity (95 %) 
compared with ADP-ribosyl transferase activity (74 %), with 1.00 % FA-treatment, 
illustrated that the B-oligomer binding domain was also FA-modified. 
In accord with these results, evidence for FA-induced modification of the SI subunit has 
previously been shown in the decrease of specific mAb (1 B7) affinity constant from 
5x 107 L/mole, for untreated mutant PT, to an undetectable level with 0.052 % (w/v) FA 
treated mutant PT (Nencioni et al., 1991). In addition, specific modification of the B- 
oligomer has also been demonstrated by a 2-fold reduction in the haemagglutination 
activity of mutant PT after treatment with an unspecified concentration of FA (Nencioni 
et al., 1990; Nencioni eta!., 1991) 
Moreover, the present study demonstrated that the mechanism of reversion to toxicity is 
by reversal of these FA-induced modifications in both the Si catalytic site and the B- 
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oligomer cell-binding domain. After incubation for 11 days at 37 °C the CHO-cell 
toxicity of the 1.00 % FA-treated native PT preparation increased by almost twice as 
much as the ADP-ribosyl transferase activity. This greater increase in CHO-cell toxicity 
compared with ADP-ribosylation activity demonstrated that FA-induced modifications 
were reversed in a proportion of B-oligomers as well as Si subunits. 
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The overall aim of this study was to investigate the relationship between the molecular 
structure and immunogenicity of PT. A molecular model of PT was developed and 
corroborated using solution techniques. For the majority of the study, the size, 
conformation and epitope integrity of five commercial toxoids and a series of FA-treated 
native and mutant PT preparations (0 - 1.0 %, w/v, FA) were evaluated. In addition, the 
toxicity and immunogenicity of the PT preparations was assessed by in vivo and in vitro 
methods. 
8.1 Molecular modelling and physico-chemical analysis of PT 
highlight novel structural features 
Computer modelling and analysis of PT in solution revealed some intriguing new insights 
into the structure of PT. Results from analytical ultracentrifugation demonstrated that PT 
may exist in equilibrium between holotoxin and separated A and B-oligomer. 
In addition, a combination of fluorescence, circular dichroism and computer modelling 
uncovered that native PT and the catalytically inactive genetic mutant PT, PT-9K/ I29G, 
are structurally comparable. Interestingly, both forms of PT can bind NAD+, as shown by 
fluorescence studies. 
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Computer modelling and fluorescence spectroscopy demonstrated that structural 
adjustment following `catalytic activation', by cleavage of the disulphide bond Cys-41 - 
Cys-210, is required for binding of NAD+ in the active site of the Si subunit. An 
`activated' NAD+-bound model of PT was produced, and demonstrated that further 
structural changes occur on NAD+ binding to reveal a G-protein binding site. This novel 
molecular model could provide the basis for further studies on the structure and function 
of PT. 
8.2 Different chemical treatments of PT alter the molecular 
structure and immune response 
From studies of five commercial PT toxoids some interesting comparisons can be made 
between the molecular structure and immunogenicity of PT. The five PT toxoids were 
detoxified with different chemicals, and included the mutant PT, which is stabilised with 
0.035 % (w/v) FA (Table 8.1). A degree of cross-linking and aggregation was not 
detrimental to the anti-PT immune response in mice. This was demonstrated by the 
slightly aggregated mutant PT treated with 0.035 % (w/v) FA, and highly cross-linked 
and aggregated glutaraldehyde plus FA-treated native PT. Both of these toxoids induced 
good protection against aerosol infection and higher total IgG antibody responses 
compared with untreated PT, which was not cross-linked or aggregated (Table 8.1). 
Results of glutaraldehyde-treated PT and tetranitromethane-treated PT showed that much 
higher aggregation correlated with a decrease in antibody response and protection. 
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Table 8.1 Summary of thesis results for untreated PT, 0.25 and 1.00 % 
formaldehyde (FA)-treated mutant and native PT preparations, and five 
commercial PT toxoids 
The majority of the results described throughout the thesis are summarised, by rationalising 
the raw data as + and - symbols (detailed in the legend). For the 0.25 and 1.00 % FA-treated 
PT preparations, the cells are split where different results were obtained for mutant and native 
PT. 
PT Toxoid 
0.25 %1 1.00 % Commercial PT toxoids 
FA FA 
Property Untreated Native Na t 
(Mutant Glutar- Glutar- Tetranitro- Hydrogen 
PT, aldehyde aldehyde methane peroxide 
\ 
0.035 % plus 
tormaldeh- Form- 
Mutant n yde aldehyde 
Unfolding' 
- ++ +++ + ++ 
Cross-linking" 
- +++ +++ nd ++.. F .1I nd 
Aggregation` 
- ++ +. {_+ + -I-+ ++i. ++-i " 
Anti-S1 +++ + nd nd ++ ++ nd + 
bindingd 
Anti- 
B-oligomer +++ + nd nd + + nd 
bindin e 
+ 
Total IgG + 
\ 
+++ ,.! -++ ++ ++ + 
responsef ++ ++ 
Neutralising nd nd nd nd nd nd 
antibodiesg _+_ + 
IgG1/IgG2ah + +++ + ++ +++ ++ 
Protective nd nd nd +++ ++ + " efficacy 
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nd: experiment not done 
'Extent of unfolding; by Fmax of fluorescence spectroscopy: 337 nm =-; 338 - 340 nm = +; 
340 - 342 nm = ++; above 342 nm = +++; 
*= fluorescence spectrum shape is atypical 
bExtent of cross-linking; based on highest Mr detected by mAb in western blots: < 60 kDa = 
-; > 60 kDa = +; > 100 kDa = ++; 250 kDa, gel limit, = +++. 0.25 and 1.00 
% FA-treated PT 
were not analysed so results based on 0.1 and 0.5 % FA-treated PT, which included species of 
at least 250 kDa 
`Extent of aggregation; based on SEC profile showing V2 or more of protein: eluting before 
13 mL = +++; eluting before 16 mL = ++; eluting before 17 mL = +; eluting at - 18 mL =- 
d, eExtent of antibody binding; based on comparative densities of mAb binding in western 
blots (for commercial toxoids), or extent of mAb-binding in ELISA's (for experimental 
formaldehyde-treated preparations): no data available for the 0.25 or 1.00 % FA-treated 
preparations, therefore results presented for 0.25 % formaldehyde-treated sample was 
obtained for the 0.1 % FA-treated preparation. 
1Total IgG response; Relative geometric mean total IgG potency: <1=+; I-3= ++; >3= 
gNeutralising antibodies; relative geometric mean neutralising titre in CHO-cells: < 200 = +; 
>200, <300=++; >300=+++ 
hIgG1/IgG2a ratio; ratio of relative geometric mean potencies: <1=+; > 1, < 10 = ++; > 10 
'Protective efficacy; Geometric mean CFU per lung: > 500 000 = -; > 200 000, < 500 000 = 
+; >20000, <200000=++; <20000=+++ 
JMutant PT toxoid; Mutant PT (PT-9K/129G) is treated with 0.035 % formaldehyde, in 
order to stabilise the protein (Nencioni, L. et al. 1991) 
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However, these toxoids still induced higher antibody responses than the untreated PT 
(Table 8.1). In contrast to the other toxoiding chemicals, hydrogen peroxide treatment did 
not cause any cross-linking or aggregation but induced the poorest antibody response and 
protection (Table 8.1). 
Although some molecular aggregation was beneficial, the loss of local structure was 
unfavourable in maintaining a good immune response. This was demonstrated by toxoids 
with an atypical fluorescence spectrum shape, namely glutaraldehyde-, tetranitromethane- 
and hydrogen peroxide-treated PT, which induced relatively low antibody responses and 
protection against aerosol infection. Higher responses were mounted in response to the 
0.035 % FA-treated mutant PT and glutaraldehyde plus FA-treated PT toxoids, which 
both maintained a fluorescence spectrum shape characteristic of untreated PT. Atypical 
fluorescence spectra may indicate gross amino acid modification and thus widespread 
loss of immune epitopes. Atypical fluorescence was indeed found to correlate with a loss 
in the protective Si epitope (Table 8.1). 
The type of immune response induced by the commercial toxoids, as determined by the 
IgGI : IgG2a ratio, did not directly correlate with the extent of aggregation, cross-linking 
or unfolding (Table 8.1). Other physico-chemical factors, such as specific amino acid 
alteration or biological properties, such as toxic activity, may direct changes in the type 
immune of response. It is intriguing that two highly immunogenic toxoids, 0.035 % FA- 
treated mutant PT and glutaraldehyde plus FA-treated PT toxoids appeared to induce 
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opposite immune response types, Th2 and Thl respectively. Cytokine studies of these 
immune responses should be carried out to confirm these results. 
In this study the total IgG antibody response correlated with protection against aerosol 
infection in mice. These results are an indication that circulating antibodies may protect 
soon after immunisation, in this case within a five-week immunisation period. However, 
there is ongoing debate about whether antibody response to PT is a valid indication of 
protection. Studies have shown that patients with circulating antibody are more likely to 
be protected against whooping cough (Zackrisson, Taranger, and Trollfors, 1990; Isacson 
et al., 1994) but that the titres do not always necessarily correlate with protection (Ad 
Hoc Group for the Study of Pertussis Vaccines, 1988; Tran Minh et al., 1999). There is 
evidence that cellular responses are important for protection (Mills et al., 1993; Mills and 
Redhead, 1993; Mills et al., 1998; Ryan et al., 1997a), but these were not directly 
assessed in this investigation. However, the very different IgG I: IgG2a ratios of the 
protective toxoids, 0.035 % FA-treated mutant PT and glutaraldehyde plus FA-treated 
PT, supports the current notion that both cellular and humoral responses may be 
important for protection. 
The results from this comparative study of toxoids suggest that aldehydes, 
tetranitromethane and hydrogen peroxide induce a variety of structural modifications. A 
low level of aggregation and cross-linking is beneficial to the immunogenicity of PT 
toxoids and even very high levels of aggregation appear to be much better than no 
aggregation at all. However, large changes in the local protein structure were detrimental 
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to the immunogenicity of PT. In addition, these different chemical-induced modifications 
appear to alter the type of immune response. Biological characteristics such as residual 
toxicity may also have played a part in shaping the immunological properties of these 
toxoids. 
8.3 FA-induced cross-linking, aggregation and amino acid 
modification of PT modulates the immune response 
Studies designed to probe the effect of a controlled increase of FA-treatment on both 
mutant and native PT afforded a more detailed description of FA toxoiding. In a 
concentration-dependent fashion, FA induced PT aggregation, inter-subunit cross-linking 
and unfolding. The principal chemical modifications are likely to be methylene bridges 
between FA-reactive amino acids within the PT molecule and amino acid modification by 
lysine cross-linking from the reaction mixture (Tome and Naulet, 1981; Tome, 
Kozlowski, and Mabon, 1985). These cross-links have been found to be either stable, acid 
labile or reversible (Bizzini and Raynaud, 1974; Tome et al., 1979). FA-modified amino 
acids may also change the charge or hydrophobicity of molecular surfaces, altering their 
association. A low concentration of FA (0.035 %, w/v) appeared to stabilise the holotoxin 
by inter-subunit cross-linking between neighbouring subunits in the native structure, 
preventing their dissociation. Additionally, at this low FA-concentration a small quantity 
of high molecular weight species was produced, associated by reversible interactions. 
High concentrations of FA (>_ 0.50 %, w/v) caused less uniform cross-linking, gross 
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chemical modification of the amino acid residues and the formation of heterogeneously 
sized molecular aggregates. 
Structural correlates of immunogenicity were assessed for the mutant PT preparations. 
Immunological results from native PT, however, could not be interpreted in the same 
way, due to the significant immunogenic effects of residual quantities of active PT. 
As found for the commercial toxoids, some aggregation was beneficial to the 
immunogenicity of PT. This was demonstrated by the higher IgG responses induced by 
0.25 and 1.00 % FA-treated mutant PT preparations compared with untreated PT (Table 
8.1). These antibody responses were higher despite the destruction of A-subunit and B- 
oligomer epitopes (Table 8.1). These results suggest that some FA-induced modifications 
are beneficial for the induction of a high IgG response. This may be due to increased in 
vivo stability of the toxin, and indeed FA-induced cross-linking was found to prevent 
holotoxin dissociation in vitro. It is also possible that intact epitopes are efficiently 
presented to the immune system on high molecular weight PT molecules. 
Although the quantity of total IgG antibodies induced was not reduced by FA treatment 
of mutant PT, the quality of response clearly was. This was demonstrated by the 
observation that the number of antibodies of neutralising quality declined as a function of 
FA (Table 8.1). This may have been due to the alteration of important protective 
structural epitopes on the surface of the molecule. The decline observed in A-subunit and 
B-oligomer epitopes by mAb-binding in vitro indicates this. In addition the IgG 1: IgG2a 
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ratio increased with FA treatment (Table 8.1), suggesting the immune response had 
shifted towards a more Th2-type response. It is likely that the size of the molecules and 
their chemically modified surfaces affects their interaction with antigen presenting cells. 
In addition, the cross-linking of the FA-treated species is likely to effect the processing of 
antigen, by antigen presenting cells. Therefore, the FA-induced modifications could lead 
to a change in the cytokine environment. It has been demonstrated that antigen size can 
effect the differential induction of Thl and Th2 responses by altering the pattern of 
cytokine secretion by the antigen presenting cells (Brewer et al., 1998). In addition, a 
different study demonstrated that FA-treatment of a variety of B. pertussis antigens 
altered the proliferation of antigen-specific T-cell clones. The study concluded that this 
was likely to be a result of altered proteolytic processing by the antigen presenting cells 
influencing antigen presentation to T-cells (Di Tommaso et al., 1994). 
8.4 Detoxification and toxicity reversion of FA-treated PT Is by 
modification to both the A- and B- functional domains 
The effect on the toxic biological activities of native PT with increasing FA-treatment 
was investigated by two in vitro tests; a CHO-cell toxicity assay and a cell-free ADP- 
ribosylation assay. For CHO-cell toxicity PT molecules require both a functional A- and 
B-domain. The B-domain facilitates entry into the CHO-cell, while the A-domain exerts 
the toxic effects. For ADP-ribosyl transferase activity in the cell-free system the PT 
molecule only required a functional A-domain. The greater decrease in the CHO-cell 
277 
Chapter 8 Discussion 
toxicity compared with the ADP-ribosyl transferase activity, with increasing FA, 
demonstrated that both the A and the B-functional domains of PT were modified by FA. 
treatment. 
These assays were also used to detect reversion to toxicity of the FA-treated native PT 
preparations. After incubation at body temperature for 1I days, a greater increase in 
CHO-cell toxicity compared with ADP-ribosyl transferase activity indicated that FA- 
induced modifications to both A and B functional domains were reversed. 
It is likely that the detoxifying modifications to the A and B domains are a consequence 
of the FA-induced cross-linking and heterogeneous aggregate formation, as characterised 
in detail for FA-treated mutant and native PT. The detoxifying modifications could be 
due, at least in part, to specific FA-induced cross-linking between amino acids composing 
the functional domains or by the cross-linking of lysine from the reaction mixture. 
Another mechanism for detoxification may include burying of the functional domains in 
aggregates. 
It is interesting to speculate that reversion to toxicity could occur by the reversal of these 
mechanisms. Some FA-induced cross-links have been found to be acid labile and 
reversible (Bizzini and Raynaud, 1974; Tome et al., 1979). In addition, non-covalent 
association such as hydrophobic and charge interactions may be readily disrupted. 
Disruption of unstable cross-links within functional domains could render them active 
again. Large complexes harbouring unmodified functional domains may undergo 
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unfolding and dissociation, also releasing active molecules. Indeed some aggregates 
detected by FPLC and SEC-MALLS could not be detected by the denaturing technique of 
SDS-PAGE, suggesting a degree of dissociation. 
8.5 Active PT can both suppress and augment the immune 
response 
Assessment of the toxic biological activities of FA-treated native PT revealed evidence of 
residual toxicity and identified reversion to toxicity of the preparations. It follows that 
this difference in toxicity between the native and mutant PT preparations may have 
contributed to the large differences observed in the extent and type of immunogenicity 
they induced. The results demonstrated that, relative to the corresponding mutant PT 
preparations, the most toxic native PT preparation inhibited the immune response, while 
much less toxic preparations augmented the response. 
The lowest FA-treated (0.25 %, w/v, FA) native PT preparation, in this experiment, 
harboured the highest levels of residual toxicity (1 pg active PT / 100 pg protein, by 
CHO-cell assay before incubation), and indeed induced a significantly lower total IgG 
antibody response compared to the corresponding mutant PT preparation. It is very likely 
that the high residual toxicity caused the suppression of antibody production. There is 
some previous evidence that pertussis toxin can cause immune-suppression to different 
co-administered antigens (Asakawa, 1969). In this study a marked decrease in mouse 
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antibody response to sheep red blood cells was discovered when the mice were pre- 
injected with active pertussis toxin. The antibody response was decreased significantly 
with a dose of 0.6 µg of active PT. This is in direct correlation with the concentration 
range of active PT found to inhibit anti-PT total IgG in this investigation. That is 1 µg of 
active PT was inhibitive and 0.1 µg of active PT was stimulatory. 
In contrast, the 1.00 % FA-treated native PT had much less residual toxicity (0.16 µg 
active PT / 100 µg protein, by CHO-cell assay before incubation), and the total IgG 
response was three-fold higher than for the corresponding mutant PT preparations. The 
proposal that these augmented responses were induced by residual amounts of active PT, 
concur with the known immune-enhancing properties of PT. Early work in this area 
showed that PT had the ability to enhance the IgE antibody responses to coadministered 
antigen (Munoz and Bergman, 1977). In addition PT, at low concentrations of 0.2 - 0.5 
µg/dose, induces enhanced protection against intra-cerebral B. pertussis infection when 
co-administered with other B. pertussis antigens such as FHA and fimbriae. It has also 
been demonstrated that trace amounts of PT (0.2 µg/dose) stimulate proliferation of 
murine interleukins, in response to lysozyme (Shive et al., 2000). 
Additionally in this study, an increase in FA-treatment, and thus a decrease in the residual 
toxicity, of native PT was found to correspond with a decrease in the IgG 1: IgG2a ratio. 
The response induced by 1.00 % FA-treated native PT yielded a markedly lower IgG 1: 
IgG2a ratio compared with the corresponding mutant PT, implying that the response was 
more Thl polarised. In correlation with this, trace amounts of PT (0.2 pg/dose) have been 
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shown to preferentially induce IgG2a subclass antibodies and other Th1 markers such as 
interferon-y cytokines (Shive et al., 2000). It has been demonstrated that small 
concentrations of active PT (0.12 µg/dose) administered with heat-treated whole cell B. 
pertussis vaccine induced a huge increase in nitric oxide production by murine 
macrophages, which was associated with better protection against intracerebral and 
aerosol challenge with B. pertussis (Xing, Canthaboo, and Corbel, 2000). 
Since the immune suppression and enhancement by FA-treated native PT preparations is 
relative to that by the catalytically inert (mutant) PT preparations, this study suggests that 
both suppression and enhancement of the murine immune response is ADP-ribosyl 
transferase-dependent. 
ADP-ribosylation-dependent immune enhancement by PT is supported by studies which 
show that in lymphocyte cultures, native PT but not PT-9K/129G can promote T-cell 
dependent production of IgE by B-cells (Pouw-Kraan et al., 1995). In addition, 
enhancement of the murine interleukin response to lysozyme by native PT could not be 
reproduced with the same concentration of B-oligomer alone (Shive et a!., 2000). It has 
been speculated that the active PT stimulates antigen-presenting cells via ADP- 
ribosylation of their G-proteins leading to enhanced cytokine secretion (Shive et al., 
2000). 
The ADP-ribosylation of host G-proteins leads to the constitutive action of adenylate 
cyclase and thus the continued production of cyclic adenosine monophosphate (CAMP). It 
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is conceivable that native PT both inhibits and enhances the immune system via the 
immunoregulatory effects of cAMP. This messenger molecule is produced in immune 
cells and is an essential factor in modulating immune responses (Koh, Yang, and 
Kaminski, 1995; Bell and Brunton, 1986; Bihoreau et al., 1991; Kvanta et al., 1990). The 
concentration of cAMP induced by residual PT activity was not investigated in this study. 
However, the literature suggests that immunomodulation by cAMP is biphasic (inhibitive 
and stimulatory), which may explain the apparent inhibition and stimulation of antibody 
response caused by active pertussis toxin. 
At a high concentration (> 250 µM) cAMP is known to inhibit T-cell responses, as 
determined by inhibition of Ca2+ mobilization, PIP2 hydrolysis, interleukin (IL)-2 and 
IL-2 receptor expression (Lerner, Jacobson, and Miller, 1988; Anastassiou et al., 1992; 
Imboden et al., 1986; Novak and Rothenberg, 1990; Kammer, 1988; Krause and Deutsch, 
1991) and IL-2 dependent T-cell proliferation (Johnson, Davis, and Smith, 1988). These 
results correspond with those of the most toxic PT preparation (0.25 % FA) which also 
induced a suppressed immune response that appeared to be Th2-polarised (Table 8.1). 
In contrast, at lower concentrations (10 - 100 µM), cAMP was found to be stimulatory to 
humoral immune responses and lymphocyte proliferation (Koh, Yang, and Kaminski, 
1995). It has also been shown to enhance IL-2 production (Chakkalath and Jung, 1992) 
and IL-2 receptor expression (Scholz and Altman, 1989). These findings correlate with 
the Thl-type immune enhancement observed with low levels of active PT in the 1.00 % 
FA-treated native PT preparation. 
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These studies cannot rule out the possibility of intrinsic immune-enhancing properties of 
the B-oligomer, as has been indicated by studies of the structurally related cholera toxin 
and heat labile enterotoxin (Williams, Hirst, and Nashar, 1999), but they do suggest a 
specific immune enhancing role for the catalytic Si subunit. 
Cross-linked molecular aggregates of native PT appear to be advantageous for immunity. 
They form a vehicle for the slow release of native structure in vitro, which may liberate 
protective epitopes, but on the other hand leave the toxicity of the preparation 
unpredictable. Progress continues to be made in the vaccine field, not least by the 
increasingly detailed descriptions of purified antigens, but the balancing act continues. 
Further studies on the physico-chemical nature of immunogenic molecules and 
immunogenic markers of protection are required for further progress in this area. These 
studies could lead to the selection of molecules that can direct the immune response, and 
could also extend to the development of in vitro studies as alternatives to the use of 
animals. 
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Appendix 1 
Information for the secondary structure of PT (PDB code 1 PRT, (Stein et al., 1994a)) was 
obtained from the Research Collaboratory for Structural Bioinformatics 
httn: //www. rcsb. org/pdb/cp, i/exl2lore. cgi? iob=chains&t)dbld=l PRT&page=&pid=269829 
97264039, and is predicted using an implementation of the Kabsch and Sander method 
(Kabsch and Sander, 1983). 
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